var title_f29_46_30432="DIP plain radiograph";
var content_f29_46_30432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Desquamative interstitial pneumonitis (DIP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Frontal and lateral chest radiographs in a ten-year old child with DIP show bilateral ground glass abnormality. The child is now known to have mutations in the ABCA3 gene, consistent with a defect in surfactant function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Leland L Fan, MD and Cynthia Epstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30432=[""].join("\n");
var outline_f29_46_30432=null;
var title_f29_46_30433="Patient information: Dry eye (The Basics)";
var content_f29_46_30433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83060\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/13/43216\">",
"         Moisture chambers",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/34/547\">",
"         Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dry eye (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dry-eye-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9361609\">",
"      <span class=\"h1\">",
"       What is dry eye?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dry eye happens when your eyes either do not make enough tears or the tears that they make evaporate (go away) too quickly. This causes your eyes to feel dry and irritated. The medical term for dry eye is &ldquo;keratoconjunctivitis sicca.&rdquo;",
"     </p>",
"     <p>",
"      Many people have dry eye, including about one-third of older adults. A few people with dry eye might have another disease, such as Sj&ouml;gren's syndrome, diabetes or Parkinson disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361624\">",
"      <span class=\"h1\">",
"       What are the symptoms of dry eye?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People have different symptoms but the most common ones are eyes that:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel dry or burn",
"       </li>",
"       <li>",
"        Look red",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Being bothered by light",
"       </li>",
"       <li>",
"        Feeling like something is in your eyes",
"       </li>",
"       <li>",
"        Blurry vision",
"       </li>",
"       <li>",
"        Watery eyes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some people the symptoms are worse when it is cold or windy or if they are in a dry environment. Some medicines can cause dry eye symptoms or make them worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361639\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your eye stays red, irritated, or painful for several days, you should see your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361654\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. The doctor or nurse should be able to tell if you have dry eye by learning about your symptoms and doing an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361669\">",
"      <span class=\"h1\">",
"       How is dry eye treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?3/31/3572?source=see_link\">",
"       Artificial tears",
"      </a>",
"      &rdquo; are the main treatment for dry eye. They can keep the eye moist and help with the symptoms of dry eye. You can buy artificial tears at the drug store or grocery store without a prescription. They come in liquid, gel, or ointments. Your doctor or nurse will help you decide which form is best for you.",
"     </p>",
"     <p>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?3/31/3572?source=see_link\">",
"       Artificial tears",
"      </a>",
"      help with the symptoms of dry eye, but they do not cure the condition. They work only as long as you keep using them.",
"     </p>",
"     <p>",
"      Other things you can do to help improve your symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Try to blink a lot, especially when you are reading or using the computer. This helps keep your eye moist.",
"       </li>",
"       <li>",
"        Avoid excess air conditioning or heating as much as you can. Also avoid sitting directly in the flow of the cold or hot air.",
"       </li>",
"       <li>",
"        Use a humidifier in your bedroom and any other space where you spend a lot of time.",
"       </li>",
"       <li>",
"        Use swim goggles or &ldquo;moisture chambers&rdquo; if your doctor or nurse suggests them. Moisture chambers are special devices that fit on your glasses. They can help keep your eyes moist (",
"        <a class=\"graphic graphic_picture graphicRef82900 \" href=\"UTD.htm?42/13/43216\">",
"         picture 1",
"        </a>",
"        ). You can buy moisture chambers at most stores that sell glasses.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your dry eye does not get better in 3 to 4 weeks, your doctor or nurse might send you to see an eye doctor (called an &ldquo;ophthalmologist&rdquo;). The eye doctor can do more tests and might suggest other treatments. These include prescription eye drops, oral medicines, or surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10259671\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/34/547?source=see_link\">",
"       Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/46/30433?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83060 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30433=[""].join("\n");
var outline_f29_46_30433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361609\">",
"      What is dry eye?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361624\">",
"      What are the symptoms of dry eye?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361639\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361654\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361669\">",
"      How is dry eye treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10259671\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83060\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/13/43216\">",
"      Moisture chambers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/34/547?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_46_30434="Neonatal vertical suspension";
var content_f29_46_30434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Neonatal vertical suspension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 674px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vertical suspension measures the strength of the neonate's shoulder girdle. The examiner holds the infant in an upright position by placing the hands under the arms and around the chest with the feet unsupported. In infants with decreased tone of the shoulder girdle (shown in the inset of an abnormal response), the infant begins to slip through the examiner's hands and the legs are extended. Vertical suspension is also helpful in evaluating for subtle increases in muscle tone in the lower extremities. In the presence of lower extremity hypertonicity, there may be adduction at the hips combined with hyperextension at the knees and ankles. The lower extremities may appear to cross over each other (scissoring posture).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30434=[""].join("\n");
var outline_f29_46_30434=null;
var title_f29_46_30435="Hashimotos thyroiditis Doppler";
var content_f29_46_30435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hashimoto's thyroiditis Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 309px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE1AbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDhrzw+luwJnVkY5MiHGaLnw7I8UcQMio/KuW5z71avPEdu/wArWgTymwDtyatWHiu1CpEy7JHz87fw0AUx4e1GQQrErSL93Ibk0+bQnsZQsuC47Zz+Fb2l+JLYu5imYTKCu4r8h96L64E9uZmvLVVP8chANAGJH4ake8DR55GTlun0qS48JIjo2IpJxyQXNWbO9tmnBScySIeWDcfhU0kI1W4eQXyqidRuxmgDJtvD8887RuDFzwCeDW0PBQhWR4Z4t5XlXOatWmmBgrvqUSkfdDNniny6e5Y/ZtTgCNwwagDEj0GxidRLMXkY4LqcKpqyfCtiquzXG/PIAamXOjQEyRXOowKuchlPX6VAltZw7RHqJ8xeCzDJ/CgB+maPp73siTZdFXkk/d/Gmx+FNMnmkla9LwH7qhuRSLFpNrGzS60Vd+oVdxptla6FvLz6vMUxyijBNAFmTwtpUdsIY9R2u56E9vSqml+HNJWeYyz7inAXdUF1ceH4I5ALydgOmckgVkW2p6A5AlefzAeCMjNAGvJp1tskEYGVbgZ7VtwaXp8los02IkC9m+Yn6Vzcut6JE6MqXL46rnA/Onrr2kmNgLGRwxyCz5AoA6CXwxZ3kAyZWgPOd3Ssy+0LTRb+QWkzH0ZjxVe38WaUsggRHVz9/k0++8RaRHjday7Tzk55oAu2ehWC26oLlDGfvZPUelU10yyt7+VfNPlZyoDdPY0+y8XaOkLR/wBmiRSOrEjFH/CU6W5CxaOJJCPlBU0AXPsnh+FBG7SPI3LMhziqv9naFbOzo8iyHkEnccVY0rXrK33F9FeN2PeMkVNJq1pPemWPT2aTHKKlAGfFa6RHdB5ZJpbYnjI6GtN4tCnYuquwxtwEOF96zbrxBqM7G3t9AZrcDncmKhsr/wARPbstto7ccAgUAXZrW0iRBaW8zoW+8R1pLq2s1LldPYx9/LBz+NRQ3PipYRJeWgwDgKOOatpb+LghLxRrE/3QrAnmgBsGkaV5ACR3BZ+VByShqtJZ2nmMI7Z3ZflY7SD9aZJo/imKXak8K9zl+T+FEWieIBcIzXkZVuu58YoA0G0uHyojFA0LEY3nk/lVq30SyHDQmaTqXHGT6VFdeGdRurTLazAm3+FWwaqx+FdQtUDHWhk/w7+v40ATSaPG92B9im2McNjjio9U0O0hnSHypIw/RWbJNaFnoV0FIvNdYR9QAuWqCbwkl5OJU1Oebb78rQBWm0iFLQrHbmIDjcz1Xj8P6aY0kSZmccMqHvWrdeBklg2nVblgxwVzVi08A2kEJit9TmiAH3g+eaAM628NRh2m+STHQdDilk8OQR7pI4Vkz95CuDj2qtceB7xpnCayZG/gIbBNSN4f12JNkuqNMqjCqDgGgCvFodlE7OIXEec7mfOPaootIhdXdtqRO2UBPU+lU7qx8QGQJCwZd+3aKJzrWngG6gEiqOAh6UAWnsNPXd5wLFlOFB4zUFholtPFui1BI5SfmXGQtJp3iaIxMl3puEz6ZyfWkTW9JknKwwhWfjI6LQAybQov454nUNxIz4J+gqxd6BDOqJEh3kcyF+agl0+xurmPbdBS/RVbhfeoLnSJI4gYLvcUbA+fr9KAFs/CcwBeK5R48/OpbpT/AOw5kBaGcYJxlmqhMmoQqo+bOcgA4LfWltdQcuGvo5BGDgsegNAFlfDF3c3AJnRlxnarfKT6ZoTQrmJ3DROAvG3t+FI3iHZlLVW8odcio/8AhOblXwgUAEDeRkigAOiy3BPlWzE+hB496SHTr4OUaBii9W2kV0dn4xtpEVpY2PclRitCTxfZzQeXby+XtHBdKAOUEEV4oST9yqcHHXNMl06HcftDSFB9w5/rXWWOpaQYmWd41c85ABDGpFj0m9jaOR41PoOhoA5N7azZELp5a5weOtRC1torg+TEzI33WBruF0nSwEXzUfjlewH1qw2h6FJakvcunYlecUAed6lLLDL5SM0WRnBGQfxqgY/OlifzXCBhkKevNdzc+GtNKYjvzLn7pZ8hRUB0KwjtDG9zHFcAgqwbKtQBKBpkMM1xtTeeqsM1DHHouovEZdN8lT9585J+lZtnLNcXh8pW81uCsgwD9K6LSvOJYm0DFeA5+XH4UAU5PDOmlS8Ny4izwVOMexrPl0jSlx58F2UJxnPH5Vq3CXk3yuBFGWO4DqfpVOXRBNETJdTRqvKqr5NAEreGNCjVGxeyFx8ojkAA+tamgaJoNpIYb23uMOOMNmsLyVt1WG4SRmP3JHk21oQXEtqYxHEjqTj5nJ/WgDcGjeGlV5Y3nKA4XL4IP0qomkaJIpeR7oD2NRQai9vOY49Pt5D3flsfStcNqs8G6AWwXGQvl4oAzotK0JlP+gXM6L/EXxVhNM0W4ASKylRR/Cep/GrVhp2vXSs8TWSD0fipZYNQh279Rto5hwREu7FAFU+HtCimV5dOJIHAbpUkGhaLNI7Q6eUjxggDn8KkFm4BefWpZT3VIuhqtFpDszy3GqXHlv8AdCD+lAFW50jwxbtJusrhmx9xgOT7VWtNL8Ms/lNprZb+JsZFbtvoVvcFSsl7I0Z/jGCfpU2p6HG9uyT253DkFDhsfWgDn18N+GDLJIbOVwvGM8CpLPQPDkJDw6fOEz1ZsitvTtImSyEkKHJ/vMOlWrLQfLEjyy9fmChuv4UAc1LZaC14GjsYSy8EMuF+pNXXsNHuFRms1UIPugfLW29tCIzGzmNHH/LRehoms7ISQMt1GqxrgjO4NQBk29jpcSEnSUuICc5CZxTzcWC3fl2mlMsvRWZMBR7VpC2hlI8m4ZATxg4FV7jybVmt5b2Yo3dl6/jQA67upo7JIWt4kB+ZGkweaht77U4YXc29sDjG5ADu/GklWOHT/lnHk54D81havqselPHJbIjEnLMjZA/CgDdgvbqWJhvigmbu/P6U7TlaISFrpeThykZ5+lc1J4tnuZABbAMejlRx+NVJfFd2JiY2wVO3cOQaAOquIp2O2xWeTd0Z04Wnlby1siZTif1wB+VcQ3jXU0nzJcnZnHyVnaxrt1M/mTzspblVU0AehwzvcKomifzR/wAtFHX61LHaRTDddR+Yc8MpryUa7erx57mI91zkfWoZNS1CPG26kMB6sG6UAep3n9nQORIdqDk+tSQSWMpSYz2vlAfIknAH415Wb9yAokd0P985Jp8oPliTLEf88y1AHpl3c2cku8X1kGHAWM5FVbSS18xjHcBpTwTCeFry24S6kZZERkUHop4FW4ppoWLRzFc/eRqAPS2URgzXEyyxDoA+GP1qVrVyqy2qARyLzhvmBry26uHkUH7aVGfu5qxa6o0UDEzv5mMbg+cUAeiT6VqT2qvGyIFOAS2Gx71a8mVLALuilKDpuOa87stXu3hCxvK5zyzP+lW4PEepWJfd5ciKeBjGKAOlhl1PK/NsjXkBV5+lJPNLcAs8chkXgkrwfrVC08YXqPG08Ebs3QAYptx42eSZ4mtDEmcs2OtAFmKwtJ32ywRZ9FfFUtV8N6ZEZjFAytjdlGyK19O1fSru0ZpnMZbsRirFpq2j72VxGJOgdxkGgDz99DsmIkS5nU/x/LgfSoLLTtUkkP2DJt0OVZu1erS/2eTujjtwjL8x3Yz+FZK31jagpcMoY8BEOTigDz+a01xp2a2ZZmYYZk5NQvNqsYEeo2jyR55G3p9K9FTTYJiRaXDwBzuyE71ZbTrSKSNbnVzEwPUKDn8KAOBj1TTVUCSyZJTx8w61Uv8ATtJmQuhETNyQxzXrzeGtJvEWUXiygc5Me3P41kah4Ns51MsaQSc4wsmMCgDy+00CTyg6XUbL0RWbGKW90rUEG1U8xTxuByK7K58CwGFlGoLEqndszkiqy+Db37M5tL5XQcqxbGfoKAOWWzuIY1E0JLjsgpXvdRtdxgiKoO+2ulg8L65HcLM1z5jAfLgZFWpdP19FyYhKh6xkAUAcvBrbvbMlxG+49wOfxp1xqcnliLMgQjp0Fdro8l6kbo2g25YdCy8/nUEttqO8vNoMRBPIPPHtQBwwvXitiyKzkHBNEfiK4jWMLDEqAgYcZJrtLkGSN4k0BIW6jmszT9DuXuMvpIZi27EjYA96AOlspdEupmZWEUit8oc/Mp9q6Erb3kKpLc2qupypZ8fnXhNtfq9wwZmU5IyetaL3NxEVTaHX038kUAe0zQWMG1vJj80jBl8z5QPWq82m6VcbRbXYZzy+zkt7CvIW1a4MZIO+NTwjPwtLBrd7GC1sxJP8Q420Aekvo1mly2+3lmGPlEpz/wDqqxbuuDbQwWsJPGH/AKV5rbeJ72AkyXbhu5HOahOvTXbl7hgEBx8pw1AHql4HskCyXtrEpXhUAzmpbXWdPt5Yw9xJwMPnoTXks0wuT8jTPgcZzU1jcHeECSeh3nIoA9U1rxXp0KAJcCTttTqKqW3jLS4mjb+zyyfxOw715nczA3JieAMoH3gKtNHIsUfl73TuvtQB6de+OtNDAR2ca556cVnXvj1YFQ29tbAt6DJFeeuRyUWVcdMjqagktZZQGBAkJ5BGBQB10/jvUZ5CFuGVCcfu15FVZvE2ozSrH9q3Drnpj8a5w2MkYCorAnq2akvdPmgspZ2yIY13E9eKBpNuyOmXXJ50ZFm/ejjJY4H0p8mqXcG1nklmY8DB6V51YSXf2j7RbuGlI5QjK49MV1mn6j9utj5Y8k4Kujc4b2PpWNKvCo2lujvxmW1sJFTns+vmdDdavep5DNPGC/8AAWzmq13qJUMWcAyfw+lZltZvsBuG/wB07c5qCS2afzFUkMPu/Wtjzy1c3ktvtxI7oeV2t901ce9uLhIkDPuxnfnIX8KwSzWuYgRJPt3CMsAWqSO/vtTt5BpGn3UghH+u8vahH1ol7kHVlpFbvormlKlKtONOGsnsjUsr+ZY5mecmQHau85XH0rKm1KSWWSKN0MYGWkK8Z9Kl0vRdc1siOKxWAqctI2Tu9qg1zw/qWm5mkmTg7TGF+X8q855rhVP2fPdnr0+HsbNXcUvJvUtWl1deSqgeZGOcqlCXU0LMHgicS9ExzWVdS6notmJIJ4SrjoVzW1pV5ZXVvBKyZaRMnnkHvXVQxNOur02ceNy3EYG3tla5VupXd1EtoqRp1ASoJ5FkK+XbMykenSulhv8AQFys6zOe+1+hpl3faZnFpDKygcIW5NbnAck0sduw3qVH8WO9RgW91NuO7yx/Cla0mp6VFcyQzw7XxuYOc7R1pk+oaIJFFu00cRXPmmP5M/XrUucVuzaGHqzV4xb67ES6Za3CjZdiFVGSHXv9abbae7NtS6jlGcAg1cZnMAMTRyowyGHpWDeTRWTxvtJZ2xtBxx3NNtJXZnCEpy5YrU6OXRNQlVYIMSKeSVPSsfUdHuIWISF2PTmsnWfEV1p94iabKQCuSzHOR6CltfGcsSK+ZjcdkPKk/WuuOCrSgpxjdMz547DzazAN5kAyvXdTUKMu1OE7gVWvvEutXcyTPLGiqf8AVKg2t/vetdr4e8OarrmjR6w4sFimLRLGkfQjuw9fSpzDDTy6h9YxGkdPxNcHBYysqFNrmd7Xdr21/I523uhb25jALbumOoqCG9nkd45JV2KchD/WtcabBaXctpqR+xXkRwwY8MD0IHvUM2m2SuVE67uvUA1yxkpRU1s9R1KUqc3Te60K0l/MpzEVVQOF681HHq86NvnIdj/yzxU50m5KGaApIE7qwxVC9gnkUO8HToVFUZk9vcPdZkM0ZVm+502+1bVy4tLONhbufM4ylcvCVtyG2KAegxxmr8N/OcM0+WJx5fYD1oA1Z7m48oOBIzEYEbenrWBd3E0U/wBoCtHztxuyRV2S+fBP2nzJxyCBwB6VmTXUU0h8xWVSM4PXP1oA17HXdS2gxXMgRTj1Nbv9p/abYsXaSdPmJOBzXGQy26WJ5licHjJzmr1sPNtwEBY4+Y55oA7WPxfJ9hWBCC4HzFT19q1rDX7KTSy3kpE2cYZuprzS3jNtuhlRtzcqe4qZJmeMpOxDKcpgUAemvHb3ckTyy2qL94gE5xTD5c+pGO1mjZB90KSOK85tb2K73eZK4lTgsOAaSHULqxuFENxtU9Mf1NAHqFpNqVjKzh5fJz93qorTl1Oa5YMRKjgdGT5a8s/4SjVIVVkudwLcjHAra/4SfUZkUNKiqOeB1oA7GbXbu3jCSGB2PRVT+tZi+K752JnhQHOF5xWPbeIFlgJvEDqTgsvBrWhvfD5lRmt2wB1c5NAEd3rt6IjKxhkyeMkArVdPEN3JHGhtoy7nBZTVTWbjR52cx7o8HCsBwaowQ2Plxx/bSRuByeMUAeaR+U124jkdDuP3hWpFNmQJGokbHLE4A/GsJS5uWKcfMRg9a2LNmjV87NwGQSM0AOiUsWWQhI93ABrQSd1h8pv3ePu/Lyay5rho0MzFPk5PtUD6yr5kkV5GA4GMfrWtOhUq/BFsTkluaEySTRtIAgA7k0yyMgbake6Ts2ODVWbUtNgeFrUTXJY5lDjaFHoPU11WgJf6zZm58P2EEJhz5huG4IA/hPr7UVqE6FP2tVcse70S6al0ourNU4at9PxKscV8+DkjHTtXS6Jpf2i3aa5vIISnzMTyQBXMRXl/ql41tFEx1AkqsIHOfWsu9uJYo7u0klf7S6MjIP4sVjCSnNQXXX5dzWeGqU4SnJWs7P13LOqeJbl9SFzaxs+lxttEbLhpl7k+h/lWjp/iazu51LWdxajohDb1P19K5/Srprm0it1iK28bYnlx0UjBq9p8n2Gxv7GG5iuLeQYWQx4x7qTzXs5nLAYVOFndJWt3ff8AUxy/B4vHSSglu9+y+T17I6P+04sYYCUHnOOlZes60lvZhlgL4cKMnFS2c4h0ZJdipNIu1CV3bm6AAVb0zwvrkz3en3FuqQWkf2qaedRnbgHC568mvLhyRpyxE/hhq1fWxXs37aFBuzm7Jva90t/mctfeJpxabIUaGZiNv8Qx9fWt3T7qe80wHUMRMchk7e3FVdNtoTK6GOJ4Yz8rbMgN1PXvVi01qzm1CSGAL5oyMOvytjritZ1aVeF8PBpb67/8MOth6mGqOlVa5l2ILfTbi1ZZdMYSg/eVz29RW74fhnitpkkYCZiZDjoM9qqXErx2szK8akKWBXjbVjwV4au/E9+0EN7JvA81Svr7+3tXjYmvh8DetU00Paw0MZmdB03NckXfU17C4nTcxQOnZiOKpXs7NKHxGGzjbnin+ITfeHblLDWYN43bRJCdo9uK5TxHqVzY6pFb28UYUoJORlm68V34KUcck6DTTPIxWGq4SSjWVr/O/wBxH4zguY9QTUrePzYEh2+Yv8BH/wCuvZvAPizTbX4e2ayzIsnkus646v2/HFeSrcRavoUsEkjQTyRnajD8ifrXPWTX+l2e6ePFrNlWTOSp9x2r38KqWMw0sDimknp063+88PH4WU5069L4oSUvu6fM+mPB3iTTf7Pa7G0xycLisDxVB/a8k1rbqC8p3KDxXlmmXmptpFmLRFgRBn942OnQ4q9J4m1SOyuUkjLXRZfLuVbGzB5471+VT4XrUMVOVF9Wrt9tmfqeHzjApKu2+eSV0k3rpoV9f0mTQ74WviUSqqIsnyPlNrdM+lEE1rNK8Fi6b0Awg42jtVnxW3iIW/8Aa/ii2a4tr2NNhkxkKOnTisjXtLvfB+t2uo3Yjka9gErxKMGNGAwPrgCvuMtp0MXDkw9nJRu7bNpR5vxb/A+MzKeKpyUsbL4m7a+btp5Ja/cX5oxH+8uAqBepbvVWS5a3jaUhSFP8J+b6Vd0OJvFGpwSrb3Eumxn5nYFULf3frW/488BDw+9rq2jxPHpMsf8ApEbybvLc9MA8496y9tTjXnhqkuWcUpWfW9vx1Vl1uROg4UaNZe8qja06Na/kn6WMbwR4cm8RXdzdXULeSfnAI7DtW7quiQahp89taxCMxfKBiuj+DfjG1uNIj0uSxL3cjNCJkGPkzgEj1xW7a+HLmHU7uMxsBuJ3EdRXxedQx+XYjnxseRPWOqd7Wu/x6n2uS55gcWqmHobU7LVW7/5HiUGn6nar9nhsJHMXyk54I9qn/wCEZ1e9uIri4tG8pT/qwM7R3zXtMdoVuJQqcg+nWu2v5I7TTIZLWFMMAJBt6jHNPC5zi8yxEMFRSTlfe/RXPOzXEZfkFN490nLXvtd/8E+TfFujpbWtyy27Mkfzq6dYz6H/AGa46CN4pYWlAAkGVr2L4kXduurX9pom6Ozu4lSZSc7mBPOe1O8N/CO2v7Cx1Ke+WOyEbPNDglt2Dznpjiv1fJ8JisBg4Sxktd7atpW2063vtfyPhc54gy/FV3WoRcYy2v1fe3S/n87HCaHDFLFPv2lihxmvXPhhrmn6b4S+zanyI5TLGAep9K8SWH7PqaokhCurE4PHBx/kVYn1l4v9FiPygZ/GvZxWGwmc4P2WJjeDe2qej+88qrSxWHxHPh52ktbq2mjXmtmdR8Rb2LXdak1CaIb3+7t42+ld14c8KaTqHhHTr8QiaWRSkzty2/3rxAahcP5Qu8hZMMrDkYr6J8OWNx4b8EpakCS4usTBFOSigZyfTrXy3HDw6ydewkouMoqKVl5NeiWvyPa4XWKwmZ0aUbu/Nfe1rXu/nbfucDr/AITmsJmuNHypTlov4WHuK5yHXFnvBBKq2r7c4/vHOCMV7joqQX0Vy0zoHji8x9x4Ueprxzx7D4elt7ldP2PrHnqYrmFjsZf4tx6DHrXxfDWMrVp+xxCfI9FK2idr6v8Arc+24hpUKik6VvbQs2lu4t2vbyfXtcqwRX+pSX39mWsbpapucMmS30rDME7RtdOQQGw6AYGPYV1fwg16/wBG8RPZyRJeJeKBKpTJxnGBWv8AFGXTbXxbcQwsoMv7yVFH3SRnBFexjqWKwsY1fijJ3Tjqkl30Wrd7bo83Ka+CxOMlgKsFCUYX97dyb6ei9H8jgJYY0cLHyzDI2nrVNAVlU+YZYs8rjvWvqJ0ubSrcWNuV1CCRsyDPzoaoTIl3MxtE4RQzFeCMdcCrhiPaKDit73vpa3n6akyylU3VjKesbWtre+2i+4pXg3ptdNoJ+XJxitLS5o7YIvzgsMfuuWpLLSH164u03ApaqGVcYJz3rf8ABOiX1rfZ1CzlFumRFMy/KR6Zr0cxw0sFgPrrafl67HmZV7LH5gsC3Z9e+1ygL6AnJHmScjY4O4VX8xWkSPLJETlsjkV2PiHwxbiwuLsEpMil8jiuSUrPamRJFaQjDBemR1FeRl+PjjYOUVtuepnOUrLpx5ZXUr276EoNqZGFuWlJ4bAwBVO6miin2JnI9eakhimjOY0yH4wOKR7PyZ1eeNge5XnFd54pZjvIGjVTgOeuBnP1qzaS286NKGlMinbtxwBWbcKix+bECjjoSvX61B9uuobwWjxvb3G0Pgr94EZz+tVGEpXstg2Ny5eJ4WCgxSL9wkY3VJFtWyRZonE7nnDdqxZTc3E0bXJK7f4h3p19e3NpKpgdWA7jkipA2Lx4oAkagEewqpAGlmDyovUYANc/e6lc3M2Xc5A4HrUK6iT5YUSK+8Akn3oAzmnUyssQzJuIBPaleGYk5mY7uCM8Vq2NgjXTsVAyTUr2oSWTf0HSvuMJlNKhHVXbPIq468rIyYLKJj05FKIXJZFH4Vet4wshOc+tKuFnLA9a9BUopGLrO7MaaDy22/xHivW/gtY6rPpeqrDG8lsm1iCMYPPT1rg9G09dS1uCNz8hcbq+ntR0aLw74Mso9NfyTNLH5jjj5e+a+X4nw8K+GjgnJxlWkox7ae87+SSb3Wxths8eWYiNaMFLkTk79Oi+bbS8rnj/AIktbfQ/7Q1CMPaeIowj2zZxnJ+bj6V5pdSvfXA34F5MxkeUcHmvZ/2hNFmRrDVLZztZPLwwyHHUH6814za+YbqN/KdQqYy3fmvPyHLcTFUY1/ehHms12v130bV7dNj18bnWFzGnPF4dOE58vNF/zJW006X+d79SJLq906F7aLHk5JOR1z1FPt5Y2AAkiy44Vjkj8Kk1QgKc/Wl0fS7i6QzpbHDEeXIR/nivUznAYenH2uz/ADucuCxdZxcU7JmppF07ahYxXcu6COQN7Z7V7D428dafpl/c2CTCfz7PyFYkEK7AYz7V489kkVylndtsncBhgEcdqp6mba3uRHbB577A+dvmEfpmvmsLg/b4iad5KcHGy82tb9PP1PQxcoSoYfnVpUp86fR6f5o6OPyLaCOwjdVmmy2O5Pv9axItJj0+/Zi7B2ztBGAv0qXUks7HVLMWd4144CPKxXBV8cj8KsPOt2x8yXZ7MORTpzqU+am049GvQ0xVOC5KkZc3Mua/qWoLSOTOB5jDrk5De1dX8KdbtfDfiqaO4ikijvIvJjZELbXLDH09K5W3Ih2CCdFPtXN63qd7HqSzIZImtH3BkbBY5+9nt7GtsPgo4yooTWiab+TT/M4q05KjOnF25k1u+qa6dj6T8faRp+sXm66dfmcLwf61zE3hrwPoWk6nNcag91LExch33tux0rzXTtS1PVbdAuptsT59wb94G981R1zSjMIZLPzN7OBKC3EgzyT/AJ714WR5O8NCrhMbN8krbOzVnfrtfY9jN8W5fVZ4GrrSve60d0lb5a/Mm0+GO6cXUG545yQvykBRk1qrpjW83mtIhC98dadJJLAqpAsZhRcIo4rD/t4w7lnhLM8m0FB9we9eukrqMfkefLnq81V9N/mX5AyDcfn+bPHatfwRpj+KPFUNtHLBtth5wQnDSHpx64rFi1S0nyGgcoeAc96i8OSzJ4in1Czk+z/Z28tQGxx61vRyyWaKWHjLlunr2+RhLMZZYvrUIpyjsntc+gfFupaBaaabO7WK5uYVK/ZyNyhiOv4V82eM9Yu9c10xvyqLsAJ6KOK1PEmvn+0Xd5DJO56Dkk1R0q2tkkGoavIYppiVWIjJVfU+n417kMHh+H8E6dKd5u123dt2S+S02PDwFLEZhiFXrRvo7JLRXbk7fNtt9Sxomp6z4dtI10eeV4YpPMaAgMGz1IHrU3ibx3qGsxQwO0sszMFlhyQGI6A/StiF7ayG7KCMn7x6GnOIpNyRRRK8jbiyryx9zXk0MVThGoqlJSc921r069tD2KlFzqU6vM06e2u2/wDmyT4Nauuk+KJxqUi2EyEyMG43D+6D711fjD42S2s8p0OPMaMVUzryx75HpXC6x4cGoqHkkkWZF2b0P3R9O9Yq+D3SUSNeloY8MiMvzMff2rWSy/F144vFwUpRhypNJrffbqtNdum7OSWC+JRbSlJSdm1stv1/Poep+EviLC8dxda7sg1N5gRCn3dhHUV1HiDxlaD4falcxXKPLKGjiCNyp7g+leKzaeGUwvbo8mMgk8fnWdPrMb6Pb6VBA8C2cjyzF2y0jHHX244rwcl4ZoPNVi4J6XdlZJaaL06WXz0PbzvHrGZasPZKV4pt63iu3notX3Lseo2T+G4BEkt3q7q8j4OfLUY69z1rt/B/xDsJdIh0uRxEzLsJfgc1wWkXcAga4srPyzMCSQOTz3q7c6fBfmKVYYGbHJZcFfxr66ed3k4VIaLz1TPlsRw/Rrw5XJ3u3f1/Qo+ItOWfULiOwjgtWSYkCFyyN2Lfj7Vl2GgmWeRtQyT0GwkfjXcWfhxFUSKyeY/Oc9aeLKO137Zdzjt2ryfr9flcU7JtvTu3fTqe2qUI2W9klr2SsYllCsEBhe3V0HCqR0Faej+Krnw/Y6nFJfgXt1CIbdgN5G4gcg9MCoo5F+0DzNyKx+Y96k1CHTrhFZ7ZJjGf3eRyK41ClOpGdZX5Xf5nTGvUhSnSg7Kas/Qks/ETLMPs1yweSL7LNH/fUccinzeFrT+xdQnhiMl5GEMRZvuqD8wx7jFZEt1Fpeq2V5bWkBuxJvKSjcrADkGp7Txjf3eqSsloFilcCSJV4Ud8egFfN4nBVsK1LDSVt2r9u681p+B91hMfSzGD9vTcW7LmXXXo1rp+vqeofD7w/c6dYwX7W0SvIoHnlAWX2B7VwvxYspLXxr9tudv79FQEDGSPX1zXp1h4+0WHV00C+uFjtfKjaKcfd3lQSM15r8ZvEVvqGp2fk26s9vOyCRTlZF/hb61GTZPnP1pYu16coJt305Za216prVdHZ9T5jHZ9gK9aph8RT5al5Jaa3jopX811+RxImeGdikQVF6L2qvPfwTiSMQJBxksoxzV95UUGWRNox255qqzROjSNArICQc8HNfSvlejPLiqkV7SN7X38/XuQabrc2l3cE7L+6PyS7fvFK9T8QfE2ynt7Wy0aOeSyaJUVFT5tx68eua8iltmZuEZS3T0xXpPwY022k1K5W/sYbm2iIdpJR/qv9rPasM3rUquEp0sVFyhCV7R3d9NF1euh0ZTRVHFVcbSUfaKDs5baNPX5LcwPEWuam0s1tdZs4XUxv5/G0jqp96xbL7OIPPjaNEkzsDnaTjqcV798RtN0XU7SGKC3hl8ycTSSBeZGJ9a5r4geFtJg1HSooY4LNZLc/u8gEkLnH1rCjS/s3L6VWrTcalWVlHronut7vyvbqaQzuhxJmUsPCdqdOLbk9tLXs+3rbY8oDKkCyzTjy8/Lg/ePoKnhZpoDdG0u/sana85Qqqn6muk+GMmhw60Lm9jSTyJCyRzfdB6ZxXtmpa/oPibw/LpFhPYS3N2hVLbcuc/7vrxXJis+p4aXsXQm5J+81ayX9adLG2IyetRnGUZRdOWzu13/ACWp8yTZntLmO1lJDnbh/Y5qi+o6lNeC4tVUXUEZiZWAY474B61q2/l2V5eWsmzdFKUJJ5wOMU+3i0+F3uxdM8pyArjGM/zr6TCZhUpUXBRTUrXueficJQjXl73wXS8zah1i0XS7WO9sYjcPGPMYnBJx+lcp4sljit4Pso8t/MJO054x0reX7HIqiQRSSnkD0qnqk1pBH5ccSPMWGMrwOetZU6sac/aSV0uhnCm6jUI7vQyJIoDBFJKxhmdRlQMjNRW0OXReCxYEbwQOteiw+FLZdPW7K7nkAJ9BT5tFsrixiBKhg3FfOvPqcpe7HS59lHhL3G5VPe6djgZJzbqSCM5NUZb9pTt9apyyPdXDIpKx7iC1Okso1kIjmY8cA8Gv1TE5xRoy5L/cfm1PBX957k0V6sDNvOMgjOM444ro/Dvh+XV7Pzx0Izn0rjZLUnA3kt3rs/Dviy70TQv7N8gTW7OWSVR8249jWWFzalVqtc1r7X28/wCvIxzHDV1QX1Ze9f8AD/gGDJd3Wi6y6RcSQt1rr9Z+IHiHxHpcVi0y21umPmLDJx6VyUkxEstxcKolckkdc1q+E5rGVNRe8tBIDCUh56P2NedVx+LxNWUMJFSs9NtOl02dUcDgvdq47Sy3tfXtb1LM/iTWtWuLbS9S1KW9toFGwSHO3tWzrukNBbxSBfl25LdhWZ4c0XytEvdXuGO2Eje57egrTbxbJqdhc6Tb2StBPH5L3MvHle6j1r2qVSOXYSKnb3d0rLz0+88OvGpi8YlhF7qdm+nqcDqSS3k8otB5iwpvlIIGF9a3PDGoXumxyRIRc+ZCPswfpG3v7Y7V0VlbafBbm1FpGYSpVgOhz1yetcvZra2+oQyRtNBAsmwLId27n9K8mGZYbGVfZ4mOkmlE+i+qV4UZTw+vIrs39NZ9avgNUtxFqkcRczthY3VfT0PNU7XSpo9N1HXrqDyrMzeUkhB2ueg2k9eldV41ufD114atLdrgJfABFEfXr39sVz/iPUor+4sLOK9WbTYUU7Ax2cDB49a5cXWeTYuE6FO8Z3WvSzX59BZVB59gasqsnTlTs9t1rt8zm9JeKTULmQ8xhQNxHGauXEkLZdT8/pWoq2yRKgiUxdlSq7G3MmUhPHcCvOxmI+s1pVbWudNOHs4qPYoo5U5MTgHocU+1t7a4nMGt3L2dscuJdm7d3CH2J4rdWeNtsc21guCOxovJ7CdJYTIVG3BVhkGueFo1Izf2Wn9xvCrKEZxj9qLj6X6rzW5meLdKgstDtNZ035UMgTKN1PvV23u0XTw8yR5WPzAScAcZ61n2emQxQkRXDOjcKjtuA/Ctfw34dj13VJbS782W2ji3BI5Anzevvj0rtzfM6VV+2lFqMeqWtvTyObK8vmoqh7RN66ydl6XMTSHn1mykumkWJw5ULnG4e1QXEM8Un3GkYfe44A/rXVeJ/CL6LDDeWUzSAY3qeM1m3Ti3tZ3muV2qu/jq2OwHrXlYbHUcfepQWl9j1MfltXASUajvfqjL814FTEG6Rz8q9B+NVI/OxeRBvKkmfcueNp9/at/QpJdavLWHXprexWMeakzDYNoHII7nHSs2/aGbXPOt8yWokKow7jHBNd7nj8sxPuxsmt7XWvn3Jo0stxmEfPO9RNu1+2w7S7J9Lha7vCr3DnbuHzcdgue9WZbSW8hvLsW7RoU2qG+8cdzU6/Yp7qxS9uRb2KPve46hSBwMe9ei+DNKuNcsHme3P2aRiInwPnQHAb2rwM+x9eEXXmrxTV30u9l+B7nDtHB0rTqTtNp2Xls2eQWVzFeSOl2z+VEgWNT245rR0O5e3u3iaRp7fH7tz/AfSrvxC8LN4W1uFtQWSOzvPmidBweehqCJ7WCIRpGpQchQK6MJGVWMcUn7s1deZzZjjMNGk8HSipOL3+Zty3xWEkSRGQDGc4ql9ommCKlzEGHrVBBBIR5pcR5yVxwKtzW1msJaAnc3b+td58+SCa3hz5zqMdWJwAap6npFpfSo8hKuF5eNsFh/WqN0seV+2qzWYdTMq9Smeaba6nb2M8qRb3013Jt/N5ZVzwM966KanCHtYNp3t96+/wDCwrKT5fK/5f5m5aRpY2iiABLZBt5HJqzC5KlVGUIzt7fnWb9tlvJPsdgikg5d2GQvtUUT3g1CG1lKSISciMYKj+9+FcEsVT9p7Nv3j0oZViZYf6zy2gbm9mMeJWQ9PpTNUkj02KWZS8mwDI/vE9OfSsXV5rmwVpYyWXgAsOBmsiS/uJrZGmYeW8m1ifarqVFFO29jLC4WVaUG17rdv6+RZur3Urq3JnmEUagjbGNuQfX1qvtttgxM2zALDd3q7bxSaoBEB5UAPzs3BI9hWtLpWkIYxFAqyKQSWzjiuCFGtWXNN2PpMRj8DgJeyowUu/qcxLbyRwpcJBL5THCsec/hWtoTj+zr14mxIM5HeuhlMdwFD+UYR0K8VjXWEvFuE2xQhSkoUdvXHc08TgXKHuav8zLLs+Xtkq6UYu+q6HMXkdxMEkO9XL71I7dqZcR3F04N3LMxjxgYrTfVBaXUNnBFHJAuG3OpLyE88HsO1S3es2z6g1pDGd/TcBwD6V7tGeJoUfYQbUbXt5M+ZxajWrPES1u3ZlZQWiRHkbccAE8Y9K2F08xWx3yGSRmyTjpWTqN1Ha+WZ0JZv4QOTSW2qfaJtmWjk7BztGPrXOsNOS9qo6LqT7eSh7Hm0etvM1JNKlmTas+D2DcVk3kWq6NHNPDPJHBLhJACef8A61aqvdJOVv2Bif7pWkuop/IMbSGSJ8/KOTitcNiJYeoqkTGpBVIuMtjr9K8df2B4Nsf7U09L+9dWnRmfJ2qcAnH3ea8/8QeK9Y1+8XUL2QNJlpItq4VC3XH4VFbWrWjZDSEFdu2Q5GPSiWGeWTC7Np7dhRUqJYj6xGTlJSbi5fZutkun62uFGnSo03To01BSSUuW/vWd7u/9dNjnPPvImY+YwZjye5p1u0sObqNnjljORJGcEGtueIwI/wBptg6dA2OKpXE6eUFjjUL0ZaiFVxq+169baGkpSnBU5O6Wy6GczyPmSQsxZixcnkmpldpBjD7R6VatLB7xwGYJj7o7AVovoxjnESyZbYXJ6Aj0z61niKyvKrI0w2HnXmqVJXbK2nTsqMygmQcCrlvFLLcwXNwXESOAyno3NWLDTVjEchOA4B59avmzldZoGTdE3IP+FRJOUGl1X5lYefsK8ZyXwtP7melS63oCaXBai8bzBbl5AwAw4H3VrxxtWuJ7glbhliL5C5wcZrci0dGt9gXdIfvM3LVUm8LQ28scjzqoZgcZ5PPpXl4DKKOEi+b3pN31PZx+f168nGg3GH4/f+hyklldJcEEN94n5e/NMuZJIpCMH8e9d3qGijS/MP2yNoCT+8DZFcvceXG/8Mqnox5r1jwLO1zKRtqBsnb6dab9tmiYeWAozwB3rUzatGV8rYB3BrLvPKEgEZBHrQIvFnuICzq3AJOPWt7QUgj0kFWBYjLH3rnLTfGuRLkHooPWrUNvMXKLN5UDHJAPNe1k2OpYSU3V6o4sdhpYiKjF21Naz1m+e1vtJimVLCQq0gboSDxT7G4Cjy2cSOD1xyayYYhCWWMBkB5Oc5qa2lAkLOoxn6V5+OrrE15VkrXOqjD2VNU1sjrYooJpVJcoByV3cGm3ml6Xsu7i4clGjJZQemOdy+9cvPqAMmxfvCqN/cPdxbFmJCnlOgJ9KxpRTnG7trv2NFOUU+XqWdQm0RrILpq30t/u3CaY4wPQ+oo0vVoY4khWxElwPlJz97nr7VjmKTdvfKJjseaY8sSbXhDIw7g9a9uviMJpSqNyV73OaKqK7jpodaNVEkhia3+zTqOF3ZDCqVzfXTyLHGFRfUVgG6Zp0kkfeR0z1FXTdiWMyBThflJHrXlYuNFT5sP8P5G1GNSSs1qaUoaPDTTMRjrmhZo1VGS6znggiso3LNEBnKjr6Ui+XHGDwN36Vy7FHYW80CAbdjrjBJ4INQz291byNqVrNNGYApLI3ysM/wD16wLZyseHYlQeBW/YTpPE9sC7Iw6Z4xVRnOF3B2ew48vMnNXSex32la1Z6xp96dVbFvaWrTOA2CxHQD3zXC6HGlxp2p3eriO6iaNlgWTjyyejDHeo7/Qi1pGtnK6BSWfcCd3p+VYyxaqbYacsTGNnA8wcLj6118N5fgcFTqe1s3LWz6W7fnp+hvxHmGIzKrF0G4xWn46v56Isa3L/AGzeWVvZsxwoR3AyFHqa2hafZYYbSMqY4hhsc59/rWraWMem2vkQhNj4BCgZ/Gq5t0acSQRnaOCCeprTMMwljZ3tZLoefhsPHDwUIkMEUUkLL9lDRDKsCPvVb8H+LtR8E3bC2jnm0dsF4t27aQf061div7eC2HmwkFeMKc81RmdJLrdgRxnnOO9cdKqoaSipR7Pb/h/MutRjWg4S6/8ADnb+J/Hnhn4gaN/Zmo2hs5xkwPMctGfUdK863SaCwsdThkSdD8jyJwyHlTn3FMvD9s1FYEMRZE5laMFs+nNa3iWY22gqbtluZ3j8sPLyQO2PpXnYjH4XB0qeBwNHlSeurfS2jevrc97KOGq1bnxeJrNwa0XZ3v22IWxcNv8AkJYc4Py4qHz4FdlSFkRRgsOh965qDUW8mBEyoVdvSmX2ozCNo1GAwwa6lJSV0eXUpSpz5Z6f5dzRP2i9mZ4ZSkIOEAGOPevW/hx8P9L8R+GbmXVZoprtP9SicfZT2OBXl3hi9t54JFlZI2jjz83GfpUGgeL9Q8P3mpjTJgBfL5b7ieMHgr714rnjak5rDz5Jxs1dXTad0tdk+/yPp81weCWBp+z+0+XmTs0no3pv6HoPjDQtO8GSKtrM0+9PnkY5Z3+navMbkagl4L5PMgVztDdxn1+tWbjV7/UL+3uNRlaVYzkEdvrVfUdQu9QlwjbbfdlVY4Bx3zVYTCVaUXUxEr1Jdu5c8dGpCGFoe9SglzN9loaU2m3V3GhvLmSUheAelZqo9lZb2Uz7neOJVGfKP96tu21m3W2TzHw+3BB7V13hfwnaavpMupQSyJMpDAIcbjnpXLDM1gp+1xcXKN/xPWxuXUq1BRwslDztfR6fruedWs+rRxo88ZuYc5cgYkI9M10glS1uYre7lFtcyqGW3uB82D0r1bxZaWUWn6fHNbwpqBiBlEaBQfTIHevGfijG6a3pskqfNIykE9SARX6HSw+HzPCwxtKLpqUb2/L5fnpsfjlPNJwx88BO0uVtcyemnY0TaJcIY5B5Q3cMDwaJtPaIqruAuPvLTdXuLaEqZS0Tr8wUHO4+gFZDC6ksX1B55hIG3hC3AA7Y6V8xWxMKNubqfYYHK62NUnDRJdTdSxHkxzBY2ePgMVyRXPReH5rbXZb55Fb5iwQLnrW3Bqsc0KzSBk8xQQvYVEt8QrlW2KepAyWrshVlBNRe6sea462fQwPE5Vby0u2VNq5jf1BqSSzstTUDcpYdMVq3DR3B8t0idhzlh1/CsK8tI7CRZ9PR/NjbdIueGX2r38pzWFKKw9VaX3/zPOxmElVftKbs0Wbb7Xp06wT4exJ2K7dUz0/Cr8MmZm8p1wowXNY2pazHqECxKGVmwcH1rpvDemRatpyWs8e6VlKCQcHk5/nXXjMmp4io6lGSiv1ucf8Aac8LRUsRHr+BzOupIGgiY7Q0qh2zyMntWn4stYPDeoLDZTC/SYRtuLcgsuSuemc13niT4TPpfgae4tbqa61KSRCsTfdRDwc55yOorzv/AIRfV7O3N1f2v/Ets02SOOcFuAa8JUOelzx1jTlJN7czskrdfi0T69NNT0sLmOHqy5YzV5padVre/rbp566otXjiGSK3nHntKu5YlGSoAySR6URaLYXEazxRsXPUdq0/hvq+kr4pnfVpU8sW8kImBGWVlxgH1FUNAvvtUU8dlIFeBirsw6jJwR+Arnq4SrThGo4+60tfO70t6W+82hXpyqTpJ+9F/JprRp+tyzHoMIKlV2gDhCapzWKIfnXeqkgAE8VOEnlnYyhiM53A9a0g8Yjw4VF6A9/xrlaT0ZvGUoPmi7MpaZbxzHaG8pFHRueK2mtxJaFbdgGXoazblZMB4ghUcDHeoP7TW0ZCy/MvVSeaZO5FeyyRK628reaPvDGKxF82R99ysrzbhsYngDPStrVdainjEyRCNj6D+dc+0sdxcLne0mQePrWdSmpqzZ04XEvDSckk7q2pktqk7+ZE7Fo9xyCferdtc+WucBkZSCpGawSxjnYZG0se1aEQlCF4jwO2ODTlC7T7BRxHs6c6bV1Jfc+5Ru5z5jZGATxjtUOQrDIIHqauXcjbMtGorO8wswVulWcxq208Yxx+PX8qvWjIzMMSAZwTiqen3MVldRSyRh1HUVYvL77ReTTw/u1kbIX04rulh6Kwirc3vt7GPPP2vJy6W3LrNbQgrC7kjnBFZsty6SEqmfQ4qGeWby2JPI79zVOGbdlmc7hXCbFuR5Tg7cE/hUbGRh8vc5OOuaSG4lmLKg3j9aWNJ45PuNk9c0XASQYjxuY/Wq5aRiMIWA6GtaO3RojvKK596z3iaFmAcbR6GgBsQJkGVxU8zbYwkSsq55qrk7wAc5rd0trUER3r5FA02tUZdqj55DhO/FXY7U3P3lOxenFaqvpyT4QMwPA9BWvaXVmIVTeu5euR1oEYNnaSB13khR2rVt/LgyWLAdyB0qxelZVYW8kJ9e1ZDWchiIM5Xd020AdE8r3UCSQOy4HIU9aoSuGG2SYK7fwjqKw3SeFhGJHEi/3e9UpZSJCzBjL0JPagDpYbrDLulcBTySegq3c3b28Uvl3LESDIYVz1jJGIWLvukxk+lMlkuG2GEr5bdyelAAmoXL3Gwu8hznHY1vLq8UEe2eNvMYc+wrlkikjl8xpQpzyBUlzctJhN25h7dRQBr3GqYvkuIfmQIEA/xpuua6dRgghdCuw81gEzAY8wKgqQuGUbTtzxurmlhKc6iqtao9SlnGIpYd4aL91q3mXYhvhOJECqTweM1SMc7uQnIHU9aeY08naZFO30OKqLLL521WKkdMd63jFR2OCtXnWac3eysTlMEZ3Kc0ksjAYCrle9XTO5t2XOSoyc8113gXwTe65dub+3aO3S3M6OBw+MYH61q4VPYzrJXjBXfpuYxnTVWFKpLl5mkvm7FHw94e1DVo7cqHaBz8+BwBWr8RNGtdLtbe1tn/fnhgo5r6D0zR7LQ/DUNvEgEcW2QMRyxI5r588eRs/jC6u5BI1s5LIV5C18ZhcbXxOYqNR8qilJed0mvwZ9xQxGHqYCt9Up3irxem7T5W++6Mu10iOOFFk+cHGd/Vq3fDvi288LrJZ2cNvLbM2/NwxHlkHOBjkiq1u008AEGmX0isAQ5TGfpmseWCW61Sa2j026Dxg+Z5i4IAHpX1c8PRxvPTqRUuVNyT6eflb8z5SEsVhIxlG8VO1v721v0O80LxdDr2uvL4nuYrWOFd7yg/LL7IPX2rE+IniLRPE+rWMtvbyW8FkhSM9fM54Y/lXKxxSNJ5M1uFC9MdaurCUwrxnZ03EZOPauqpjK2IlCcZ2hFWUVon5v9Ox5sMowuAnNOl+9vu3fl8l69b3Ev1LxJcRS/aHjOSvfBqa4nub7T44ILWSNW+8zDAAqKSNE5TCbegIwTUS6i6bhPnaei5rgq4SnVmpy3R7mEzivhKLoU7Wf4GyCsdlCrRL5ajYmPvVQEEqJIqASFznBPIqE36tFGqPg55A5wKjhvJF82UByoPymuo8ncsTRSQyq+0sAPxFPlMP2XzPMLzMeVNVRdS+eNw3B/U9KqvFNJLkEsUORg0AS63bxS2imWRY7n7yEDp7fSt/wJ4tj8L2pS+0+C6fduhuGYjH4Vz6zozA3asCfQZqeWFHO9kDqegz0rSdes6EsPGbin2dn961CFOg6inXpqaXR7H0RoPimLxv4QnmTAvIpRG6KuCcjIx6jFZ+sWG3Q2tbtcxufnVvSvFNA8R3WgajDNbvIkIbcYlPyluxx69qn1PxZ4gvPtdwb0yi4YuA64EYPYelacP1o4C+Dm2oRs4t677r0T1Xk7dDwuIeHZYyccxwsoxc27xWlmtn816a+pk+IdDtNP8Wi1h2SQXAIx/c4zxWjaad9gJaGMBG4YoO1YtvBKZReXchnvH6eij29617O5nPUqsfqT3rqzPEwr1m6T93833PTwdKdGjGFV3kupshopQFWRk2jJLDAqAzpJKdgjcY2qR3rPMshkZnlVgR2qaO4R7XYBkqedowBXmnUST2TK3mJON4HKZ4rEv5y5MTBQx/OtaS3SYFLU53dctms29sXhjy0qkjue1AGW0MSuw81947HpUEJUy8YWQMMfnUl3GAqtu3sex4qCS5UGNDHyWHOPegDMmuIZJmdYyuGPvmrEV1boMklx/Ep4IrH87YzqM7tx+lb+jLp1wi/bIz5o9+tAF6O+0k22JNPck/xFqwL5YnlaS3gKqOAOtdm2lWHkebCpdR1BPT8K5vV0SFgYyVz2xQBjmCQqHkjIWo0Yxn7vHvU0t1KwCk5j9KahZwcLge5oAR5iWBFJHGMs2fwNNWIx/MwP0rS02xGpXK28PykjJJrbD0J4ioqVPdkVKkacXOWyK9vI6MGj+XHpVmfUZyNsgznvioJbcWd1JEz5ZTj61EfMyfMBZe3FKtSlRm6c90OMlNKS2ZJMYXhDEky/wCz0qFmHAIJq1bpEZMNhfYVM6xLIQg3HHWsijNiADNnipYlQsQrMD15qeaHbF2XPbvVaIAYAYk9xQBOZEQkK5LewqxHfRrbjcAzDv3qi6uMAgbSetSwJ5hxIuV/2RzQBK08kkuVJUetb2nQF1VpJmkkXkbfT6VUtdGkumURcKRkEmpbiwutODMkmCP4gaAN954rePbKsbMR94jmubuSpkJRV3Oemc1UZpZiDK8jXW7hT02Y60u7y3DNtyOK3rUXR5bu90n94ovmV/Oxdjl8+MRyRquTglR1qKWJUcxAsTngVHHNHsdi2CvzFR1P0qy8ols0YRMjvz15rGztfoU0rJ3Kl3YtncJSR/FmqzfunXbjb61enkBtSNzkjjnjNZkpyAIznPHPakIfPLE0fLKT7cVAqblBU9egzUckKI/zHLCp4FjIKlQjHvmgBwYxMA4B/WpIv3shYgjHT0pGRFPDHip44SULAlM9fQ0AJ5MgLCNlyw719V+BLO51DwvoohPlRx2qxy7+Oc+3Wvl3T7ZTKTK4YjtntXr/AMDbzVNS8YPZz3dxJp9pF+7Vjwqdh+dcePy95jQdGpV9nSjecna791Pb72Esb9QpvE0oc1bRRvt72/zvax69PBeXENxYNkpEPkJrk5NCS3t/LvIFd2/vCvTPtYhu4IHA3Skrn1A7VzvjrV9K07T7a9vZFiQy+WCe5r81zDLcVlWKjhn73PquXqrtJ/O1z6Xh3iSOZRfso8quk/8AFa5Jp62Wh2cL3iIfNUZJGdigVzI8U+ELnxDfXF/d28JSLy/m43r0z9a434rfEeHU9ITTNAKCRl/eTk9F9K8VjiKwF3DS7j8xJzz7e1fouT5bgYZWq3K1XqR5Zd7N+9f12XW1j5HHUMwrZlOWNm1CE+aKXkvdfXb8Xc7TXrhB411B4QhspB5lof8AYPT+VVTfOk2wIwx+RrnECRshXcX7726D0HtVk6j5hVGAypwMdDXpyhSg+SgmoKySertY65VKlW06zvPq9rvuaV9unG6RgjdgOxrBvZ2QnzPvAck9K27aRZMIrrvP3ielY+qRI0siI6vhsPj19KViStBdZxvAVT/EvetTTsTNxO3lg8p1rEiKx7t0Z2qeBnipVu2t3eSLgN0C0gN+5S4Er+UoYRKCfXBqrpe8LI+WZJX24/i4pmiatH9uBvFJhYbX55b61b068iR5QihY952nqSPauWEputKMtlqj2K9OgsBCrS+J6S+XUtmJTE29x8vGD1pscA2oVPzno1O8qMs7uu1G7E806KFgRtI2qMgnoK6jxyhcRPDcYbEjjksBwKg+1YLqFbyzycVbeKcGSRpF8p/vdqjsbRL7XNMtGkdLa4nCPg4JFa0aTrTVOO7IqVFSg5y2WpUS8ImOCXiPA/2a0gPPQF9rRDrt4Ndr8QfBFpoOmi8tZSjgfdx19q4a2Sa2KkhVDjOc9a8zAY+njqbqU+mh6mYZe8G4vm5oy1TLbwIqKyEN6g1YiVIkDSK4TvsqjGG8+MhwVzWnJkDaHx/tdjXcecVrx0RfMiJhz0IOM1TjmeWMpOQ4zndU+oQmQKpOf9odKoXTtGoiiB3EgAg8Gk2krsqEJVJKEd2UNTKiNpA2GHAHamXlnLZRWTt+8SfDFh0HPT612t78LdUPhltZlvbbaY/NECtz/u/Wug8M6LY6t8OWvdTjAlUlLdc/MHUjJ+ldVPF5bSwc8RVqKbVrKL110Sf6rpa5HsMZPEwoU6bSlJxbadlbVv5d9jwu4tijyc/xHGaiR3VweQRXpKeEpNVLtHJEkmSNp4xWTq3gfUrJCzxiRF/iXmuYZjW2ozRpsWQrx3PWneb56ZuD5jelK2j3cSqWgxnpuFPjsXiHnSRP1wcDIoAqNYgIWELkHke1NWInCtGIveugScLAVKnbjJDcGqLRxSgy/MF9+1AGc0DlhkOU9cVLGUhIa3d45xxuArQgjljX5CGjbp3FQmzYSb3I9xV06kqUlODs0KUVJWZClojzgpJulbk76uLpc8h2Fhj1FV5SrkFIwCOnPJq3BeGCPYqMjnqSc0pzlOTlJ3bBK2iGNpDwjIBbPbvUAsy96LUqY0GHc55FXLi/YrHDC5kmkOMk9DVq7sRpejzyzOWuZOpJ5Ne3k2A9rL6xUXur8TixmJVNKnF+9LY5zUoF+2OlqSyIOpNVfJclTuXcOeaWJmSP73J6g1GSBlj1HrXm42vHEVnOCsjqpQcIqLdy0GZ0wcAj0qS1RkJfcVJ6VWti2MhsAn0rQwgUOrg+v1rkNC4kuoJbGaHIj7H0qo17IwDTSlyOSpqTz5VtRG0pVG4x2xWc0YiZvmDqehFZ0/aa8/yOvFfVrR+r321v3H3WoPPKW4yBjPcCqkTtM3zfORwM1JPHuIYIAO5z1qKOD5iQTkdq0OQljYwzBznd/dHNakE6u3mOwzjgGseVZElUhDiplSVmyQAuOKANNJEeI7gSucH3qjcoA525Cj161as5GjP77AB6ccVNiKRiZGEhI4AoAy42EqY2jI71J5W5ei8d6tJDAo2hMMT1q1FAryIGjyp4z0oAwpgwcKDj3FaFqzYAZwQPXpWm2iiFnYKSAM5J4FZU0SRyYEhy35UARzsFkLK/zn07V6f8BdbNlrU8clx5azY3Du2OgrykQpuYNISKtaddPp17DcQPsdDng/erizHCvF4adBP4kd2W16dDERnWV47el+vyPuO1zqjW9yFUPCzHj3FeKftCXlrJBp+k/Ol7DKZuR8pWqvh34wSPpH2VYmjvEGUcfx+1eb+OfFtx4n1qG5mXLhMfTnrXzGQ4PMqePpuorKlGUb31afM9fvdvQ7sVleEw9GtXUk41JJxS/mVldeWmvqUobRHJVX2yHn2o8vyrZnllBdHwYsfeHrSAhkLvmM49OtOYpuQsBt/ifqa+wqQlJLldjzsLXp0pSdWHMmrenmPKwXcQKrxjFZckBiYiNhx1FT6e3lXFwZJQozgDGN3virEBguCVdsKDy1b1IqEnFO5yu1k0JZNEq5kVhIOnNJfE2xiEJieW5bLYGRn6VdjtYY4hMANpOAc5JqS2jtZnQsirtPEhH3adOahK7V0IxGtxOgQcSMPmA9aotbTQs6phgtdtBLDCTHG8T5PMmzmk1C1tZ4ZZI9okI6rx+lZgcba7woTYNp6lq04o2yGQr5KDOB1zUEkDwSccIBk5Oc1LZhyH2NgDnbQBoQT+bHl9zHHGetDTnygfPXYOsXeqBuytwEcFjjqoxUckCiVZCxLt29KAJrm5lVvMeNih6A9Pwqyku97e8tm23MDBo1A71QE0jAJI4ZQeAKSeby5MlicdCBV06kqclODs0DUZaSV127nX+IPEuq62IzrTJIkYABi4DN6kViSJMUyXJJOazP7S2oAcup/hzyKmtdSiQlUYgf7XJrnpUKdFctOKS30Nq2IqV+X2jvypJeiNUZ+Qu0aleeBUt3dsIy0e057NWf5/2kEFwinp6tTPKcyLHJG7t/CgPb61pKSirvYilSnVmoU1ds0IrtmhKzxiPjNM0XRr3WmP9k28kiZ5kKkg/T6VqeHfC174g1CC0ksbhbR2AkdW5A9RX0r4b0jTvCelwadbEAW4JEjcHJ+9j2Ncsq0cXGVDBzTqq2nRRbs23+gsbif7BqU62PpNxd7K9tUtPxMDQfCrT+FLSG+nCOQAQ/U1kePNIt/D+geVbBY8DoOM1Y8S+PdDs9Zj+2XTrbRtt2oM4PsK8r+IfjO68Xasv2VHis42wBnlh9K+bxXCmKwdWhzSblK8p/yrXRL+vM9bIuLK2Y1a1esuSjF+73k3f+r9CKW+ia6IUSxpnlkHWtWWDzrImC9kYEfdavMYtZZLoskp6nIYcVpW+uMN7pMzSMOhGBX1545s/YXdmlhn84LwyselM+1OQYmEUYHT0NZkGqSSJIQyL6jPWs6XzZHSV51ChsiOgDfiiivozE8YMmeCK1E8PItuigAjuSK5u01WWK4UJFtbttro9P8AEM/nqkgRkPtQBDNoCR5B2t3HbFY2qaW4AWKEjPcHpXYLqFncTt9pZctxhRWzomlWWoq7IspHQFhkCgDxcxvFM0RB2/3gvSoruIxxPIrEkY5Ne8j4erPPxPHGGHC461yHxK8IReGPD4aUb5rycRRkdEPXJ/AVthoe0qxja92iZOybOd8KeHUuJopmBc/eJq/8S7aOPTYXVcEOF+tX/COo21lF5ckq4A9ah125t/FGq2tlB5n2SJxJcyoP9Wo/rX3uJcaNKV9IpHxVF4ivmMW07J/gedNGrIVEZJPf0quLdh8qR7h717Ld6f4ZNqfsySLc5+XJ61Vbw9FLAJI7ZvzFfnh9ueWRWrvCflbjrinQ6e+4fNgntXX6hpU1vMz20JizxhuQa52eC7Sfe+5RnnAoAelmFVVkYsR2PSs65EcbsijYnv3q8zXUYYZLA9iKryRl5FZlHT60AU8K5C4GBViMgSbYdu7vu7UxoYkc72KO3QigqIxI0TcepoAv3gieFS7I7gY2g1BZW3nYjZcMf4s/zqqI98asowx6471LBeiEOzRyMMYB6VrSoVK1/Zq9hOSW5otAlufLc7yf4uwpixwK2+LBYnBzVadxlWG8J3zT/MjRhyGHfPashlpAizHcgHGQBzT5zvsJ9v3tvAAqst3CZQVbgDniopr7YreWGOenvTi+VpgOurm4fMbTbgACVU1WS0e8cBDgKOafbDLmUkJJjketWYbh4wxKj0+UYodugED6PKYy0Zy2O/pVRoUDRh0IA61sPcuRtVyeOG7CqUPmPITJhtvTikBLYyPaOlxp7KZEb+NcjpgjFLY2jyfaXnjVDgFAPWnRRRnL5K9uD3q7ryvZaJYTW+oJI1yreZGqjMeDjrXbhXWqp4amtJbu3bu/yuTPlj+8k9Vote/ZfmN8s3NuXjkR9nDBT901QaR4sEqDnjaRUFgdhkdFdUKBeONxq0YpLjG1vnx27VliqMaNV04u9ghLmVyGbDRq5Bc57HpSA+QS0bDB6qw5oNpgHZJz/FWdIkivlnyO2e9c5RrG8YDafunoF6CktZCt4jeZv3dE7VkJcMHCMCD61OnmK+6PO496AOjnEyPlnCgc5UcGsm8vWYF42ZSTh8GmreyGDyjnn19ag8tycu3U446GgAF074iDded5NTWs5inYmQYHb1qOO1gO/MbE5656VVuI2jZUbjn71AG1PJnbMi/M3oOgrPlY+Q5DNnOQT1p8bfu8rIMLwaiLoCu0FgetAFIXEsXzfxHmp4LmSWNgoG89Same0UAsrc479qgjYpxkegoAcsLsvmFlCj86mEH3XjK4PXd1NMkjaFVaMbieoqa3YSTobhdqgcAetA0r6IuQwBRvDkkcnPatzwnpV1ruvW1rCsm4/NjuRUXh3Rpr2/EksbiJecHvXvWgeGLbQLS31ywDLq1xGYlyeAh9B2NeXVxH1uusBQklKSdnurpX1t08z2ayhw/gf7VxUW2mko7b6f15HbeD9Og0O2jtZGRrhgOB/D9a8d+P2oa9pniFjYkppu1SpBOc45zXq+j6bcqBd3DbX6sznAFeM/G3xpa6xdfYdPHmpETG7ryNw64PesqGXTyDGRq5ZV529KqdnvdqVumzS/Pv8xk+OjxLiKk84pWjZyhKzSW2ieze3+Xby+Fp7+4kvLh0Zmw2G7Z71NBIYJ+BkkgBgelUIblYvNQISp6jrT0uDJJFs3EBgMY9696tXnXm6lTdnbyQppQp/CjFuF2St85I3GpPtMqqq8Ff5VrTaMRFIxIZmY4welZU9pJa4RlYgc5ArIC1azxxglVzxzQJRJIjIDubgc9KqNDJsU8qp7UhR4ZFYcJ7UAa9ou28LmQBh1A710llfw29xE8wLDPzDHOK4uO8ih3ZjbJ535rRtL4SKJAqtJ6nqKAPSLwabOsbWyRws3IBODW54cvZYU+zwyANnB/umvI/7UBlUylxt/u1tWevRRtG0QlTPyk+lAHu503WJVjuP3LooyGV+1Ra/wCHYfEulra67FM9vuDqwbBRvUGvPrLxlNZW3lRu8y9BluMVo2/jaW9mW2T92qcl85FOMnF3W4Db74UeHbeNzbT3jSYyFM5Fc2fDNzpiGGz/AHEBOTubJc+5716KdZhntETdBPIOdxOCaW4v9Kby1kkjWcfwsM4rWeIq1Fyzk2hKKWyPLY9Fvt5URfL13L1zTXj8QRrgM/lg9h2r1WS3imlR1Cof9k8NUlssP2o2+NhP3jtyDWIzx2Wee+kiXUBcSwJnART971NJpHmWuqEw2UzWrg+aJ4ztx2Iz3r3HUtHt9qi3hj+Ycsv9ax9W05oEQCQRDoQ3zLXP9X/e+15n6dD1I5m1hPqvIvXqeRa60SgBbMJk/eBrKlgSILKFfH5816hruho5jkcJJt7R9qxr3SoYISXgxu5HrXQeWedXjSSP80CEY5bHNZZ3bSBjcp6HivRZraAmRFtuQNxDcYrJbR1u5wjGNM8hh6+lAHMRSSRbQzLzz0p9vp882Fkz5YOQAOv1roW8LS+aTgF1PAB4apptGvrZXmeOVUK4Y+hFbUsRUopqm7X3JcVLc525tJQcP90Dp2qt9m2gB3U+1aUyzSAoZcg9AetQ29k08mydQAO696xKKaW+1Mo4Vc5OetK0pUKHUBB0wOTWv/YwIRpXOzPGahdUg3FUEi54HpQBDBDHOd0alXPGD3rX022g8wiZc54xiqHnrKmY4wmOvtVjT76MPywUr3NAF+8t7eDckIDKO1Zk6wRRlUYg9TjtVy7uXkhYkxMh6MOprIkZ4HSWXDRn+DrQBAf9aGSQk/Tio57Fn2EM5UnJI5FW7i/skI3wurYzhOlP8NXZmuLnzgmwAMinoK7KMa9KDrQ0X5kPlbsxJVURqLZD8pAI9u9MdxGcxMUcnk1uuI7iLzUCxMPQcGsO8W4jOPK+U+vOa5G7lkc0pnG0kApzkd6zZxKRvYblPAzV2JWK5kjKknrUxR0bKR7l7554pAZCRSFyzYIA6VcVWRF2q2GOCSK19NtYZpssmEPcniuhXSLeS1zDMqqOoUZ5oA42KykeYCFN/bnrmkm03UFlb92Qw9eldYkX2AsxiXDfxU03CS3J82Q8jjPQUAcoLC9U8xuFbljitE6PcTxxM8ZbPRU61bstcmmuBDdKuyXPlbf4cdjXW6Jexw3EckaxHZywP8X0ravQnQly1FZkxkpK6POrywkhfDwujDgD0qeyRGi8qVG3g8E8V7Dd3eiapFIXjSKRBlgV71zklxp2xsWCkLwHC9R61iUcNd2jxKGZSyHrgcGsuayJZSkbAnr7V6Smt2MlsLa4tIjEDgOq81l3s9izFLaMBe59aAOXtbNYlLRtuUD58/0q94f059UvVjjBCowOccmjUrcCPMTkcZGK7L4fixs4DdSSAuAC2a8zNcS8PQfLuz6HhzArE4j2k9VHp59D0vwFpFlJcLBcModFBIrY8R+K9H0PxOtpfvsiigEkOzkNzjGegryrxN4lazmW50d/nmG3g4rg7s3V/cbr26aT1P8ASvCyPC4ulVqYmDtzx5fON92un3pnbxVgcDjZ044+b5Yvm5Fs/V9vQ9N+JPxOfUoVi02WSOFlO4RdfbpXlcKeVxLKpdvmbcfvNU214yRChEeedo61H/ZUupzNsCxsoyCT1r6HL8uo4Cl7Omtd2+rPCx+P+stQpLlpraP6lW6aBSHdDkH+Gq6yRvOgjQISw5J6c1tf2FLHaZnljyOoBzVARbbtIysbJkd/eu884NW1DdcSmIeWCTwvWqT3kzxYhyfUmomB+0uJQQ5J5xxRLA8aBo+R0HNAEP2t3zFKmAOvqact19lQBI8+uec1HNbylxg5buAKh8t0XO4lx1oAtXNykgBjUI3sOKhgMe/94xH+7SK4Ee1kAJ7+tQyRBiGDEr0zQBdaR9hUD5c8Zq3GWKptQlc9DxWbCoZlRpcHPBPar8t29uQgYOi/xUAaqkMhZG8th1UnipIr9iPLVTG46tng1mrdozgrkKR83FOSeOJmMQZyehboKAOjs9dcBopVVjjCsTgimR6mySEspbJznPSsAn7RGSeGHUjiomcLEgeR9w6EUAeow+MGjtgIsZAAwexrp9G8VRCzWXy1mlP+szXh0V2sa55Iz3NbenauVhdHcxk/dwM0Ae56fry+cjy+X5UvIQH7ta4e3uZzIttFJu6nzP6V4ZBr88KoivGZOmStatprFzHE2yVVJOSR1P4UAem6tm1YEQptk4DIAQPrWXqG57BpYoElK8ZI5H0FcZF4lma6UySLHCoweeT+FXx4qks3Btityj/K2B92gB0VvbXUrSXESxkrtbHX6ms290OGKcNZlWjK5LdcfStQ38+sWrGVLaMA4Zs4bHpT4buytLdYRIJGP8K+noaAKEOmyQKkkrLKdnGR0pk87yjyZBIIsfNjnJ9K2tSvtMtjGttM4ldc4J3LWZcwT3MwazcByueD8uaAOS1fSraSYPEZRxyu3kfSqNrpsgWXynCEjADjBruP7H1UQK0uGzyF281Tl89ryOGRIkMY+ZtvA/8Ar0AceiTFAshZwnBGP5VahsrXZh3LZ6gjBFdJH4cmuJZBbXEbM3IDHFZ2o+HtZs42LW5dSeXUZxQBlnRF277RGKnqKzrixSyYm5tztPUA8111pZX1ras0CsHI5DDrVWK2e4lH2pTJI3VWGMUAcZMYQd0O7b/cYdKhZDMCwyC35V6TBoVm10EeLY3HBHWtW48K6RtIWcRMeof+lAHlNnoaXgCziRZMYDKetaNpoEWnI2VlLt/ERXoltoWnWko+z3cYOOcnNWZtJ+1Q5gugJB92Nz1rX21Rw9nfTsKyvc8lukeKTbvYoTzjoKUSjJUOCo7t0rpNf8P3dszTM0ZJPMdc3NZskePlyeWrIZq2lvE0Lb9rZHJA4qzp9nbZfzflA6Z71zYuJYm8uBuB/CK1tPaQgNcbtz8YIyfwoA0m0dLiYbYTDGB1J4PvV+0hjsmjjb5omOA4FWLS/it4fIulYhh8rEY4rT0680mdjDdxlFQYHPB96AMDUI7TdKsjN1+UmuPvbZvthV5PkHOcdq9DuYbSKUyq6SqThR1qvfw2ynzHWNlA+6BzQB5xCkNpegAO644du3tXUadPJLGFukATqoXjj61NcmydTsjQAfKAw5plxHAZFhiLk44Y8BaudSVR803diSS2NCFoch4174A7n/GtWw1W3shIL2ONI2HIk4x71yRuPs0vlwtlk7jnNMaV5DHd38Ty2oyobGcMawqzdODklex1YOhHEV40pS5U+ps+J47dJQ9soUMNwK9DWlonge11v4a3utzXb22pwsXaPeNoUH5ePpWfpdmreH3t7tSJXDbTuyUB6Uml+F7l7ZY11G8lsZDmSBJMB/Y+1dmEnTTUqmlrPa+z1VvNaX6bnBj6NVpwoTs7tPzXR/frYwNEsptUsYJJ0cx7zGSvU471oXPhyW3WQxtJHH1wD1+tdjJZ/wBjWqRR26xxKm1BuztFYlxqCR2pjgcyvKeWJ4FYVlCpJu2l9jqo1alF3pyafkcrFZqkgJl345G48KfpWlpyQNOGmVT6+lZt2z2t7kIGUcsc5zUbyM7/ACEIp52jrUxio6JBUqzqu9R3fmdpNaWEjLPbfJGv3gR1rLvZ7ZpNlrGVc8fKMVnyanLDbrGWC5GDk1SjadmMkcvIPIx1pmZfubGe2iBnlcLIc5xVXNktxHsXeMjdxjmnT3kskbYlDt2DHgVkvc7pozMqBgwHy/WgDNvRPPPgggqxxkcUwNLE26TnnqK1bm4USGdJC7ElWQiq8R+0XaHb8inlTxQBCuoOJQ+Nvbp1qrNJ5052nax5IA61qarpoE6vbqpHfaazDbTpcHCEseg70Aalhb2l3GTLGVdepBrUtdJ0m4lECy4dh64rBtLa8UMxT5T2PWpbW0eVz5Sskq96ANafwtAk220uULDsT0qaHwPqNwu6LZL7A8ViMt7aTARlixOSB1NdRo/jHVLFRELXDgcEjFAGdJ4V1W22iW0faP7tQnQbtZDIAxx/ARXW2fjG+u7wfbAwA/h28V0ei6xGsskl5YLJG5wvy9qAPJZre5kYx/Z339mRapSwSwKYpoyWPr2r3i9vtEuJlhsrCRbo/eI4ArN1yy0eGNi5xKefmTNAHikZ2RrmMjBrWsLqKJy04GSOtdmbTS77aBFGZc4CgbavyeCdOlhYyq28/dw3AoA5u21iwCDyrVCo++W7/SqepaiLmWN7IeUucZqbVPDMliWFt8wX71Yctrc5BJK7euBQBryTIltsRwzscktzTra9nUmJfl46dvrXPl5QjshWT19qgN1JjdGzLjjJ7UAdRDqHl3RTcXPU44yam+1MW3s4RR95VPLVyc15IkSMsuZT1NLDqL7gkjAOPTvQB29s8PnF2VpFZcABs7PrTbrUFtyiWtw4fOc9Oa5Ozu32SF8gZ4KUk9/5ki/Kr7f4vSgDvbHxZqFrExe6LuDwCOMVZh8XCS5V7+ASR47LjmuETUY2Hl7soB1ApE1RCxWU4x0A70AepW/ijSjJviiCkfwseprbj8UR3ASJvLjzyG64rwuK8VpWWIDGeM9RWnDq0kONxViv3T1xQB75FeweWmXQoOSXTk1V1O+09G8xI4WmPG9V6V5DD4nvI4xIJfMQ8FW7Vak8QLPHFIyGGVezHhqAPRmNncxn7QAsuMiZRk/SqNxo0stm7LL5i/wEdRXN6T4hTzQ86LyMFVOBiprjV5l3Sqz28DcKF5FAFk6HcXUebeIM6jk7vmJ+lGl6NfqzfaBLbf7bDrWSPEcULqJVcNnh0JGa1bvxG8kf7u5LpjhScmgBLyyQrLDcSM5P3Sp61NpWg2E8vlvPFvI6Ed6yrW9jllLT3AL/ANztXTpcaebNGmhRW6qyHrQBhah4StrDUvNeaMxnr7VpRaZYQL5sE0TOV6sQcVT8RXVncq0ME3mKozsHUGuEuLu6tSxj5gzyPQ0AdtrUlsYVilRMkY8wdq5TUIYy4CT7jjgjpWHdave+fCyZ2k4kU88U9pw7bfmVjztPSqcbJPuBqeXMbbZAxLdS2eRUJkuIViE0hdgeGJ5qCxu5I5WMZBY8ZB6VdRoriby7pTlujnoPxqQKLzhXddrAluvWptwcrFI5UjqCK0oI42nxdYFsowJE6k+9XzpUW9LtMSxkfdbqaAOVU/vCjOPwFbVpDJP5f2dsRnhlDdRWpf6VaXdtHLGkUJA4BOCKzV06a1UrEFAYcsG4oA6TTrLTzKEQSSuByhPApl+P7NnjW1ZljJyVB6H2rnrYuF8q2kkEy9WBxn608Xt1C6pdwMwU53nmgDTu7l7xGa7V0TOMt1rnr2GMS5tywi7nuTV3VNRnkjKohKEdzzWbbai5YRMitt6EDp9aAKrMu9l8pmcddxxVmwtsoZFgZ2H8NQyFftRadxnqAK0dP1JYpcTKTx1B5NAEVxbQ+WPPgaJ2+6W5FZbRPCWMrtt7HpXV3urWb2asbcPOOmTlVrkdUvY5ow5HIPIXpQBm3koK5Ykey1RimMk8YboGGM9TzRLK7SMQoKHp7VJZNGsyGQZO4DA570AaVrZg3HmTbtu/qOmM11aWdrJbSOCrnHykDn6VzA1WGCaVAowxODTrbXmgZo41jZOufSgDtodIsG0hHWf7NLjkMOayZrH7FteGRJ+4LDFYFxrjbGZmBY9s5AqOLWwbfbKHZ/4cUAbv2O6kgmuoFDgH7qjODWppwWXynurZ42XGWArD0rXZba1+WclifuAcD6132k69oj2QF5beZKw5CHvQBgaiAb7zbdY1X1K81ZjaCYYlgQ5H3wO9O1G+06WYLagLEeqMORV+21azhstitG6AcfL19qAKdravG5dYlePHHY0wXE6SZgWWPLfMB82acfEKxK5e2Cqekac596i07UJLyZvstu6zNzk8AUAaGrapFp8iC3tTHdOAWc9aqjX1SYSPb7z3Oc5/CpoNN1G/vPuLPjjeTwpqtrHgzW7cGSBInkY/3xQBVv8AWo55vNgVI+23ZjH41pwa7eTWPlt5RUfxr1FcxrWl67bRRG4tFHvkVmCO/VSk4dC38KdaAOg1K6SWM+fdsA3RvU+lZkdvdSbLeNlMZG47v8aoR+aF8u5hcIvQHvUsNxPbzFjwP4ST+lAFm5ht4VEc0bLMeDs6Vl6sLdRHFGGK/wAWR0q1d6hcLJ5l5Gu0jAxWcuoRKHBiLKeo64oApXiGSRPKVRAOvrVO8GzY8a4U8Z6muuttM0+9tw8d15UjDgGqd3oLKPK3xl1GRg/eoA5+M5Rvmw3YDpSLcNGQAOPfvVpLHExVVbeOCMc0k+ly+WG+bOeARQBPYajGZUWeIjaOdo60l5JavIzoW344GOlVE0+7ifPluyn0FWLi0kCqViY5+8QM0AR2xCgtgrn3q4peeExLGMjuBzTRYfuwSsjccKVxTII5ElCxGVZf7tADknmtz5BXeD2I6UxnlklVWB46c1eu1uFK7kJlxiqcsnlAfu8SDrnpQA6GedH+Vz8xwQe1bI1BzEtu8zFPTNZEN3GysfK3N047VDeRsF+QNuPPNAG8ZxbxkKAxI43NmqEeoyRuwUnB5YHvVCKVo9qyx7yR1J5FLchJFZlcBiPu96AN611YLbl1Rceh61p2euQsqxumXPPWuALSweWVKsncE1dW7KyEquCw/KgDubWaG4mZY0C7v4s1s6R4Xh1FC8l2ofOAleZm/kSLcswVh/CK1dD8RXFtchzL2xyeKAO2vvCAtJMsqD1NTHw5Y29vG4hEjMMuC2TWDP4luxbGMsZA/QselZcuvXCxCJbiTf8ATFAHZJomlywP5Rji3fwqckGmWdnpULtazDzDjcrHtXG22qbyzxk+ZjB560yPUi7OiKTIRjcx5FAHZtaIgMEiRMC25HB4A96liCQISoV3HJQHhfevPoriS0udzXJJ/uk96uRanN56TMVKE/NzjdQB1+orC9rHMhR55DjZnhat2VnbSRlJc+YoyB2zXJXF9bX4R5o2hCHgZxmoH1yXyWSJijrxuB7UAad8JItRJRdhHBx0P1ps2rATLbzbSmOSB0rFTWHkUxE5dhx/jWfLKyylpWLBuMjqaAOkubSK4jc2cxZz/Cx4NYUm6ykCuQM9Qo5rSt/N+zqIBIqY+ZtuSKyNVNyJ8KpaIDmTb1oAjubyJTiRMoenrVOS5l8wPH8oHTNaWlRrNtWTYX7HHatc6DbTj/WAsP4c4FAHLDUJZsglc9Dniop7oiIRMVz/AHhW7qGirbROYxGvpk5zXNPCCCscRBzzQBHPJlcRnPqcdaLaSJLmMBSuWGfzoNvMMkLt9z3py2MqTQtMQSWHGeetAFO5ciRwcMCSc/jTQAF3pxUMpJlc99xpVdgNoxtPXNAEwlJj2MRgdxTY5ij4AP1qOVYx9wnPemhj93oKANSK4iIOxG8zuc8VqWmoyQhVMe1uzVzYkMbgRnBqyt2zkKw3D60AdT/aiElpBnI+Yg96livylsHXL85UEYFcvZXBikYpj33c1d+1OGBmcMnUL0oA347q/uXW4kjHlp0ArqdN8RW1vBkWwLNwwIrgl1IqpMW5QevNK1/P8gjmBB6FhzQB6ZLfwwMkjXUsFuwyY0+9mqt1qyXbZ+1bYk+4Hf5vxrz251GaIczeZM3Xvj6VSmvPNQh1IK0AdtrV+JWRVvgQfvgE4q/psEM0cfzZtlPzHd8x+leXmcl0ZgzLn7oNdLp+pJBGspVwF6qelAHey2GlXc8YVZPJ/vhskH0IpknhzT55fJ058yekjZNZOkeJREGlWxVozz8vWpbbWrmbUTd2cSxLJ8rBRzQBf1HwFPBbhpri3IYZwzdKwLrwqsQVEnTGMsBxmtnVzL+6M1yd5O7bv6VS1KcSsgi/fOB8zr2oAxW0QG4EVuxYAZAHanDRrqXc2T5icKxOM1sJe2qtFJJbOJ/u/IeDVl7+d3xDbumP4WGTQBy1toupJcEBSXIyPU0PDqFsT58DDJxkjivRdJhtr+DcJGS9T+HGMVU1eHU7Z0eLZIAccjdj8KAMjTdMuXtFlJU8dj0qSPTZIHZ4ELu3UDkZpl3e3bysrqiEjDbFxmr2jwzCbyoUddwyGOTQBfivrmCNfM06Fwo+bMfJqk8+l3MnnXGlyRTnhTjFb6DU44MfYsAttL5zmtY6E0qW6zzKgY5BGDtoA8+m0qwZ2eeK6Rm5EmDgVnah4bLqogmDxt0O3mvdII7e3X7PeEPEowH2Ag1Lc6Lo9xbiRZ1iGO3GKAPmq50GaJgsBwV68daq3FtcZ6ELjG4jivd7zw9p63TESRSbx8oB61ly+GIrm1mb5gYgf3eP5UAeJrayK4STc27o1XTYIkYBZS3Y10mseG5vKM4V2UdF/u1i/wBjPJFxIwnH8PpQBh3Fsscu0gFTzj1pjgoxwcDH3TWgLSVNyMhYg43damWwtzgXc4RuvHNAGMGieJsKQR1Bq5p8cc5BLLGR0BqS8sbczqYXV0x0BxWXcMwlPlZz60Adk90FtlilSJ8dGHaoRpn27y5PNClecDuK4yOaY7t7FgO2elTW+pTxfKkjqmec9qAOpn00KTtmEaA/NjrWddxRQTZ84kdVb1oTU4JLdlClpWGNzHGaoFhcsPM+VEPNAEkrtcMTINhHHqT70NKHCrGxxHyTSTrhgIiDGRyc8mqa7yWWJSc9gaAL0ss3lC4M4OOiVE16XKOFw3du1JZjdIsc6qFAqWaGBEZW3Bv4VAoAljurd5BNIzRtjGcYBrXso7Yosp/eIe45rn5opXgAkK7OwNLavLCqLHKSp42+lAHbW0smPklcxei9x6VU1iSJYfLgL88sjGsixuZIZWa4lUKOdg60SXguLj92n7ruTQA03EMDKERgByealj1PzZWC4HtiqktsrSlgdoB+6D1pZtsRC7lVT/d60AQ3t/NLlBjy8/jUZnlWINGmZBwAaSdoIjtYM+eRt602KSSRc7Qu3pzQBC9w7MN4/edcntUM11LLdw5UAhgCw+tRXLzGVt4GB3FR21xm4jH8O4c496AKkvMz/wC8fx5pCT6AUSEGR/8AeP8AOmn5upoAc3yHIFIv3uBwaCxVdpH/ANem4B+tAEmMEhiPpUsSqRwCPc1Cu1l2nGfWpFYqpUc0APaYJlV5NSxEXDgSOFIHAqoBuyWwuPzqWJo15dWHvQBchnSOQiRSw6Ag05drMzh9o9Cc1RWQb8nhc+lWHZGYYO044xQBJ9oZPujj35qN5GYktk/hVZt28lzx2zSCRg554NAFxZYRyS6kjqo6UvnsIzmQle2T1qg8jSDBbAHam/dAHmA+2KAN6LVvJt1jiDKf4uetW7HVJkYNExVQc4J61zSEKjF8GrNlIuQW+XB6dqAO5iv2n3SXGwuRw2elXrKeG2tpD54R2PAB+9XDTzRMoCS7B3Aqa2uhbFcbZM9N1AHodrdWK26eaVDFskgZrQN5BOvmK6oEI2unVx6YrgpbhiFmWRQ4HC9hSWdxcyPtLqxzuGD1oA9Ws9RsZJhOqKJkGWQHbu+tWLjxHp7mRV/dLIMFSvSvLv7XjWdxOm2Ru/es65vXN0sq7igOcE9frQB7bYXWk/ZI2vYRGucZK9vWr13qGk290G05osbOi85rxa/8RPPDEoJIT0OTUsF+zKj7ysf+yORQB6H/AMJFcQrMpaJt5ztDdKoat4pgW3SKRHM56MrYxXn97f8AkzkmQuM8ds1QuL+VrnKsAD0B5xQB39x4nuliSJJ2mjfgZP3Ku3viG5t9OWI7CHGN5OcV5nvcElJy27qO1Sy37RRCOWUOD0yeBQB1sfiOQR+VEC86nIcmt+w8QzS2LpcPsuscktjIrym5meORTC+7PZaVdQJPlSIUf+8W5oA9WtPFMJ/duFkTOGz61eRdMuJmee1VEI+Uq2MV4wLqaKUyKyhh0wetWzrjxrvV2D989DQB2eq6dbTqRAzRqG5IPWsG60yW1YOpV4mOCxrHfXpbol1fDAYIzQNdkARZHZkzjmgB99a+TvZQhDddvUVk31vkJ5Oc4zxWhqd1AQHVmIIrGuJgUBDEEnoTQBEoBQqxKOP1qOGXnY2efvECn72YHY43D1FRh1LfMDvHXHQ0ASmXK4jB9MmoZJZNwHOT2pZHTfiPJNNcgrvbOPSgCcTN5JUEpn1qS2n8hRIy5f8AhwaqCZTjK8YpIGwxy20DoPWgDXdlWPzPMJlf07UqXBeI/wATr3PNZhuTnLA/lTvtRCjYApBz9aANBSfNR5nQccKKv/aLaHbmJWB6nvWD9pEkwLoFbHHHWkDu0pKfyoA6GaeGUgxoqr1571AkmWIUeWh65HSsuGVXDAnLe9RPJLIME9D60AbOoM4jBVlZF7jrTY7lDGpli3nsc1jhnHAJOexNOEkhIUAn39KANG4nt8jfGd3Yg1Cxiz3IPUA1TIc7izHFJuHlnB4NAC3MkY+VQwX61BBtaeJVIUbx1+tKzr5W0dfeo4SPtMWTzuH86AI5Mec5I4yf50wHAJzyOlLKf3zkddx/nSMByc9aAFJL/fpDjqfwFGSCB2ppzuoAXoTgCnhzwM4prcgY60nGOTzQA4kFuetSdQAXODTARgEDJpC2WyBigCYoUwDyKVSpbdnB96h8xjnLUgZTxtJoAkcksSx/CmJhTkANTTyeMgUowCOaAAsS2QOfalQ/Nzj60SFQflqME4PFAE4bnJG4d6mhTaCxbC+/eqvVeT+FOjYKMNk+1AFt33x7kHTsafDJuXbkFvftVcOPLYL8o96ZETglSF9RQBYd3LcyNt7jNSCd4lB3nPbnGKqea284APbmkJOeRn3NAGtNevcAM0g8wDAJFLb3EwVlBDZ7NVBCispk59xSyyqE2xyHB74oA1HWGOFXXmU9weKb9ukxgLtx1qhDJiMBTu9R6VE87xyHGcnrmgDRkvwlxGW2yKO1N1G7DSBwm339KoHBBZEznrmgyfIQVA96ALEd4CThsg9cdTU+6Nl3BSx9M1Rhxyzqq+h9avw3EEaErGd/55oAilc/KfmQ/wAJ6VHK8y7i/LEdavKYZYf3q5HYk9DWZdNiTZtIPbmgBifeDFyPrSyswYqW69M1HLuHORx3pDl0yRz60ALGdr43cVKJcOVJ+UelVGXAyw/EUsRDMAWoAnllZkChsqOhqOU72UuRt9qSTl8DhajYZcdgaAJhtbOwYYe9MVyr5DAetSxWxY5TJ96ni02V327WOexHNAFIOQ5frmiVskccVt/8I5ciBpWhYRgdzWWbVnYiMHcP4TQBWYp8p70oY43LknvSyo0RCuozTM8cfjQA7cWIJJwKkRskMOSKgDAHjpTiT24+lAFiR/3ocH86UXDlmIznFVyWKcH5RUsUrIg27fx60AOiYMpLEKewqNWbccMST3FDA8u2MmlWZdhATLeooAUYGcsSe9SCRlXAwAaj24jzn5vSotwOQc5oAsJIzNkc47mleV8HgYqojFTw2DSlnzuzwe9ADgdxI6mnWp2XEYIzlx/Oou+ece3epYiGnhK8DeM/nQBDJxPJ3+Y/zpueOKWX/Wtz/Ef50dB160ANHHNGezDikxjvSjrwaAFBwMdB6UmcYxSE96AKAHZ3NRyDzTT1OKB79aAF6HpT2YjtTGOcDvSc5oAdyepNDcEdqByKCc+9ACYOM54pWx6mmjrRnnrQA4GjJ680g60DI70ASO2VAFMz0pPajPHTAoAcXJpSWZck8+lMBzSjA5oAUk9Ofwpy5UdxTNxI460u/POaAJWYt9zg9zSq6BvnJLetRK2Bz1pdwkIBAFAE7TOy4ACrUaepNJJtxgMeKUMNp/vUAPMgKEAHPoatwNHtQj5XFZisc5JGaespGcY5oAvT3W2TqAfYVVaQyORu496hJx3/ADphJ6mgCYtjq2ajZu2TTR780dDQA7f60A+nX1ppPNKeetADicjk4NWrZo8gyqG9qpnoOKkik8tt2AwoA6CAo6f6MAGXkDNT3OoOgRmmxKvqOlc/9sJYFRtPYLTWuWORJzn1oA6ebWru9txHkeV0Yg81kSMUn/0Z+vXPWqsdz+6YR/LjpUMdyykkAFj60ASys73H74DeO9VmUF25/CmuXLFm4JpgJJ5P40APKbeSOaDJ0OOaMEkbsn0o2HOTQAjNkYAxikUn8KCME5OaTBoAkckqAenakVu3601gcDigghRxQBIEc85OPrTMnHNLu+U4PFN4HPWgBxGVxgD3pCw27fShcNxj5qTGDigBVbAx1FSWx23EY9XH86ibAPBzT7fBuIiTzvH86AHyW+6V/n/iI6e9H2bOMv8ApRRQAv2UDPzfpTRbdt/6UUUAKbXH8f6UhtsdH/SiigBfs2f4/wBKDbf7f6UUUAAt8fxA/hS/ZvlJ39PaiigBBbcZ3/pSG2yPv/pRRQAotefv/pR9lGfvfpRRQAv2XIPz/pSC2/2/0oooADa5/j/SgW3bf+lFFACi1+XO/wDSkFt/t/pRRQApt++79KT7PwSH/SiigA+zZP3/ANKcLXnl8/hRRQANbYP3v0potsfx/pRRQA77Ljnf+lBtumH/AEoooAT7Lzy+fwpfs3ON/wClFFACNa4H3/0oFrn+P9KKKAD7L2D4/ChbfLY3/pRRQAr2m1iN+ce1C2u4Eb/0oooAPsgVR8/6UC0Bx8/6UUUACQEA/P8ApSi35+/+lFFACvac/wCs4+lC22RguP8AvmiigBGtyuMP+lSC3JUDzP0oooAZLbcfe/Smi1/2/wBKKKAHNbf7fP0pPsuRy/6UUUANFvu43Y/Ck+z8ff6e1FFAALbnO/8ASnm25zu/DFFFACG1/wBv9KdDbgTxHd/Go6e4oooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal view of a hypoechoic left lobe from a patient with Hashimoto's thyroiditis. Color Doppler interrogation shows moderate hypervascularity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30435=[""].join("\n");
var outline_f29_46_30435=null;
var title_f29_46_30436="Fertility preservation in women with early stage cervical cancer";
var content_f29_46_30436=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/46/30436/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30436/contributors\" id=\"au1666\">",
"       Marie Plante, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/46/30436/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30436/contributors\" id=\"se7382\">",
"       Barbara Goff, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/46/30436/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30436/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?29/46/30436?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     More than 11,000 American women develop cancer of the uterine cervix (cervical cancer) each year. Cervical cancer is a treatable condition, and there is a good chance of cure if it is found and treated in the early or precancerous stages. &nbsp;",
"    </p>",
"    <p>",
"     Many women with cervical cancer are in their reproductive years. Advice regarding options for fertility preservation for women with early stage cervical cancer is available from physicians who are experts in reproductive endocrinology and infertility, in conjunction with a gynecologic oncologist.",
"    </p>",
"    <p>",
"     This topic review discusses the diagnosis and treatment of women with the earliest stages of localized cervical cancer who wish to preserve their ability to become pregnant in the future. Separate topic reviews discuss screening for cervical cancer and the standard treatment of all early stage cervical cancers (which usually includes hysterectomy). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"      \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23603883\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER TREATMENT DECISIONS REGARDING FERTILITY",
"     </span>",
"    </p>",
"    <p>",
"     A woman with cervical cancer who wishes to preserve her fertility may feel that she has to choose between doing what seems best for her own life and what might be best for preserving fertility. Every woman's circumstances are different, and every decision must be individualized based upon the woman's situation. Advice regarding options for fertility preservation is available from physicians who are experts in reproductive endocrinology and infertility, in conjunction with a gynecologic oncologist.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER FERTILITY-SPARING TREATMENT OPTIONS",
"     </span>",
"    </p>",
"    <p>",
"     Early stage cervical cancer refers to stage IA1, IA2, IB1, and some small IIA tumors. Options for preservation of fertility are usually limited to women with stages IA1, IA2, or IB1 cervical cancer. Factors such as tumor size, tumor cell type, lymphovascular space invasion, and lymph node metastases may also affect the ability to receive fertility-sparing treatment.",
"    </p>",
"    <p>",
"     Options for treatment of early stage cervical cancer include cone biopsy, hysterectomy, and radiation and chemotherapy. Future pregnancies are not possible after hysterectomy or radiation therapy. Some women with early stage cervical cancer with no spread to other organs or lymph nodes who wish to carry a pregnancy after cervical cancer treatment are eligible for less aggressive forms of treatment. Treatments that allow a woman to carry a pregnancy at a later time include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Conization &ndash; large biopsy of the cervix",
"      </li>",
"      <li>",
"       Radical trachelectomy &ndash; removal of the cervix and surrounding tissues, but not the uterus, along with to the removal of the lymph nodes in the pelvis",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Cervical conization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cervical conization is the surgical removal of a cone-shaped portion of cervix, including the cancerous area (",
"     <a class=\"graphic graphic_figure graphicRef63427 \" href=\"UTD.htm?11/40/11906\">",
"      figure 1",
"     </a>",
"     ). It is an acceptable option only for the earliest stages of cervical cancer (ie, stage IA1 and IA2).",
"    </p>",
"    <p>",
"     Conization is usually performed in the operating room after the woman receives anesthesia. Conization is performed through the vagina. Most women can go home the same day.",
"    </p>",
"    <p>",
"     Following conization, most gynecologic oncologists recommend that the woman avoid sexual intercourse, not place anything in the vagina, and not take a bath or swim for a few weeks (showers are fine); these activities could potentially interfere with healing. Some bleeding is expected, although it should not be heavy. If bleeding becomes heavy (eg, soaks a pad in less than an hour) or continues for more than one week, the woman should contact her healthcare provider.",
"    </p>",
"    <p>",
"     After conization, follow up examinations are recommended to ensure that there is no evidence of cervical cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link&amp;anchor=H14#H14\">",
"      \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\", section on 'Monitoring'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Radical trachelectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radical trachelectomy is defined as partial or complete surgical removal of the cervix and parametria (connective tissues next to the uterus and cervix). Radical trachelectomy removes much more of the cervix compared to cervical conization (",
"     <a class=\"graphic graphic_figure graphicRef50693 \" href=\"UTD.htm?12/3/12338\">",
"      figure 2",
"     </a>",
"     ). It also involves the removal of lymph nodes in the pelvis.",
"    </p>",
"    <p>",
"     The procedure is performed in the operating room after the woman receives anesthesia. Trachelectomy may be done through the vagina or through an incision on the abdomen, depending upon the surgeon's preference. More recently, some surgeons have performed the procedure using laparoscopic surgical approach. The cervix and upper portion of the vagina may be completely or partially removed, depending upon the size and depth of the cancer. A permanent purse-string suture (cerclage) is usually placed at the lower end of the uterus or remaining cervix (",
"     <a class=\"graphic graphic_figure graphicRef50693 \" href=\"UTD.htm?12/3/12338\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Before trachelectomy begins, surgical removal of lymph nodes within the pelvis is performed to be sure that the cancer has not spread; this is called lymphadenectomy (",
"     <a class=\"graphic graphic_figure graphicRef77184 \" href=\"UTD.htm?23/48/24321\">",
"      figure 3",
"     </a>",
"     ). The nodes may be removed through an incision in the abdomen (if an abdominal incision is made for the trachelectomy), which allows the physician to see the nodes directly. Alternately, the nodes are removed with the assistance of a laparoscope if the trachelectomy is done vaginally.",
"    </p>",
"    <p>",
"     After removal, the lymph nodes are examined under a microscope during the operation to preliminarily confirm that cervical cancer cells are absent (frozen section analysis). If any nodes are found to contain cancer cells, trachelectomy is not performed, and more aggressive therapy (radical hysterectomy or chemoradiotherapy) is usually recommended. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"      \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Following trachelectomy, most gynecologic oncologists recommend that the woman avoid sexual intercourse, not place anything in the vagina, or take a bath or swim for four to six weeks (showers are fine); these activities could potentially interfere with healing. Some bleeding is expected for approximately one week, although it should not be heavy. If bleeding becomes heavy (eg, soaks a pad in less than an hour) or continues for more than one week, the woman should contact her healthcare provider.",
"    </p>",
"    <p>",
"     After trachelectomy, follow up examinations and testing are recommended to ensure that there is no evidence of cervical cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link&amp;anchor=H14#H14\">",
"      \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\", section on 'Monitoring'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Need for further treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Further surgery may be required if abnormal or cancerous cells are found at the margins (edges) of the area that is surgically removed during conization or trachelectomy. For a woman who had conization, this could mean a second conization, radical trachelectomy, or hysterectomy. For a woman who had radical trachelectomy, this usually means a radical hysterectomy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"      \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\"",
"     </a>",
"     .) Additional chemoradiation may be necessary if cancer cells are identified in the lymph nodes on final pathology or if other risk factors are identified on the trachelectomy specimen.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      PREGNANCY AFTER CERVICAL CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Most women are advised to wait six to 12 months after conization or trachelectomy before attempting to become pregnant to allow the tissue to heal fully. Even if a woman waits to attempt pregnancy, there is a risk of pregnancy complications",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     infertility after cervical cancer treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Infertility",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is an increased risk of difficulty in becoming pregnant if the cervix or lower uterus becomes scarred or narrowed as a result of the conization or radical trachelectomy. This could potentially prevent sperm from entering the uterus. This can usually be overcome with an infertility treatment, such as intrauterine insemination (IUI), following attempts at dilating the cervical opening. With IUI, a small catheter is used to deliver sperm directly into the uterus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Cervical insufficiency",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cervical insufficiency occurs when the cervix opens or thins earlier than normal during pregnancy. This can lead to miscarriage or preterm delivery (when delivery occurs before 37 weeks of pregnancy). Women who have had cervical conization or radical trachelectomy may be at an increased risk of cervical insufficiency.",
"    </p>",
"    <p>",
"     For these reasons, women who undergo treatment for cervical cancer are followed closely during pregnancy. This generally involves regular monitoring of the length and opening (dilation) of the cervix. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link&amp;anchor=H10#H10\">",
"      \"Patient information: Preterm labor (Beyond the Basics)\", section on 'Cervical length'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Pregnancy options after radical hysterectomy or radiation",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not usually possible to become pregnant or carry a pregnancy after treatment with radical hysterectomy",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     chemoradiotherapy. However, advances in assisted reproductive technology may offer a way for women to have a biologically-related child after this type of treatment.",
"    </p>",
"    <p>",
"     Embryo cryopreservation is a technique that has been available for many years for fertility preservation. Embryo cryopreservation requires that radical surgery, chemotherapy, or radiotherapy are delayed for several weeks, and that a partner's or donor's sperm is available. Thus, it may not be an option for all women. To use embryo cryopreservation, a woman must use fertility medications and undergo a surgical procedure to harvest her oocytes (eggs). The oocyte is then combined with a partner's or donor's sperm to create an embryo. The embryo is then frozen for use at a later time.",
"    </p>",
"    <p>",
"     Reproductive techniques that are currently in the experimental phase include oocyte cryopreservation (freezing the egg before it is fertilized with sperm) and ovarian cryopreservation (freezing the ovary); further study is needed before these techniques are available to the general public.",
"    </p>",
"    <p>",
"     Since the uterus has been removed or damaged by cancer treatment, all of these techniques, including embryo cryopreservation, would require a gestational carrier to carry the pregnancy. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15015?source=see_link\">",
"      \"Surrogate pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating cervical cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learningabout/\">",
"      www.cancer.gov/clinicaltrials/learningabout/",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"      www.cancer.gov/clinicaltrials/",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H261\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11736030\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=see_link\">",
"      Patient information: Cervical cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/8/15491?source=see_link\">",
"      Patient information: Pap tests (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=see_link\">",
"      Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11736058\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=see_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"      Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"      Patient information: Genital warts in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/48/34564?source=see_link\">",
"      Patient information: Vaginal hysterectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=see_link\">",
"      Patient information: Miscarriage (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=see_link\">",
"      Clinical trials of human papillomavirus vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link\">",
"      Management of recurrent or metastatic cervical cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=see_link\">",
"      Preinvasive and invasive cervical neoplasia in HIV-infected women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14730?source=see_link\">",
"      Radical hysterectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15015?source=see_link\">",
"      Surrogate pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=see_link\">",
"      Invasive cervical adenocarcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=see_link\">",
"      Small cell neuroendocrine carcinoma of the cervix",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Society for Gynecologic Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.thegcf.org/\">",
"      www.thegcf.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gynecologic Oncology Group",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gog.org/gynecologiccancerinformation.html\">",
"      www.gog.org/gynecologiccancerinformation.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.gov/\">",
"      www.cancer.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Cervical Cancer Coalition",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ncc-online.org/\">",
"      www.ncc-online.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?29/46/30436/abstract/1-11\">",
"      1-11",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?29/46/30436?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30436/abstract/1\">",
"      Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30436/abstract/2\">",
"      Plante M, Renaud MC, Hoskins IA, Roy M. Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol 2005; 98:3.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30436/abstract/4\">",
"      Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005; :CD002225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30436/abstract/5\">",
"      Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30436/abstract/6\">",
"      Dargent D, Martin X, Sacchetoni A, Mathevet P. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer 2000; 88:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30436/abstract/7\">",
"      Burnett AF, Roman LD, O'Meara AT, Morrow CP. Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. Gynecol Oncol 2003; 88:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30436/abstract/8\">",
"      Abu-Rustum NR, Sonoda Y, Black D, et al. Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol 2006; 103:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30436/abstract/9\">",
"      Roman LD. Pregnancy after radical vaginal trachelectomy: maybe not such a risky undertaking after all. Gynecol Oncol 2005; 98:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30436/abstract/10\">",
"      Hertel H, K&ouml;hler C, Grund D, et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol Oncol 2006; 103:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30436/abstract/11\">",
"      Boss EA, van Golde RJ, Beerendonk CC, Massuger LF. Pregnancy after radical trachelectomy: a real option? Gynecol Oncol 2005; 99:S152.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f29_46_30436=[""].join("\n");
var outline_f29_46_30436=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CERVICAL CANCER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23603883\">",
"           CERVICAL CANCER TREATMENT DECISIONS REGARDING FERTILITY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           CERVICAL CANCER FERTILITY-SPARING TREATMENT OPTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           PREGNANCY AFTER CERVICAL CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           CERVICAL CANCER CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/40/11906\" title=\"figure 1\">",
"           Cone biopsy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/3/12338\" title=\"figure 2\">",
"           Trachelectomy cerclage PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/48/24321\" title=\"figure 3\">",
"           Lymph nodes female PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f29_46_30437="Polycystic ovary syndrome (PCOS)";
var content_f29_46_30437=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/46/30437/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30437/contributors\" id=\"au4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30437/contributors\" id=\"au4037\">",
"       David A Ehrmann, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/46/30437/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30437/contributors\" id=\"se5918\">",
"       Peter J Snyder, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30437/contributors\" id=\"se3550\">",
"       William F Crowley, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/46/30437/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30437/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?29/46/30437?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PCOS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Polycystic ovary syndrome (PCOS) is a condition that causes irregular menstrual periods because monthly ovulation is not occurring and levels of androgens (male hormones) in women are elevated. The condition occurs in about 5 to 10 percent of women. The elevated androgen levels can sometimes cause excessive facial hair growth, acne,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     male-pattern hair thinning. Some, but not all, women with PCOS are overweight or obese, and they are at higher than average risk of developing diabetes and obstructive sleep apnea. For women with PCOS who want to become pregnant, fertility pills or injections are often needed to help women ovulate.",
"    </p>",
"    <p>",
"     Although PCOS is not completely reversible, there are a number of treatments that can reduce or minimize bothersome symptoms. Most women with PCOS are able to lead a normal life without significant complications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PCOS CAUSE",
"     </span>",
"    </p>",
"    <p>",
"     The cause of PCOS is not completely understood. It is believed that abnormal levels of the pituitary hormone LH and high levels of male hormones (androgens) interfere with normal function of the ovaries. To explain how these hormones cause symptoms, it is helpful to understand the normal menstrual cycle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Normal menstrual cycle",
"     </span>",
"     &nbsp;&mdash;&nbsp;The brain (including the pituitary gland), ovaries, and uterus normally follow a sequence of events once per month; this sequence helps to prepare the body for pregnancy. Two hormones, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), are made by the pituitary gland. Two other hormones, progesterone and estrogen, are made by the ovaries.",
"    </p>",
"    <p>",
"     During the first half of the cycle, small increases in FSH stimulate the ovary to develop a follicle that contains an egg (oocyte). The follicle produces rising levels of estrogen, which cause the lining of the uterus to thicken and the pituitary to release a very large amount of LH. This midcycle \"surge\" of LH causes the egg to be released from the ovary (called ovulation) (",
"     <a class=\"graphic graphic_figure graphicRef79496 \" href=\"UTD.htm?13/13/13530\">",
"      figure 1",
"     </a>",
"     ). If the egg is fertilized by a sperm it develops into an embryo which travels through the fallopian tube to the uterus. After ovulation, the ovary produces both estrogen and progesterone, which prepare the uterus for possible embryo implantation and pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Menstrual cycle in PCOS",
"     </span>",
"     &nbsp;&mdash;&nbsp;In women with PCOS, multiple small follicles (small cysts) may develop in the ovary. The follicles are unable to grow to a size that would trigger ovulation. Therefore, small follicles (4 to 9 mm in diameter) accumulate in the ovary, hence the term polycystic ovaries. None of these small follicles are capable of triggering ovulation. As a result, the levels of estrogen, progesterone, LH, and FSH become imbalanced.",
"    </p>",
"    <p>",
"     Androgens are normally produced by the ovaries and the adrenal glands. In addition, some tissues (such as fat cells and the liver) can convert other steroid hormones into androgens. Examples of androgens include testosterone, androstenedione, dehydroepiandrosterone (DHEA), and DHEA sulfate (DHEA-S). Androgens may become increased in women with PCOS because of the high levels of LH, but also because of high levels of insulin that are usually seen with PCOS (see",
"     <a class=\"local\" href=\"#H9\">",
"      'Insulin abnormalities'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PCOS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The changes in hormone levels described above cause the classic symptoms of PCOS, including absent or irregular and infrequent menstrual periods, abnormal body hair growth or scalp hair loss, acne, weight gain, and difficulty becoming pregnant. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=see_link\">",
"      \"Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Signs and symptoms of PCOS usually begin around the time of puberty, although some women do not develop symptoms until late adolescence or even into early adulthood. Because hormonal changes vary from one woman to another, patients with PCOS may have mild to severe acne, facial hair growth, or scalp hair loss.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Menstrual irregularity",
"     </span>",
"     &nbsp;&mdash;&nbsp;If ovulation does not occur, the lining of the uterus (called the endometrium) does not uniformly shed and regrow as in a normal menstrual cycle. Instead, the endometrium becomes thicker and may shed irregularly, which can result in heavy",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     prolonged bleeding. Irregular or absent menstrual periods can increase a woman's risk of endometrial overgrowth (called endometrial hyperplasia) or even endometrial cancer.",
"    </p>",
"    <p>",
"     Women with PCOS usually have fewer than six to eight menstrual periods per year. Some women have normal cycles during puberty, which may become irregular if the woman becomes overweight.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Weight gain and obesity",
"     </span>",
"     &nbsp;&mdash;&nbsp;PCOS is associated with gradual weight gain and obesity in about one-half of women. For some women with PCOS, obesity develops at the time of puberty.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Hair growth and acne",
"     </span>",
"     &nbsp;&mdash;&nbsp;Male-pattern hair growth (hirsutism) may be seen on the upper lip, chin, neck, sideburn area, chest, upper or lower abdomen, upper arm, and inner thigh. Acne is a skin condition that causes oily skin and blockages in hair follicles. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=see_link\">",
"      \"Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=see_link\">",
"      \"Patient information: Acne (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Insulin abnormalities",
"     </span>",
"     &nbsp;&mdash;&nbsp;PCOS is associated with elevated levels of insulin in the blood. Insulin is a hormone that is produced by specialized cells within the pancreas; insulin regulates blood glucose levels. When blood glucose levels rise (after eating, for example), these cells produce insulin to help the body use glucose for energy.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If glucose levels do not respond to normal levels of insulin, the pancreas produces more insulin. Excess production of insulin is called",
"       <strong>",
"        hyperinsulinemia",
"       </strong>",
"       .",
"      </li>",
"      <li>",
"       When increased levels of insulin are required to maintain normal glucose levels, a person is said to be",
"       <strong>",
"        insulin resistant",
"       </strong>",
"       .",
"      </li>",
"      <li>",
"       When the blood glucose levels are not completely controlled, even with increased amounts of insulin, the person is said to have",
"       <strong>",
"        glucose intolerance",
"       </strong>",
"       (sometimes referred to as &ldquo;prediabetes&rdquo;).",
"      </li>",
"      <li>",
"       If blood glucose levels continue to rise despite increased insulin levels, the person is said to have",
"       <strong>",
"        type 2 diabetes",
"       </strong>",
"       .",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These conditions are diagnosed with blood tests. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Insulin resistance and hyperinsulinemia can occur in both normal-weight and overweight women with PCOS. Among women with PCOS, up to 35 percent of those who are obese develop impaired glucose tolerance (&ldquo;prediabetes&rdquo;) by age 40, while up to 10 percent of obese women develop type 2 diabetes. The risk of these conditions is much higher in women with PCOS compared with women without PCOS. A family history of diabetes, overweight and obesity, as well as race and ethnicity (particularly African American and Hispanic) can increase the likelihood of developing diabetes among women with PCOS.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Infertility",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many women with PCOS do not ovulate regularly, and it may take these women longer to become pregnant. An infertility evaluation is often recommended after 6 to 12 months of trying to become pregnant. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Treatment of infertility'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Heart disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who are obese and who also have insulin resistance or diabetes might have an increased risk of coronary artery disease, the narrowing of the arteries that supply blood to the heart. It is not known for sure if women with PCOS are at increased risk for this condition. Both weight loss and treatment of insulin abnormalities can decrease this risk. Other treatments (eg, cholesterol-lowering medications, treatments for high blood pressure) may also be recommended. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"      \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Sleep apnea",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sleep apnea is a condition that causes brief spells where breathing stops (apnea) during sleep. Patients with this problem often experience fatigue and daytime sleepiness. In addition, there is evidence that people with untreated sleep apnea have an increased risk of insulin resistance, obesity, diabetes, cardiovascular problems, such as high blood pressure, heart attack, abnormal heart rhythms, or stroke. This risk may be changes in heart rate and blood pressure that occur during sleep.",
"    </p>",
"    <p>",
"     Sleep apnea may occur in up to 50 percent of women with PCOS. The condition can be diagnosed with a sleep study, and several treatments are available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"      \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      PCOS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     There is no single test for diagnosing PCOS. You may be diagnosed with PCOS based upon your symptoms, blood tests, and a physical examination. Expert groups have determined that a woman must have two out of three of the following to be diagnosed with PCOS:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Irregular menstrual periods caused by anovulation or irregular ovulation.",
"      </li>",
"      <li>",
"       Evidence of elevated androgen levels. The evidence can be based upon signs (excess hair growth, acne, or male-pattern balding)",
"       <strong>",
"        or",
"       </strong>",
"       blood tests (high androgen levels).",
"      </li>",
"      <li>",
"       Polycystic ovaries on pelvic ultrasound.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In addition, there must be no other cause of elevated androgen levels or irregular periods (eg, congenital adrenal hyperplasia, androgen-secreting tumors, or hyperprolactinemia).",
"    </p>",
"    <p>",
"     Blood tests are usually recommended to determine whether another condition is the cause of your signs",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     symptoms. Blood tests for pregnancy, prolactin level, thyroid-stimulating hormone (TSH), and follicle-stimulating hormone (FSH) may be recommended. Insulin levels are not used to diagnose PCOS partly because insulin levels are high in people who are above normal body weight and because there is no level of insulin that is &ldquo;diagnostic&rdquo; for PCOS.",
"    </p>",
"    <p>",
"     If PCOS is confirmed, blood glucose and cholesterol testing are usually performed. An oral glucose tolerance test is the best way to diagnose prediabetes",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     diabetes. A fasting glucose level is often normal even when prediabetes or diabetes is present. Many clinicians who treat PCOS patients also recommend screening for sleep apnea with questionnaires or overnight sleep studies in a sleep laboratory. In women with moderate to severe hirsutism (excess hair growth), blood tests for testosterone and DHEA-S may be recommended.",
"    </p>",
"    <p>",
"     All women who are diagnosed with PCOS should be monitored by a healthcare provider over time. Symptoms of PCOS may seem minor and annoying, and treatment may seem unnecessary. However, untreated PCOS can increase a woman's risk of other health problems over time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      PCOS TREATMENTS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Birth control",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oral contraceptives (OCs; with combined estrogen and progestin) are the most commonly used treatment for regulating menstrual periods in women with PCOS. OCs protect the woman from endometrial (uterine) cancer or overgrowth by inducing a monthly menstrual period. OCs are also effective for treating hirsutism and acne. A skin patch and vaginal ring are also available.",
"    </p>",
"    <p>",
"     Women with PCOS occasionally ovulate, and oral contraceptives are useful in providing protection from pregnancy. Although an OC allows for bleeding once per month, this does not mean that the PCOS is \"cured\"; irregular cycles generally return when the OC is stopped. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Oral contraceptives decrease the body's production of androgens, and anti-androgen drugs (such as spironolactone) decrease the effect of androgens. These treatments can be used in combination to reduce and slow hair growth. Oral contraceptives and anti-androgens can also reduce acne. Other prescription skin treatments (eg, medicated lotions) or oral antibiotics may be recommended in some cases. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=see_link\">",
"      \"Patient information: Acne (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Before prescribing an oral contraceptive, a clinician will perform an examination or a blood test to be certain that a woman is not pregnant. If a woman has not had a period for six weeks or longer, the clinician may first prescribe a hormone (eg, Provera&reg;) to induce a menstrual period.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14686258\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some women who take birth control pills (not just those with PCOS) stop having monthly bleeding or develop irregular spotting and bleeding. Irregular bleeding usually resolves after a few menstrual cycles.",
"    </p>",
"    <p>",
"     Many women worry that they will gain weight on the pill. This is not a concern with the currently available low-dose pills. Some women develop nausea, breast tenderness, and bloating after beginning the pill, but these symptoms usually resolve after two or three months.",
"    </p>",
"    <p>",
"     The pill is safe and effective, although it slightly increases the risk of blood clots in the legs or lungs; this is a rare complication in young, healthy women who do not smoke, but it is more of a concern in women who are obese and in older women. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Progestin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Another method to treat menstrual irregularity is to take a hormone called progestin (eg, Provera&reg;) for 10 to 14 days every one to three months. This will induce a period in almost all women with PCOS, but it does not help with the cosmetic concerns (hirsutism and acne) and does not prevent pregnancy. It does reduce the risk of uterine cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Hair treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Excess hair growth can be removed by shaving or use of depilatories, electrolysis, or laser therapy. Many women worry that these treatments cause hair to grow faster, although this is not true. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=see_link\">",
"      \"Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       In women with PCOS, hormonal treatment of excess hair growth is typically approached in a two step process. The first step is to prescribe an estrogen-progestin contraceptive (eg, a birth control pill). If after six months of hormone treatment sufficient improvement in excess hair growth has not been achieved, a second hormone, an antiandrogen called spironolactone, is added. If hormone treatment with an estrogen-progestin results in a satisfactory reduction in excess hair growth, this therapy is continued.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Hair loss can be treated with medications in some situations. Other options include hair replacement and wigs. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=see_link\">",
"      \"Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Weight loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Weight loss is one of the most effective approaches for managing insulin abnormalities, irregular menstrual periods, and other symptoms of PCOS. For example, many overweight women with PCOS who lose 5 to 10 percent of their body weight notice that their periods become more regular. Weight loss can often be achieved with a program of diet and exercise.",
"    </p>",
"    <p>",
"     There are a number of options available to treat obesity. These options are identical to those recommended for women without PCOS and include diet and exercise, weight loss medications (although their use is limited), and weight loss surgery. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Weight loss surgery may be an option for severely obese women with PCOS. Women can lose significant amounts of weight after surgery, which can restore normal menstrual cycles, reduce high androgen levels and hirsutism, and reduce the risk of type 2 diabetes. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"      \"Patient information: Weight loss surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Metformin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Metformin (Glucophage&reg;) is medication that improves the effectiveness of insulin produced by the body. It was developed as a treatment for type 2 diabetes but may be recommended for women with PCOS in selected situations.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If a woman does not have regular menstrual cycles, the first-line treatment is a hormonal method of birth control, such as birth control pills. If the woman cannot take birth control pills, one alternative is to take metformin; a progestin is usually recommended, in addition to metformin, for six months or until menstrual cycles are regular. (See",
"       <a class=\"local\" href=\"#H16\">",
"        'Progestin'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Metformin may help with weight loss. Although metformin is not a weight-loss drug, some studies have shown that women with PCOS who are on a low-calorie diet lose more weight when metformin is added. If metformin is used, it is essential that diet and exercise are also part of the recommended regimen because the weight that is lost in the early phase of metformin treatment may be regained over time.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Metformin is not usually recommended for women with PCOS who have difficulty becoming pregnant because it is not as effective as an alternative treatment for ovulation induction, clomiphene. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Treatment of infertility'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     An expert group does not recommend metformin for women with PCOS who have excessive hair growth (hirsutism). Birth control pills alone, or in combination with an anti-androgen medication, are a better option. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=see_link\">",
"      \"Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Treatment of infertility",
"     </span>",
"     &nbsp;&mdash;&nbsp;If tests determine that lack of ovulation is the cause of infertility, several treatment options are available. These treatments work best in women who are not obese.",
"    </p>",
"    <p>",
"     The primary treatment for women who are unable to become pregnant and who have PCOS is weight loss. Even a modest amount of weight loss may allow the woman to begin ovulating normally. In addition, weight loss can improve the effectiveness of other infertility treatments. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"      \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Clomiphene is an oral medication that stimulates the ovaries to release one or more eggs. It triggers ovulation in about 80 percent of women with PCOS, and about 50 percent of these women will become pregnant. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A few studies have shown that taking metformin in addition to clomiphene increases the rate of ovulation; other studies have shown no additional benefit of adding metformin to clomiphene treatment [",
"     <a class=\"abstract\" href=\"UTD.htm?29/46/30437/abstract/1\">",
"      1",
"     </a>",
"     ]. In addition, it is not clear if metformin is safe during pregnancy (but metformin is FDA category B in pregnancy, which is generally interpreted as reasonably safe); women who take metformin before pregnancy are usually advised to stop it once they become pregnant.",
"    </p>",
"    <p>",
"     If a woman does not ovulate or is unable to conceive with clomiphene, gonadotropin therapy (FSH injections) may be recommended. Ovulation occurs in almost all women with PCOS who use gonadotropin therapy; approximately 60 percent of these women become pregnant. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"      \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413332190\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31056288\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=see_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/56/9090?source=see_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/27/39346?source=see_link\">",
"      Patient information: Ovarian cysts (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=see_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31056296\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=see_link\">",
"      Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=see_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=see_link\">",
"      Patient information: Acne (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34970?source=see_link\">",
"      Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=see_link\">",
"      Epidemiology and pathogenesis of the polycystic ovary syndrome in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"      Treatment of hirsutism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24297?source=see_link\">",
"      Treatment of polycystic ovary syndrome in adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/polycystic.cfm\">",
"      www.hormone.org/public/polycystic.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.womenshealth.gov/publications/our-publications/fact-sheet/polycystic-ovary-syndrome.cfm\">",
"      file://www.womenshealth.gov/publications/our-publications/fact-sheet/polycystic-ovary-syndrome.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Nemours Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/teen/sexual_health/girls/pcos.html\">",
"      file://kidshealth.org/teen/sexual_health/girls/pcos.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?29/46/30437/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?29/46/30437?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30437/abstract/1\">",
"      Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30437/abstract/2\">",
"      Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30437/abstract/3\">",
"      Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986; 293:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30437/abstract/4\">",
"      Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30437/abstract/5\">",
"      Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1876.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f29_46_30437=[""].join("\n");
var outline_f29_46_30437=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PCOS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PCOS CAUSE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PCOS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           PCOS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           PCOS TREATMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/13/13530\" title=\"figure 1\">",
"           Menstrual cycle PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f29_46_30438="Calcium channel blockers in heart failure due to systolic dysfunction";
var content_f29_46_30438=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Calcium channel blockers in heart failure due to systolic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/46/30438/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30438/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/46/30438/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30438/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/46/30438/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30438/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/46/30438/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical therapy of heart failure (HF) with systolic dysfunction, as recommended in the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on chronic heart failure can be summarized as following (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following therapies are appropriate for all patients, unless a contraindication is present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An angiotensin converting enzyme (ACE) inhibitor to slow progression of the HF and improve survival.",
"     </li>",
"     <li>",
"      A beta blocker, also to slow progression of the HF and improve survival; the benefits of ACE inhibitors and beta blockers are additive.",
"     </li>",
"     <li>",
"      A loop diuretic and dietary salt restriction to correct fluid overload.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, drugs that can adversely affect patients with heart failure due to systolic dysfunction should be avoided or withdrawn. These include nonsteroidal antiinflammatory drugs, most antiarrhythmic drugs, and non-vasoselective calcium channel blockers (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=see_link\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following should be given to selected patients in the absence of a contraindication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and a nitrate for patients (particularly blacks) with a reduced LVEF who have persistent symptoms despite therapy with an ACE inhibitor and beta blocker.",
"     </li>",
"     <li>",
"      The addition of an aldosterone antagonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or, if not tolerated,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      ) to improve survival in patients with NYHA class",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      symptoms (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      ) and a reduced left ventricular ejection fraction who can be monitored for preserved renal function and a normal plasma potassium concentration. Aldosterone antagonists also may be used to assist in the management of diuretic-induced hypokalemia (plasma potassium &le;3.8",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      in patients with mild-to-moderate HF.",
"     </li>",
"     <li>",
"      Angiotensin II receptor blockers (ARBs) as an alternative to ACE inhibitors in patients who cannot tolerate these drugs; the addition of an ARB to an ACE inhibitor may be considered in patients who are persistently symptomatic and have a reduced left ventricular ejection fraction despite being treated with conventional therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      to reduce hospitalization for HF or for rate control in patients with concomitant atrial fibrillation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these pharmacologic therapies, two types of devices are recommended in selected patients with HF (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An implantable cardioverter-defibrillator (ICD) for secondary prevention of sudden cardiac death (SCD) and for primary prevention in selected patients. The criteria for ICD implantation are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac resynchronization therapy (CRT) with biventricular pacing can improve symptoms and survival in patients who are in sinus rhythm and have an LVEF &le;35 percent, cardiac dyssynchrony, which is currently defined as a prolonged QRS duration (&ge;120 msec), and moderate to severe symptoms (NYHA class III or IV HF) despite optimal medical therapy. Most patients who satisfy these criteria are also candidates for an ICD and receive a combined device. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calcium channel blockers might be expected to have beneficial effects in systolic HF by reducing peripheral vasoconstriction and thereby reducing left ventricular afterload. However, these agents also have negative inotropic activity and several studies demonstrated greater clinical deterioration in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    compared to placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. As a result, these drugs have generally been avoided in patients with systolic HF, even for the treatment of coexisting angina or hypertension.",
"   </p>",
"   <p>",
"    The second-generation calcium channel blockers",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    have little or no negative inotropic activity at the usual therapeutic doses, and may be better tolerated than the other calcium channel blockers in patients with HF. As described below, studies with these drugs found neither benefit nor harm when used in patients with class II or III HF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Thus, they appear to be safe and can be used for the treatment of hypertension or angina in patients with systolic heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/6\">",
"     6",
"    </a>",
"    ]. However, in such patients, ACE inhibitors and beta blockers, both of which improve patient survival, should be given first in patients with hypertension and beta blockers should be given first in patients with angina or atrial fibrillation.",
"   </p>",
"   <p>",
"    The clinical trials that have evaluated the use of calcium channel blockers in patients with HF due to systolic dysfunction will be reviewed here. Calcium channel blockers have a better defined role in the treatment of HF due to diastolic dysfunction, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment and prognosis of diastolic heart failure\", section on 'Calcium channel blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NIFEDIPINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    in HF depends, in part, upon the baseline hemodynamic status of the patient. Short-term use of the drug can cause hemodynamic deterioration when there is evidence of more severe HF, as manifested by high plasma renin activity, hyponatremia, and elevated right atrial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adverse effects of long-term therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    were illustrated in a randomized, double-blind, crossover study of 28 patients with NYHA class II or III HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ); nifedipine, with and without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    , was compared to isosorbide dinitrate alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/2\">",
"     2",
"    </a>",
"    ]. Eight weeks of therapy with nifedipine alone or in combination with isosorbide dinitrate resulted in a significantly higher incidence of hospitalization (24 and 26 versus 0 percent with isosorbide dinitrate alone), episodes of worsening HF (9 and 21 versus 5), and premature discontinuation of therapy due to clinical deterioration or other side effects (29 and 19 versus 5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VERAPAMIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    does not appear to be effective in patients with HF after an acute myocardial infarction, although it does not increase mortality. This was illustrated by the DAVIT II trial, which randomly assigned 1775 patients with a recent myocardial infarction to verapamil (360",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo; therapy was continued for a mean of 16 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/8\">",
"     8",
"    </a>",
"    ]. In patients with HF during hospitalization, verapamil had no effect on mortality (18 percent in both groups) or the combined end point of death or reinfarction (25 percent in both groups). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40469?source=see_link\">",
"     \"Calcium channel blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DILTIAZEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    in patients with HF has been evaluated in two randomized trials. The results are conflicting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Multicenter Diltiazem Postinfarction trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Multicenter",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    Postinfarction Trial (MDPIT) randomly assigned 2466 patients with a myocardial infarction to therapy with diltiazem or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/9\">",
"     9",
"    </a>",
"    ]. After a mean follow-up of 25 months, patients with pulmonary congestion on chest x-ray who were treated with diltiazem had a significant increase in cardiac mortality or recurrent nonfatal infarction compared to placebo (hazard ratio 1.41). In contrast, diltiazem reduced the incidence of cardiac mortality and risk of recurrent nonfatal infarction in patients without pulmonary congestion (hazard ratio 0.77).",
"   </p>",
"   <p>",
"    A subsequent analysis found a similar effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    when analyzed by LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/3\">",
"     3",
"    </a>",
"    ]. Among 623 patients with an LVEF &le;0.40, the incidence of late HF episodes was higher in those taking diltiazem (21 versus 12 percent for placebo). The incidence of late HF increased progressively with decrements in baseline LVEF. In comparison, diltiazem had no adverse effect in patients with an LVEF above 40 percent.",
"   </p>",
"   <p>",
"    An increase in recurrent infarction in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    -treated patients with left ventricular dysfunction was also suggested in a retrospective analysis of almost 7000 patients entered into the SOLVD trials, most of whom had a remote infarction and one-third of whom were taking a short-acting calcium channel blocker, primarily diltiazem [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/10\">",
"     10",
"    </a>",
"    ]. However, such a deleterious effect of calcium channel blocker therapy was not seen in a retrospective analysis from the SAVE trial of 2231 patients who had asymptomatic left ventricular dysfunction after an acute infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     DiDi trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    in Dilated Cardiomyopathy (DiDi) trial randomly assigned 186 patients with idiopathic dilated cardiomyopathy and NYHA class II or III HF to diltiazem (60 or 90 mg TID) or placebo, added to standard therapy; however, only 153 patients completed the study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/12\">",
"     12",
"    </a>",
"    ]. The following results were noted at 24 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      group had an improved cardiac index at rest and with exercise, improved stroke volume index, and increased exercise capacity compared to those taking placebo. However, there was an equivalent improvement in mean LVEF in both groups (8 versus 6 percent for placebo).",
"     </li>",
"     <li>",
"      Subjects taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      had a subjective increase in well-being compared to the placebo group.",
"     </li>",
"     <li>",
"      There was no difference in transplant listing-free survival (85 versus 80 percent for placebo).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that the hemodynamic benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    in this trial were secondary to a vasodilator effect. These effects, which have also been seen with other vasodilators such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    , have not translated into improvements in survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons for the difference in results between the MDPIT and DiDi trials is unclear. A possible explanation is the different patient characteristics. The etiology for the HF differed and patients in DiDi may have had less severe HF than those in MDPIT; the mean left ventricular ejection fraction at entry was 34 percent, the baseline mean PA pressure was 20 mmHg, and mean cardiac index was 3.0. It is possible that patients with more severe disease, as in MDPIT, would have had adverse effects related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     AMLODIPINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , a calcium channel blocker devoid of negative inotropic effects but with vascular smooth muscle relaxing activity, was best evaluated in two major trials: PRAISE and PRAISE 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     PRAISE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PRAISE trial randomly assigned 1153 patients with class III or IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) and an LVEF below 30 percent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    or placebo, which were added to baseline therapy consisting of diuretics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/13\">",
"     13",
"    </a>",
"    ]. The primary end point of the study was death from any cause and hospitalization for major cardiovascular events.",
"   </p>",
"   <p>",
"    At 14 months, there was an insignificant 9 percent reduction in the primary end point with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (39 versus 42 percent for placebo) and an insignificant 16 percent reduction in all-cause mortality (",
"    <a class=\"graphic graphic_figure graphicRef70884 \" href=\"UTD.htm?14/28/14798\">",
"     figure 1",
"    </a>",
"    ). The amlodipine-treated group had a higher incidence of peripheral edema (27 versus 18 percent) and pulmonary edema (15 versus 10 percent), but they were less likely to develop uncontrolled hypertension or angina. There did not appear to be an overall excess risk of cardiovascular adverse events for patients treated with amlodipine.",
"   </p>",
"   <p>",
"    Thus, the PRAISE trial established the safety profile of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    for the treatment of patients with left ventricular dysfunction, especially in those with a history of angina or hypertension. In a secondary retrospective analysis, the effect of amlodipine appeared to be dependent in part upon the etiology of the HF with improvement being seen in patients with a nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/15\">",
"     15",
"    </a>",
"    ]. However, this benefit was",
"    <strong>",
"     NOT",
"    </strong>",
"    confirmed in PRAISE 2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     PRAISE 2 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation in the first PRAISE trial that there was a survival advantage with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    in patients with nonischemic cardiomyopathy led to the PRAISE 2 trial, which evaluated the role of amlodipine in 1650 patients with a nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/14\">",
"     14",
"    </a>",
"    ]. After a follow-up of up to four years, there was no difference in mortality with amlodipine (34 versus 32 percent for placebo). When the results from PRAISE 2 were combined with those for patients with a nonischemic cardiomyopathy in PRAISE, no difference in mortality was observed. In addition, short-term data from the Amlodipine Exercise Trial found no benefit in parameters such as exercise tolerance, quality of life, or NYHA class [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FELODIPINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     Felodipine",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , is highly selective for vascular smooth muscle and it does not have negative inotropic activity. An initial placebo-controlled trial found that 12 weeks of therapy with felodipine added to standard therapy did not improve exercise time or signs and symptoms of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/17\">",
"     17",
"    </a>",
"    ]. This was followed by the large V-HeFT III trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     V-HeFT III trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The V-HeFT III trial randomly assigned 450 men with chronic HF who were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    and diuretics to extended release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    (5 mg BID) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/5\">",
"     5",
"    </a>",
"    ]. The effect of felodipine on exercise tolerance, symptoms, and clinical outcome was evaluated after 12 weeks and at an average of 18 months of therapy. The following results were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At three months, there was no improvement in exercise tolerance, quality of life, or the need for hospitalization compared to placebo, despite a significant reduction in blood pressure and serum atrial natriuretic peptide levels, and a small but significant increase in LVEF. However, the beneficial effect on LVEF and atrial natriuretic peptide did not persist during long-term follow-up.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"       Felodipine",
"      </a>",
"      prevented a worsening of exercise tolerance and quality of life at 18 months. The difference between exercise duration and quality of life between felodipine and placebo reached significance at 27 months after randomization.",
"     </li>",
"     <li>",
"      Mortality and hospitalization rates were the same in the two groups (",
"      <a class=\"graphic graphic_figure graphicRef78557 \" href=\"UTD.htm?13/24/13709\">",
"       figure 2",
"      </a>",
"      ). The only apparent side effect associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"       felodipine",
"      </a>",
"      therapy was peripheral edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the above studies confirm the lack of benefit of calcium channel blockers in patients with HF. These agents do not improve exercise tolerance, quality of life or survival. Although the PRAISE trial suggested a survival benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    in patients with a nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/13\">",
"     13",
"    </a>",
"    ], this was not confirmed in PRAISE 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/14\">",
"     14",
"    </a>",
"    ]. Based upon these observations, the use of calcium channel blockers in patients with HF was",
"    <strong>",
"     not recommended",
"    </strong>",
"    in the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    appear to be safe and well tolerated in patients with HF and can be used for the treatment of hypertension or angina [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30438/abstract/6\">",
"     6",
"    </a>",
"    ]. However, ACE inhibitors and beta blockers, both of which improve patient survival, should be given first in patients with hypertension and beta blockers should be given first in patients with angina or atrial fibrillation.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/1\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/2\">",
"      Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/3\">",
"      Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991; 83:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/4\">",
"      Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/5\">",
"      Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/6\">",
"      de Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. Am Heart J 2000; 139:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/7\">",
"      Packer M, Lee WH, Medina N, et al. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol 1987; 10:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/8\">",
"      Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol 1990; 66:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/9\">",
"      The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 1988; 319:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/10\">",
"      Kostis JB, Lacy CR, Cosgrove NM, Wilson AC. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Am Heart J 1997; 133:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/11\">",
"      Hager WD, Davis BR, Riba A, et al. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. Am Heart J 1998; 135:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/12\">",
"      Figulla HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 1996; 94:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/13\">",
"      Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335:1107.",
"     </a>",
"    </li>",
"    <li>",
"     Data presented at the 49th Annual Scientific Session of the ACC, Anaheim, CA, March, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/15\">",
"      O'Connor CM, Carson PE, Miller AB, et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol 1998; 82:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/16\">",
"      Udelson JE, DeAbate CA, Berk M, et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J 2000; 139:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30438/abstract/17\">",
"      Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group. Br Heart J 1995; 73:428.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3455 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30438=[""].join("\n");
var outline_f29_46_30438=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NIFEDIPINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VERAPAMIL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DILTIAZEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Multicenter Diltiazem Postinfarction trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DiDi trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AMLODIPINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PRAISE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRAISE 2 trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FELODIPINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      V-HeFT III trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3455\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3455|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/28/14798\" title=\"figure 1\">",
"      Amlodipine in HF I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/24/13709\" title=\"figure 2\">",
"      Felodipine in HF V HeFT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3455|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 1\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40469?source=related_link\">",
"      Calcium channel blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_46_30439="Molluscum eyelid";
var content_f29_46_30439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75198%7EDERM%2F66482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75198%7EDERM%2F66482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum on the eyelid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solitary nodule of molluscum contagiosum in the middle of the left lower lid. There are no signs of secondary conjunctivitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gold, DH, Weingeist, TA. Color Atlas of the Eye in Systemic Disease, Lippincott Williams &amp; Wilkins, Baltimore 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum on the eyelid with conjunctivitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 287px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEfAZADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2vzPMOG7D0pjSkZPRRUJlbBHeoWYj5i2PY159z17Es0m45BwPSmCXDg45PXFQNjeQSOOaifdkEYNK7RSRZeRWY449jTBdtAGQBWB5BIzj6VTViTyW9sUkr87Qpz6E1Lm1qi1HoWRcEP8AMSA390d6a0sjKcKdvoRVVHfBUtsH0oDHcdzt+VSpNrcdrEodypxs9SDTZ5SiIUbzGHI46fSomR2jMhG0A4JxxVSdjG5w4kUcdcULQe4uoXpdQzy+aTzjGCDWa2pSgAIgGBg7vSo7mdYss7qQOxFc7q+rzBmDKkcTIWR246dQPw5p8zNYxVifXNVNpDmby3jPAJGVx+NeYap5+rXry6Jp8TXSIVeKJNomQcgDGMMOx69qvGa81+9azspXkiz80jdFHoK7rRNBfQ0zHGbyMYZhHjzfw9TVwunfqVUUYxtI5XwdpGkS2lvfx6pdWU8p2hpWXaGHVcuCpIPUcH2r03T9Ov8A7M4TxPEkUcZYO9rDnH+8DioHsLK5Ju9D1iHSLm+Pk3DzRK8Vww/hnhcYJ7bhhh6muTm0sx3tykmjaNHKsmGu7c+YkmOpVcDA9jXRFqC5mcEpSqPlNHW9QSy8OajcWGsT3c2okWjIxCqSTtGMDHTJ4ri/CaPp1lPaoUMFvcyeSD/CrYOM/Wug8S2he3gvS263tnwFBG1XIwDj1rlxffZ4JSSFyamVRuyNKdBK8mTX97KLxZXZI1jbfhGOWbtk+lcprniINcNzuY9hWfrOrzXU7RQsAOhaqdrp8kxAiQszdWPetLKOsjmq17Plp7lW6ubi5b52ZU/ug1X8r0XP4V2Fv4TmIDzSqB6CtL+x4rC3JxBux1Y5NYzxtOOkTCNCdR3mefi3fjCHnpxTzbSBMkYHauyuFEsK7WjGP7ox+Nc/q00FsPnfLA4xV067qdB1KEYLVmIwJzlTQCVIypx/OmTX4LHy1IHWoJLpmzjIrrOM6Gwu7BC5u7EyKBxtcrk+lWZW8PTYMEGoWjEc7pA6g9/eubtb/wApX3rvLdDnpWnYanZPG0dzGyuTw3apei2GnqSGKBnKwuxAPBYdR61XnhAJwyuB3Wt0WOnTRM0Td8KB1xVm40ONrVDBKiN3VjyaydWKdjX2ba0OSR3ibMUjJ7dq1bDW5IcLPnb/AHh0qO80ia1AZ9uD6HpVAwnoav3Zq46dWpRfus9I0XXvNhH73K57Guit9VLQqVkcbevzGvF4lmt3327FD+hrf0jXSX8q5zHJnjng1EqdtUerQx6npPRnoOqsbmFuYyMZVnQPj8xTND1fWYI/sFrJpKRZ3j9yyEe/y9fzrP06788iMnOQagv7RG++GKg5DKcEH2rK9melyqa8xNRmutO8P6pdz6xezX00lxaxxwy7Dt3HcqjJYR9SRkA9811fw0Npo+tziW0gtvsekQ2iGJjvZpWLSux/vHA47DAFcBcIUbUUmnwZQLkOsYDyDjILegYAkd67TwtpjTyz3BZpZLhw7O44OBwMegoc+VHNHDKcryVrHXXPiKbVdRNjZwotlp1u0fliVmjnZ2BAk24O1QgO0H5s4PFSuIoR50iTXutXp2zalMvywL32KPugDIHfmtjS7eEwgSW0qMAGAjjyD26jp+Nbb6PcNb72igjYjIQtuYj3x0qrza12IlCnB2ZzniOx0/U9MMt5PHFEBtWeSQIIvYZNcHZvf6DKgWN7zTi/y3e1gp+nGW/Diuyv9GitdUF+YFF2oADlQ+0f7IbIXvyBmtK6s/7Tszuu711kGGHm7f5Cp5VK7juaRm4aPYyrG+WWHz0cvlsYBxj/AArUivY2OxpRHIDgBW+Y/gOTXneo+H7jw7LLdqst/pzHc0LSNlPfGcGtHw3rtrImy0RYD1KgYJrG9maOHMro9Ct7hsBfJMagfxH5vy/xq7HL8uZyxAGOuKwrG7QRhmZmb9K0I5EmTMh+c/dUCtU+pzNFvz433DJLelSCfysRyFVU9hyapmZEGzaFbpkU6KV43V/KVs8AkdauMhNGoJNyKCWEXbJwaVFUD5XwAPqTWe8+5j5hxJ2qRGwoB60ORFjaXawJ4+XsDUEsm1x0YdRmq0rfMG3DnjGabK7CMkru+lYc3QjlHSyksSwx6Fagduc8/XNIjJty27d1x1FQyTYJw31BFQ31LSHmVVYAg5zTmySflUDtioEYhwZBk+3enjBIJB+melS+xWxYwWAAKj6moJSSpBJIX+7TJGQN8rYP8qrvJtJdH6dRmpuJIkNwu3acFSM8nANVZ5oymRlmByIx1qs04jkYGIy2x/ujLRHvx1K9+ORWVquvQWduZIJ0nfoqxNkk+nFWl1KSu7IXVL+1sYnmvWCIcnryPwrze9uv+Es1F4Le4itbOPo8rYwexPoP6GtS903Utbmjm1JmiWRsJGe1dpa6Jb2Wmx2nl5SM8yp8rbvZhz/T2rSK7GrfL1MjwTBp8qz21k8SXttxcWxkXeje3PzKeoYdQa7CV7e1tSG8trhsBVLjcfw9K5vXtO02KJpdZ0y21G0C7UkMSrcR+2Fxu+qkH2Ncxa6Lo13C72W1dPXK/vreJ3X23Fd4/HmqXLE55c83Y7bXr66hltri8jtoFZcyqrDEmOjcnr9K56HW7bUb9obZlmjVPMaSM5APpnpVZfC+hwLCfstvLM43NHPEG8sdsE1NbQRwKtvaxJGu75Y41AFJy5nojSnTVilquyQlgpGegxya47xNaSxW+5/l3dFr23RfDA2i5vl3P2U9BXCfEW2jS6+78oOMV10qNveZyYrE2XLE828PaALyYPM2EB6etdhPbQWYjgRNgPQ1HpMSDayN0/gArRv4YmAJLFuoz2rhxEnzavQ4ab7GbJbz+YoGD9e9VNQQhQ/lgsowVrZmEy24Vdxc9CK57UElt0MjOdxODuNcfuNnZS5upz+oXYghkIQLnt2ribiZp5mdySTXSeJXfyDgDBPUVzAr2MPFKNzhryblYCuPfNG0ntTgKmjbBrcwuQFSvUEd6Qc1ZkXcST196ZtAGDxnvTsK5o6HeFZhE5O0niutilsEmD3G5nXkN1ArgICVnQg9+tdzpAjkZA+x8DOG6CubERildnRRk72OhsoLG9iJmX92eRnvU39haaImMaqVz3PNULiK5aTbFIqA9QBn8qLcXlqxedlaM+2Xb6CuKnT0upGk6jTsyK88JSzMTZkAYzg1yt7pssDlZkZGBxmvVtInmMJYA7T0VxyKx/E1gZYwzFNzdhXbRc9mc0qiuchod1PDIIpP3i9vUV2luRcQYPX361h6FpH/ABMIwzA5PT0r1OfwcZbAXFr8swXPTg1vUoNx5kengsbZ8kzgZrGK6hZJ2dJI2BidD8yHv9R7V6V4F09obCBpZPO4w0hXaD+ArhHcwTvDOhSVeqkdfpXeeHL0QWkTqGa3/uDkqfpXBNNHsz95c0d2el6bNGgCkqCB5bZ7jrWlfakZYI90cXyHbuAwcVxWn3UbO0jFRk/KWOSB6Cr0+phCBgAHq2KPrHLE82dH3ivrSl5vMIXZyD7Cseyu2s5nRUkdd2AVTcPyFP1XV0lgO5vkXpgdfrXB3aLf6jJeC2S4ywjSMXrQMT6AqcUqdVOeh1xpv2fvHosV3FqHnLCsMq9GQLyp9wea838daBdWt0t/psSIi/eCcfpW9DYeG0vUGoJqOnakvCyzX88Zz/svu2mr13oeuQMZdO1m91Syb/lhdSRs2P8AZcoQ344+tb1Ic2qMadVwlocj4b8R+ZsjuhsccMWFd3aTCbHlTZXrgGvOddsof7Qj3SS2k5PNvdwCBif9kglG/wCAmrNleT2Nz1ZI+nXmuZ+6dfu1FdHpsc8QfAwc8E9asC4JYdCO2e1c1YXcEqhlfcT19a21uo0QbAC2OuK0UtDmlGxaEh87fGpLdAAKezSKSZj8x/Sq1tI33jUjSMZflJI75px0WpJqsEDYHPfJqOVtucknjGAac7qwJGR6A01sFeSM+gFZqxmQx+WAxbcD2FBb5gGC4xwaidwzEHcBnpimLtU8M7MKnoXYsEEEsJBn0xSFmGWUA5GCaieRgMomMdc96g87cO49qVu4WJpNoB+XGevNVJPKdsBivue1E1yApUrnPc9qx9SvPITdwPoeamTSLhFsg1XWUsFIkk2EnCsOjH2Pr9cVHp/hu3uo5dY8QRq05GVV+Gx25HOfxqXRNJW8ka+1OPMX8KEZGPpUtybu/wBQihsmEdpF8ogkBeP6DnK/gSPaikr+9Lbp5lS/kj8ws9MDhruG/wBRhJyIovMWVfycGrdxYamkccQ1y5FuQDIot4lJPfBxTrm6kS8YTWUq+UMKbZ1kB/Dhqz9b8YzxQxIml6hNIDhBJCI1z7kmurmtuzJxbtYp6vDa2h8+Saa7kB+VpzlgfQDtVXWLKz1FfNktkL4xu6Pj0JHX8azpZ7qeWOW+iAncnao+4g/mTTp7nylxnzJX7461zyk7nRGmrE0WERRGCXI2qCcmu18G6D5b/a7tcyH17VS8FaA7r9puly56A9q9GtIFijC4+aurD0r6swxFZfChl0oWHCDmvKPiFCHfeY8kc16/PANpD9cdu1cJ4r0sz2zFME8gZNdr2sjy6qVrnjljNGkjBsoVPFXpZR98nzDjHSh9NEN4yXC4U1aKwlvLXgdmNePiVysVOxU3BUywIA7HrXO6tqMUzFBG6hTjcw6n2FdPOUVTtUBR1LHrWPeQxSfvJIgMdMCvPpK0uaSO6Mk1ZM4rWrZZbdiCSeoHTFcngg4PUV6PLpqTq0iyMIxyAy8GuT1bTCsrS2+GHcAcV7eHrRa5ThxNJr3kY6jmpo0zSRqQxDAgjtiui8JeH7rxFrllpWn+WLm7lEcZkJCg9efyrujG+hwSfLuY/wBnOAcdagki29q+qW/Z3ujpxRb3TxdFRyRJgH6//WrwLxD4Xv8AStbvNMuo1S4tZTFJtORkensauUY2umRGUr6o5Wwt/Nul+UlB1xzXc6Zab5UQIu38uKh0zTRaxYweD8wwM1ux28iRZtCFkHcjP8q8zEVW9InoUYJasu2OmFYioaQg9z/Kr0WiSBkkuzheqYotPPWFcgK56jPH4VoQzP5flyMW54Ydq41Ke1xT5dWSQiGGH92Syjr61gXtwsju2DjOBnt7Vt7GjLtnPGee9Uliyssf2dJA47jlT6ivRo6I42tbh4WsPtGoIyr1PJr3fT7QJZIhXIC9M1wvgPRVjxK46V6dbLtQDt1+lejB2jY1pxblc838deDFvoXubddk6jIK9TXlVprN3o128My5AOHjPGfcV9M3KZByM15R8SfBkd6r3dkoE/VgOtcmIp6cyPfweIt7kzIt/EVu1ss4mEIIy244x/Sm6l4k/wBEPlXSbzyrbgcV5nMkttI1tdodnQg9DToOAsTkYPCvjgj39DXmuinseolG+uxuX3iaa4l8rJMjH75HBNdJZ6ZpstotjFNi6kXzhOjbXDfTpmuSbT3tUiuI1EhH34nHDj2pmpWgeKK7sLt7YK24fxmB/wCYrSFKMTHEyk1ZLQ6yDUfEWl3Bsriay1aI/cjvwIZD7BsFT+NRzX2i/bUjOheKPD2puMg2DFoJW9lVwD+GK5x/EOrafAG1m2TVYjyt1Dz/AN9DFQz+N4bYo1hLBPaSH97p9/GWTPqGPT9a6YXvueZVceujOqu9X1OCP7HqNn4ru7Jz83l2jtgerRzow/Jq5vUtVtNEnjNhc6wYWPyxappqww59N5YFfwFdFpPibQrm23WV1quiXZO3y9K1hZAW9oHPzfQCnXV5ezxz202v6vqeFLtb3dgY5SPdWjZPzIpTi4/1/wAOYRqa6Mw4PEs4vcQHSIG2q433ZYOD12AhQSPQmu00W/ur+SFP7YZJWBOyO1jjBHsTuz26GvOLLWYNJv4JG1LUbbIeB7a8s4pYo4zyMIW6bgM4xjtTYtYtNRuWEjWTzNGXaTStOICJtOAEUqfMzzk5UcdelZOnbbQ3+sN6Sdz2JkX7S0C3l5NcoA0hknISIHoW24AJ7LWmIoI4BI7yBF6vJK2T6Hr1ry/wpea8sUT6TYHUdObJD6gTAqSd8EMXkbt82fwrqtLfV726Ny15pd7HGxVSqSIocdQBzjb0J65ov0NFLm6Ho7HYCQOaRi7DI5z3JqOYllDL8uDzmkLo0GBkc9awJIzCQxJ+biq1zK6cjAx6U/zNxKEnaOh6VBK4XG45A4Ix1plxXcVHyNxkJHcVFdTdwOPXFQiZeRzjtmqtxMAeSMelJuxajdhdXSrExyRiqOl20uoXPmzgLD2BFNVDd3GMHy/austLX7Pp7v5eEUZJrJL2kvI0nL2astyhqt0626W8CheNvFWNKSG3szuz9oPCHsPc1WsY/tFyZrghYV6bzt4qO81CxiT/AEQyz7m4WONnzj3xj9a6I/zdjG1lyl26tAlrNIxSRU+ZiTjFcBq94iu9zKmEQ/ImeTWrrOrXbRbHRI1PKKxzj3IHU1x9zOJbjMjNK68s7dj7DtUSaZ0U4SSLhmMimaQEO33V7gV1/g3w2bmRby9XjqoI6Cue8MWD390JnXKKcKPWvaNGsFghTcMtjOK1pU+Z3ZjianIuVFnTrRVQrCuE7HFXni8tcfrUokCACMA4qvLJliGYZ9zXXHQ8xNyZGWZsdBjisy/hDnycD5hmr/nLv2JtZsZ4PT60x03ckfMfXvW8NxzhdHlPizRsSHZzk9v8a42WyMZPmbxjkZr2jW9LSaKQliXftniuK1bRW8ptwKk8AEZ5rOrS5znlBx1Rwsh8wblUkjt/WopLeS5O/YwUdj3ro5NPMOWHAAz0AqPyT1xjHP1ryqtKUZDU9Dn5rZ4YsSKMkfKKxAELGJIwzHqevNdNqcDaghXzfIwABxUUFhbWi5GWOM9eTWCTS2uzoVRLd6HKahpMTDMsajHPAwa6n4UT2fhXxba6u1p9qa1DqU8wDG5cAjPcZqpJGL6fy2iMY3cHPWs2CI2sc8LvibeMkf3ieK78POpH3WznrKE9UfTI+MtmSu7R7kLn52Eynb9B3ryj4g38fibxHe6va2y28EqLsXjeSq43NjuaxrdiLdUkP7wAAn1qVZQB8y8Hoa1+sOfu8tjGVNR1uc3HduiRlLWKXGRIPut9QK6G3FtJHvQbSOp6cVHeWFnNCvmDD5+RlHSrC2JhSPYT8nB9D7VhKmt0iXVvoxkcDmViok2DkbjkEeoqff5bbChLgfKT0/GrjOrx/u0O5R7jNFppb3chD5XPfPWtaVFz0sZznYxZBPM7J5mSfTnNdL4d0eVyjSkuc5GOmK19H8OpGylY85HU5yRXf6fpkcCDep24zwK9OGHUERDmmyHRrNYYAO4HzZHU1rRExpwcoe/pTY1ETGT5Qg4IP86mjPy7Gxycg07HpQjZDOecgf41VubZLqJtwB3e3SnXcptVIkOVJwp789qd0iXAGSOSegrJystTa3U888ZeCbXULSSSKMLMOflFeUPotxpMhEyExng5FfRNz5yqWOGTGMiuX1e0huUO+EHOVJrmlCLd0ehh68oqz1PJY7NWjP2SaS3J6qPnjP8AwBuPyIrI1G1mBkYq0UuOZYASjj/bTqD7jNdbqtgdMuWQEmBjwfSs+4TgFSPwrFpxZ2OMZo4ix1e9025b7DIhJ4aBm4cexp9rqOl+dO2oQXVqz8qYsAK3urAqV+mK1Nb06G6G54wW/vDg/nWDa+bb3JthcpECcL9oO6JvZsg4+taxkmebWpzhre6NvTNQ0a4hEd9F4ZkRW4kuIpLaQ/jHkH8q3rPTNG1iVYNM+G8d0rH5r0anNb259wzqMj6Zrz42l19q822mtLWaJzloGyAw7jGR+RrtYfFnjlrKO3uLWLV7RAfmhbbI/pudTux7DFNKNtzilzN6rQb4p8CWVjBdXoNjbzWioxs9OSR0jG9cmSWQ/eAPpj2rqvC88em3NxDE5ijZ8RuoBMozyxbG4joB+lcTq3irzdDu9NutN1KK6kURrbxBY7eNyQeQvzMcA/eJNb+vaiNStDcC/wBN0pdo3utx9ouTx91QoCqT25LVhOEtuh0UpUlsjV8S3lu+pwWOlyJBqlw+y41BH2C3XGWDEfffb25xkdzit3T7GdIYoLaWeDTokEcaTRr5kijoDgAgfXk+1cP4Jvfsaeetlc3V4QUh82MQpax5+7vYABmPLEAk+td4Li6a3Q3VxF9quG2RRwqQiHHJJPLYHOTjtWbjbQ2i3L3md4yqDliCMdc0xbdmRmQqcc49qFjYLkfMD0zUM08iny2ZQcchTSVuqElfYgZkMhzn+VQyN24/LNSPukwXb6DGBUEnBxjBqXubJFKcqejc/SqUyO5XArQlXzHyKPs+HAB3Z6isnG5qnYn0iwG4NyPQetW76aSWf7IpO0DBGeKlt3e0t+V4/hpYUNvvkkZTI/OCuea0grIxbbd2P/s5II0aSBFRxgZAbJ+tZmu37w2It3YrbxHIXPFal5qkvlDzBE3GAAP6V5x4vvmubk23m+ZnrGgCqv19auTVrIqjTlJ3ZgX+ovdXEjR/ODkAjoPf3qDT7Y3FxHEmSinLH1ou1ESx20PMr8HHYV1vhvTo7eFZCMsevuaIQO9+6rs6jwzDHbICoGBxiuthu4xtZ5uTwAvWsTQYU5lcAHPArpIY4h+8KqzdcAVtra0Ty6zjzajmvore1aUMAq8tntTDdpPbB4yGdui45FVbkEzuHiV4JBkg9setJCRLAJ2Ty3HKKvb60QcnLyM+SKVzTs1jQAbPm6k46mrAcNIXcDH3QTUCF9uQAzY6g4qzIQYAoPXjGOc13wfKYS3K0luksodWw+en9Ko32lrI68DA5yfWteIAR8jDeg/nUrlIwfObpyeK03MZX6HAax4cAjdlXAx9SQOg/E1z11peLYpOrEqFDEDqzdh34r16SCJgh6jdux9OayLnTkl80mJvMZ2BGMDoMfzqZRizmlByPJ7nTGitzHFEPNA+63bPr+FZT6bNEpMUauxGcZ6D1r1W+0XzDMyKFkGRHk/LnGAT+ArIuNAlhsp5Fk3KrMc8KWwcCud0I3uS1K1jy86PdG/jlIIVDuOBj8KLjSS9/JceW3UZXtxXph0e6W5jja28wjkkEAKBx+OatxaNDNFuERXBKuCec9/896Xsk3uYtyjoedfZJWRSNoYdsdarSaTOWBXO3O7b6GvTZ9ERSSqEEKCvHX3q4uhFlkVIVBVcLxjJI4qqdJRZEpSZ51Z6ZJ9lERQEg/fPatSDR5CAZMsScj/61dvZaM2yPcu4ugJ46HHOfxrRGilZRjcwA5HTjPX61uqMd2SlJ6HntvpBebKhvlyMtnGQM/hXT6fpD+TlgdjIGQle/XH55FdZa6SkHzIoyBjkdx6+vBq7FaokRRQAUPI9M804pR2OmFPuZNtbLBkqpbDAru6cgd/Sr8SFcgDKleR6H2p7xLvVeVYgrgdD6GpAo8naSQUGGyfbrTjLU61FLYgMkcbhZlAGDgkdapI0hbhPLTJwx5Lf4VMkbyRDcfmAzg/p+lCnzoOflGaTbRsrRGzRCdVWZtwqEMRH5cvc4BPeoVuFeZ4HfG3kAcA/jU8+yXC+g6+lYSlzaj1WjK85WKbHVH64/hNYuvLDEI5U5yfzrblBeIpywI+8DzXP6myPANiHz4jyMdaxk7G9HVnN+INPjvrbIUq7HniuDmia0uWglBI/hNemXM4kAJUgHqD2rkPENg02+SP+HkGplqelRvszm7m3WQFSwU+9cnrNi24shw/bjg/WuziImiIYDevBqle2m9CPSstUzScFJWZ566BVYSwGNx0aLgURsJIVVYrcFTyzSkE+3PArW1W3lhfMcYOOue9Ydzyd0kDoP7ygVvGVzyK9H2bOz8OavpzJClxHPcSQZ+zadaKVjiY9XZyQCx/vHp2rs9Es5Z5oru6uYJZoiWgsw5eK2z3BPLSf7R6dq8dhlupAixCZyv3WACsvtmt+C71zan27TrqS0TlpLTbHK31cZ/SplFMyhO26dj1HVpYIHj+1QSveSDMUMfzvJ7j+6v8AtHgVJp0ctqz3d+yPMVwWVspCg52Ke49W7/lXG6N4m8MWhkVJtc0q4l/1oZd7SH3c5J/HirDapa69L5VnqE8Wnxtm4k1G8jtlkPZQFBJHc1k6b6G6rrqz3Vy4TbGT7mqTW5ZiyqzH8quS4A+ZsDsKSNg6bEBBHeofmXFvoUplONpBBqKJQfft1rSaB2GR9zvS29sockJkAUmi+bQz3iCgkDgc4xTbPbJcbUTIHJPpVy6RkGEBwepot4Dbwl4xh2Gc1E76JFJ6CMyzXCoqbUQ4OehNab27LbsdoBA3E9ar2MB8oMCCxOfm9aoa9dmJMxuY1YYkweD/AIVcdFzMizlJJHL+LNcWC2YIo8/naR/WvOJ7+SMMzMWduST3NaXii+Sa68mHop4CjJY+g9a5+0glu71vOVkCHGxhg/jShHm1Z69KmoxSRr6HbPJIJ5wWYnIr0LTIiDGwXC44HvXOaNEDgY2qtdTaSncqp24AraVloFVPodLYLJ5YyAxbgY7V0VrtSFFI2v0Y44rmdLDxTD5s+o9K6SWdXtPJgb52Gdw5xRB21PGrp3sRuq3M5h+Zo0bLELwx9M05Lb7OQSO/f0/xrSi2pa7oyOBxx1NVbveYtzZVR1HrW0NNTm523ZE8SqucKASe3SmhpFmJkwVA7fzpqSkMNqZBHyZ4GKd93esoBI5OO/tWyaI6kSP/AKTI5k3Io4wcVKWJkRSwJdgM47k5rPtMCEOQ4eV2c98KDx+HSraMRPbMkhDO5chh1wv/ANem5MuS1Ndok2sxyQfmJHBOOcVFhGto+cGQjt0yc/nSwES7tvLE7eR1460kxYhI3HyqwYkLx19aUpKxzW6ELQktGMcluT9KhSzNxbBJUxvZtwwCeGJx/KtmJfMKnIwOhFV7URxooAIYO/A5PUED9ahzs0LoQxadG1yzbeSg69c1VGnbrOYoBkZIAHOQ2a240bzm6AkfMfSoxHixyclgjZ9z9aXPrYixVk09CR8g+YkYHoR0qWSGOLaYh8oID+oBP/6qswK0kSuxB2KpPORnGTz3prkyyTxBDtzgPnAHGQatVLE+zQx7eOLcSMKOenanPbIQWUDkYyPTPFSzv/o56sSvOB2pDIqbSMbGXAAHen7USgIAFYoxG88+/pmq0jLGzPgZA2sfpSmYm8bEZ2hMF/f0rJ1i+EM3ALo4O1FGSzj09qaqI2hTbdh0kxliYo7gqQVB6/jViYExOBjlSMelUEhaKz38+ZwX75BNWLmfYolBLLtKbR6Hv+FNz5WzVrWyI4pghTfgGRcDHcjg1WWUpI8bhkHJXngiobiO48uARhSu/Kk8bSfbv/8AXqO+kfyQskZeY/dbsfX9Kn2jZoo6kN5II7aOUlf3Lb2z2z7U6C6RokIYFn6EetVtbSSWyfyCQVTK5749TUdhN5sSq8TIiABt64J+prnlJqVjXlThcsrK0b7ZON3Q1kaswRjJDkSA9T0NXLwxpGyRvlTyDnv9awL2abY7MxbjjB6ConPQ1oQvJNGdFeKN32jkknIqG+ZUiOBmJ6r2UyzI+3JIznj+dEgJYMmSnSojM9V00mczqkX2O4WaIHYeoxSHZLHuHQit3VbbzIWDDII6VzFg/lXD2zdjkZqty7XKOqWAmjPHPbFcveWk0LndHuTuK9IaINkAcisjVrB3TdGBkdiKSdjnqx0POXxbziS1fY3eNq3NH8SSo/ls0EB/29xH6Uy8ht2cxzgJJ2DD+VZc2nRbuQ2w9xzitbp7nnThOLvTfyO5jkXxCiW8KebET++vJYwiqPSNR95vc8CuxsfB/h6W3XytOWGZBhZEb5uPU815Jpx1Owx/Y9/kf88pMEfka6nS/GXiSxIF3osE6jqyuUz/ADqGuzMpf3k7n0PNCUYmQcdaaiLIN23CjvWhJAqIDKCzH1pESIxBs4I521PKUmUoyFG1cgds1aCCOMk8k0qxhsMyjk5FQ3r7kYdDnjFO1tWWtWV2aSY+S2AindT0QzyKi7Qq9zTbZCuXfOQOferqBVXcF96xS5nqVJ2Ibt/sqMyurR47V5L8RdccKLOGTaznLEdhXX+NNZFlaXM7HbgcAdK8QmvZdUvmlkJbd61T956bHoYGhf3mNsPNN9G8cvKHKsRnn6elbtpJNdXTy3MgaZjyQoUfgBVW2twskY244xVyKMwStt4zWl7I9uNBI6fT0O0AEAdyK3LCJPMZcY7571zWkyP5bFTzXQaU7zNyoLLwGrGUm2c+IpuKZv2zPbIBxLvPB7qK6a1jW2tRtXIkGdy8kmszR7dIwCxDMevFaF88drZPKoHmAjbz1Jppcup4FeXNLlQlpLJcSFVkkMcZ2uoHG4VPdSxvdRI0kiq3ZuBTLMx2UqsoCKQFmJ/vf3j9adezqb5cgNgbV/HrWtN2jqcsk3LRaD7mVpSmxWAhJO4cH8PwrN1HV1TSs286PcSAhuOU9Sff61oussK+UkgYuONwyT71yKQebrZjg27fNaR4zyvy4CkH681q27pFUIRlq+hv2LQWkEVvC4O9R5hBy31P6/nWo9wkM9lM7BIAGUbztyxxjr+VVLIObp2jjjCocEkYJz3/APrVdCxyXE0b7ZdqhSOqgd61k7JKJnJq+pcsbt3m3bMhi23a2ckH5sGo9QvZkIEcTMoBDgjgA9Mnp2IPoTToWES2hUbF2PsIHyngYwKi1JP3d1GQBvZH3K3+z3rJyai2ZxScjTsizWayhMu65A3fdyPypkT5+0CNwZomBAA/2Rn61B4dcy6baiUHzIUEbqexwO/epdPZnmnkOAMsPocn/wCsKzcm7ESjZyRoq4MXmKWIKAkAdT2/nS4YDy8nJXGfTg1XaTcAkYJxLt9Mcc0+4V324cjntx+tDbTM0iKzdTsidSCIgR6DJ9Pwqa1XZHIVzkHGM57dqybSf/iZlCNsinYMnOVILZ/WtW3/ANcyt910ByPY1cHzJMc48o+IjyjGQcjPfrmqxKzWlu8jMCCOASPanyN+9k7MVAx05rMhmm3Sxy4MKMrDCdc4OCabtfUUY31RclkEEU+1yWUHG7qDjiseFFmu5vMCs8Souf7vc/rWjftullUnhomBIHTHNZsUyLq6CT90zw7kz1lHf8v61psrGsU7NmpOEEcqsyqCvbtVKE7rfL+WwI5xyORipSUMTryqBTntVFHnihkVkKDltxIC8D9aTn71xRWhZkOGjBOAoLe3pWTfuxnSZGwiAko5POeAMepq4zh5m38Isa5B7MecVm358xWhjbDnDMwG4gA+9TOWmhrTVnqVbm5eOKXds3KjcNn06UzT5I1sxNO7yGQAkkcA46AVmXEIcMZLm4leTJGPkAH0A5pNMuZ23LIfMEH7tXUY3cdSPWsHN8x2OkuTQsTzm4fLELAvRSOtZNwySlzt47gVZurgQsEjKlzyc87frWXBOxuGQBw5bPmbcA5rGU+h0UqelzMurc6fPviYqspy6g84p63QaE+WuMHgVYvk8tZWQ+Y2PmZucVmxEGMFQd2aEz0Ye/G7LjNvi5OWPqK5LW4TDeJNHnIPOK3JJ9shUZyKzrzbLkHliK0TKVM07BftEAcYwRzinywIQT1OOai8IHcWgc8r0rbvLRUzjANOXc4K0rOx5p4lto1J86LcnrjpXK3FqY032kp29dpORXpGuwbonDDcuMc15zeQtDIwibaQfunoaqLuckldXZSjlug/Cpn1FdFaarqKRov9oJCnfy4cuPxNYCzAt++icH1TmtWwuimCpkkH91ozmrfoZqK/mPriWF/MLbvlPaljUSRkJhiKtKisNztk47VWxJGp2kEH8xSa6mK10IPmSNs9c8CoJlB25Y7SecCrRnjjiCNES5/iJqKAGfeiEljzjPSs6j0saq+4oUquFXdGOcYqtqM5toC4IVtuMg1cbyxE4LEMBjivPPiDrhsNNcQklidiZ9T3qL8qNKNN1ZpI89+IGvSanftYQt+5jPzkfxNXPWELRuMjmr1lZM7IWUtJI+T71rXWlywvvKEbQOCKaaSPpqNFQsiGEsoDE/Sp1ldgSCDnjpUZXOCOo7VPFlomKryD09Kq9ztsXNJkImKEYHcmux0iNYmBHIPOK4aJ9kgY5yelb2n6lIoTJ+ZegFYSdmc2KpOcfdPQraRkgkZSu7HGegpHkM80EJI/dYlZug49BWFYaorxsJHCfwkHtUNjq/m3jTTRBsKUGG5obvqeJ9Unq7bHZxSzXCTtGcITzuAwQKzrKwnfU2xdyOY49y+YOjHt9MVUi1dbeJgkTE46s/b0rWsdVtjiWWVFLrub5s4x/nFXHlbSuckqdSF7Ih1S8+x2UzXaOblk2QqncngAH1zXP6Pc/Y479pT5IDLEkhBKqBjI3euSeta+oXia7cwwxRyxQQqZnaRdu8jkBc9emSaytFJFtaLJCZhcEvjOMNuyT+VdMHduV9EXThy0mpLU7XTlgeHFvIrRyAk7HySPfmr8LpDHkIEQ5BYdAP8ACst02zsEtW8uXDKykAofUexp8chhjuRcEMgQldoIznPAH1q3O/Q8yUbsu28u5kHzPHHGPLyuOc9R68UTyg6xHA6Fk8sPIByCOQCR6cmoY5zbxB7kjJQLwegx0HvXO2F3dXHiNJeGZ0eFkVMMq+uT16D8zWbbsk+ppTp815dEjd0qWW1uZI7RY3hySzBsCM59PYfpitTSnKxyQwZlSNmXzD1fJzmq1giRvfbY4/uAEKvLnbxn3q3HcEtEVd27HK8nGPXvWLtormdR8zdhba4DxxfeUyTklc8jHAFaNxIVizGmXHOB/X2rn7ecPDNH5gWRLiRgp6nDZH9RW0GjeIPggMvHUYzVRd2zKpG1jJyyeIFdTk7RCVPTbt3Z/PNa8b/6ZEcYLIRj1HGK5G+llXUFmkeVIogiuvl9xnJLdRj26/hXQxl3nicFjBH+8JzzyvIx1PHPWrjKysaVYaJ+RbiffPJKwyp3DOOgHFVF8tmuAv3MAtz1zkf5+lMiZZLeBQCysCW4xlTyKp27N508YWQsibAw4HUnv1xWl9VczUdya4Z/LjLIxcL5R2jI3dOnpjvVK7i+1WMNwm5bm3BdGB9uVPsRWhLulbCt5bOwZSeSGHP4j2rBE92mn3atbkuDIikSDa3UDrzVXstTamr7GrZSi7jDSM2WTenpg9/c1T16+S2eFQyPMWG+MElh0xwPWsrT719ljDbgxK6bTI5BAXHp3Ibj2pdZhWyt/OjZ423/AHvvcHk545Jx+dZylpojSNFKpaXUsTXL20TvMC8x+dhkDbx6nrWS9/NtkkEOZpcLGhfJwf0FMv5Lm7hmcbbaNQABMA7ueDtGOg6ZxWLe67KD5U6Qw3UbgLGrn94vquRz6Y61hKT3Oyjh3LYv395cwWaylFLK4CgH5m7EDPH+c1nWWoC1jS3uYZkYzN+84eI7jkZYcZ7VbijPNzqG1pSgXHGI8/wqPT1Pel1GG3ayJumXYflCjP6Y71nzN3ZuuVe40Vb2dduSFQK2SV5z7VlrdzqvKeX82SW61TuorqPU4Iftk6xMd2JMMQOg5Fal6sRhFurgKT8zHvWbudipxppLe5U1C6jMOIDkN94n+dYhutjcHgdO1al79ngARBk+pNc5dSn95xnPSqTOyjTVtizcTFo1Zfv9TUEZIwzdT0xSA/6OhL8kciqckxV+ScDpitIvUtx0sb3hln/ttI4xnf1zXeahblUKkc+1cb4FvdMEqm802W4nE25pVfGU/ug5+Xv9c13ev6jY3M/maVbPbwbcFW7n1xk10uC5TwsW37S1jgNZTlkP5VwOqW4DOsgyD3HavRdUG9jkda5DULJmmPPyGsoqxGjWpyUVq8MmSpdCeK6XRnCY6hcUW9i8R2th1PT2q2bJiP3B2uOxq5MS00PpNVwgCMWYn1qKdJTjBwoPPNWWiJbIGwdailDOgBJAz19aHscUSndYQgI+5e/NWbG23ANwCO9RHZvCvt9MgVcQhI0WPqeM4xmsmk5XZc27WRS1WZbS1cqww3c814N4m1c6p4gK5DQQNhR6n1r0X4p63/ZdhLjlyfLRc4BJryazgmVlmmgaJpDuQsMZ+mamer0PWy2Ci+Zm3YKRfROWKHqoHatjUFml+bkkjlhzVO1h2gSOocnnNaKEBSUB56rmsLs9rS90YN3PMVijeNAsfA2rg/iafb/J+9U49R61p30NmLASM7i5B+ZCOAKp3em3lpZWl49rLHZXefKkbGG/qPxraN5LQ1U46dP1K8wXIPIB5GO1SWszROcggYyTVRXIyMkjtUtpc7CyyKWHpSkro0a0NC5DyygwN8pwMetdjpVtDHbw7f3cgGCw9feuUtBG7xsufLXnYex9a37UiSQlmAfqPQ1i58p5+Lu4pLQ6+xjiWHLt82eSwHX6elZxsbabUpV+zJJu+ZCQCAe+KqxagWiWPlXUg4x6ehqxJdxzTiKBz5/mbjsOGVcc1snFpHi+znFsuapJ50LRwxtIQmGkicAwnt+PtWX4dSWK704JOZYEVhiQ85z2I7exrZtkMEQigjYg8gE84PfPese4dbC9ERIVZWyrY+63vXXS5X8REHeLpo7YPGsnP7snjg9T/WsTUNU3X7BdzwpGyqUGSWxz/KsC/wDE626PayAPdMMbI+XDeoFSadc3QRLuWOKBtgx52SR74AxnHvVuSSt1MYYOUFzTR0CPNBaQ3crRERx58kJgsccAc/QU/QfMW2l1K8MZnuiHkRTgRrjhR6/X1rCsbeS8jjuZrqWOCMjDRrgPycsQM49qvRfY7zVIYlX7VBHHtGQXAbdk5OPfr61lOei0M5wSTj/XobFpclL6782Rw24OI1cEKCOM4zjpWoHAEciOW3kBsds1kbAtzd/ZUhj+QJt28cg85HQ1aSeP+zcx7k2LjacHaRwaiNLU5Z90RW5WHXJoGHz3OZkb1A6gD6/zrVgkkiBw4KA52nII5rBu4nuNaDfaEDxRjYygbgWzgkfh+IrQt7zzLaRZ2iiniG1wOx/vD2NVGF7sdRXSILyKO5uL+F2BS42LuY52cdAfrzV21vTJZwM8RKMdpOc7jyAfYHFZHlm71C6j879wkewlQBvOclfw9ffFZVnfPbX01rDuLtN5kZfKgKeG25/Kmlpoa+z542+Z1mny4TyWYqYMoQf5/TFUhchZphKhVcsNq5yapvqILQ3n3SzeS6YPB7Z9+evvU1piSeWbe+5TjJ5/D/8AVWja0sZclrtltr1Y/kiHMY8xR7D1NUrKZW0kS+ZlpSWVuOcnPSi8RRFdSSAblX5SvGMjgfWsvzpLe0aJonLKMISwUY2+nrTu0jWnTUloVbaffqV+9uFEQCryc7jnJIHpU2sO022PzhkjLMHIOBzjHSsCzs5/szyNdYMzbgQv3R6fgKrT3MkEzwhlOMqzEfyqJJyVz0VQTneL2Na7uzsXZOpJACKFwM+pqt9nELhpi0jH5mYnhR6e30qO3jJIVo0EQAyWxyOuBSNEqqwYHylO7ZnPUf8A6q5ZyRoo8uiFnvFSYAxoqYDKSePc1ALxZmluM52ny09PrVG6uUkBa5gcL/AoOf1qqjAgNMTGqD5UHf8ACstWzphh0lew3U5Y/tUTCRnk5Vj2xUU9/GyCPeNnfvVG+uVuWfyk8vb1FZgmYKV2qT0GavlbR3woqyv0LszFmI3FkByCTVOcKzEnIHYZqNpXGCSAeoFQtKXyRjd3pxjqb8tgEmzr+AquzPNOIoxkscY9qiklwwz+NdF4R003tx9pfO1TxWyV2Y1pKMbs6TwzpS2oV9rAEZK5zzWjdbdzmJSiehrTGI4wFA6dRVC9ZSCuBz6VpNpKx4U588rs5y7kLZUrketUDArkq3Q9/StO7tJc7kyVzmqfPKsCG9Kzg7aDlFW0M6W3KtjkMOhqeGASgBx8w7jvUkqE4z+HtTV3xMGIO0daZja2572CzOd2cAdzTJA3lHdkIO1JbCSVixIbjmpmkKkAFc+mM0m7o4VoytDGMbsZ9eOlSO/kw+bKTjBI9qhkcgsS5D9wf8KzdYv4vsgSNmZtvrWUZJbmii5NWPHfiNqEWoeJbaC5EklrCd8ixnByfSs+6vJrlx9paR7ePIhyMYHqfermoWPnalPcN825jVmKBGtyhA2Yx+FONRbHtQgopWIIr4wqvlsXXFSW9yxJkikIz1U1VuNP2AeUW2VVME0fTOKpqJ30qh0AuFuI2EqEuo65qvNHdGyiElxM8EWfJhZyUjz1wO1U7KSRW/eY8vuT2rSt5UZpAHBRuQc0o2R1X7GdwAq7cDuTTGjwWzkZ6VNdBzkoQQTwRSqkyp+8dFA9ec1OiNr9R0N0YlGSzYPSriamVZHQ/dbmqHll0wCrZ6bTzUAQ4Kl9hzkFlP8ASk4qRm4xe51q6vEsZmMpUggouM/N9Ks2GsSPq00yWuJJYl3scYUjj8sdq4d/M+95gBHvmtXS9SaKTjywSMZ3dfes+VxRhPDR5Xbc9Mtb0xhJJHDrwBsGDXNeKLtbt1ga4aPczDoAcAcdapxaqsahg4JLfdJ6/Ss2+voZL/a2+RJV2tgA7D2IPb3q4ycrI4KGEcJ8zNuztIWtWwrz3DliZSfLycdM+nFSXt5eW1n5V2YsfL+8Kn5RnkdweKbYOsNgkS73yvApt/fJ9jeJ8txwQDyc8fiDW8Z62M5KUp6q51Gmiza0jdwyhRjfCSv4Hb/UVf0SQRW8kaOfLjmkVY/vbVByM49eT9DXKWF4yRRofkZwCXBwff2/Ol0iVbiB7h5HM053vh9oC84IAxnjHXNOb95NHn1KDald6HUm/dZ7xrZUnRwrHYwJ3EYPf26VQN1NPPdRWc6mEIWklRfmRsnKD3zz3qqXgtrpTF8pkCgnjDdgPY+lM0y8vJdGCW0du6pLIpdpiCxDEEkAc5+tZ81zONFJXXkbbyCGyEaLAomK4ZQWctgZJ9e/NMvb9DMstmZHutmTFGPvJnGGz05rJje5hsGmSSzZyNq/MYmX0HOQPpVP7SwvrdCDDdK37xyd+8+ikY3ZHXP5UOq47BTw6ep0NoGvGnmdjbNJH5ZjTqMHqxxyfp2rGvrt4L2JxCXMZ8narDGAM8E++eDUy3kttqEjCZHWVQHwrcHtTJoWe0cBlKlt6lFAYEc5Pr9OtXqveiXTjyyvLZjLvVpHDN5DRTFcupYEPjp07jIPuK2NHkI02J443dT8zlM/N+FcHqV7cyJPFK0cJbLLhHy4Axjpx+fFaugzefZWzLPdW87IoaQFQQuBwO2OPTNHvN3OmthEqaZ0STC5vXZX3RQnaEPYj1z2rO1bVvMWWOJAdwz16HGOtZdheiG7vo3eN5VkIdweMcYJz04x7VSuJljnlkDgmSTKpEMknr16CtVO6sxQw1p6/Ilt3vSssPnoBHgDZ6/7R9azo0aWSTdM8kisWZ84yPb0570+WZpdQZQrQpJyQCADx69c1LFi1SSOVB8xwRncce/t7Vy1Kr2R6Ci469y00UZhCKCZHXLMemPf3qokhtldm8yd93yZOTipFe4dgDMsagYwACxqvJdQpIYmOHHfPB+lc6JhB6rcgu1lnZpXYg/3c9KyrgyMMliHJ79TWlcXAjI3IS3IOF6VmzP5k4wAw6kdq0Ujsp3GpbhDuRwWPNVZgyM5XaCT1NXEEakq7EZ5+UZzVC4bD7h909qSbZtG7ZUdiGYsOaqyuo5z+VXfM3gl8n0qncJ84VUy7HAHc1qn0G3YZaW7X93HBCCcn5iB0r1XRrFbGzjjjPQc1j+END+wwiWbAlfrXQzcL8re3HauiKsrs8fF1uZ8qFnl2naOcVXVS5LHpTFLCQkjIHWo5LjB2ooOe2cGspas47WHTqFjYsSQPQZrCu9ruCh247kVqNcltyDHPHzcY+tZV7dzWzlZLdbiP/pm2aqxndoiK8DPJ9RS/wAGCOPeq0WqWvmfMskX+y4rQjms7jiKVc+h4qrC511PZYLobSkIwGGCBUnlhYy/8Y5XFU450jx5aAEjGalWWaRSEB44yOlQzgt2ImXzHLhTLITjYOuK53xDE6rJtjKkcY9K6Vd8LgE7GIPNY+tJNdF5GUhcdhgVly3TN6crSR5/ZR+bF/qzgMRz3p81lsRmTgHqDU9jDJFdTRkgKG+UVcmOV4G4EEE1lT21PQdRp6GLFbs6PyCF7U61SGK5jeRQyEYIxnFIsptZMgFkJw1a0Ihe3JCjb7Dmto6rlZv7VmDPbwfapVUMFP3QRVGK3K3BgXCk9/QVuyW+WDKeOxYVl3AEbH5cuTwRTaaVj0KFW+w9fKSEozIVU8n3qtdmHo4Jweobr9aVm8tg7qcbTge/rVGGZpZ5DIhcE547VCXc7IdyaBD9pDxL+7QccnrUlzc+WQXRfMJwAOf1pkiSwyAR/NGDuKtUV2/mq20fKxwOOntVJamnxMa86ebkRgn+6DxVu0+zTzwRzyxWsbuFeV0ysYP8RA6gVSubZYYgGO4sueM1BZjynLCTao4OT+lW4J6kyjzJ2LN5xI6ROsioSoZDlTg9QT2PvUdpMY5N0hUHpgr2qaW4jU/dCxnI3L15qrFMhb5kyPVjSUbCs7WNyO+yMDaQOBscUklzO8oaNWc4AYrjn0rEWWMSMdoIPTmpnWEfMcqexVuaRg6aRvtqTC3eNm+YqynMZyoIpbbVozBEsfl74gBtXj8q5ppZ1JDFnI7qcH8aYLqI5MynOMYPQ/nSV+hm6EWrNHVvqVwwkJzGwQqhHO3PcVZ0nWVS2WOBNvlAR/O+MD16VxsVwqHeHwPQAin/AGpkidS5Az2xj86Ti9zOWFjKPLY7uTWreG6MczWlzMeSsEyyqoPUFgMD1p1i/wBuWRGlRXY7wqMseCO4Y4X9ea4W11OOOQYbG4dccfjVyXVw0ZjaXYmOijIpOLe5k8Hyr3d+53EdxbR2y2+p6ro0Nw2NyC5Mztj2jDAfTNaOnmzk0wyxa/ooKkqYpneB8jjOGGf0ry06hbGTaEdm6ZHIqVbqFjnzZEkx2PGPrWym4q1jGeXN/a/D+vzO6uEhupGjuNW0NI1GAsbyzMT9AmP1rGjmtbYRwRamsyxHyzcR20n7tc/3WwXx7YrnBebmHnTzzJnqXx/Kqsc0IYuSxUZwNx/Wmpt7G9PBOKtKX5HQ6v8AZYrq3aDWtPvoWypMAdJFb1dGGR+ZqtFdEmQoWMZP3iCB+Gaw3ux5gJYMfTbir8V0hGWbt0qZX3OmNFxik3c1JLgIB5aFgv8AE3BqNtUG50dCdvcfxVkz3If5huC+hGB9arecvlnglj6d6xcW9zSNJdTUnuH8wSSjAP3dhPWoftJ4yQcnOAOapC4VXUjO5Rx6L/jUdxdOSWkZn9CeCfapUe5pyo0ri6HRVBAHOe5qoLtRjjLjqFqnE7vlzggfw5puTDNhACDziqslog5UkWXund2PlnBON2elIsqBD1x9ahWTI469TVKZ1LkLuAPemo9wbsh8t26gAspUcgeldf4Q0Hz2GoXKyAYyqv296xvB+gvqV2txcKTaRnIBH3jXqSFIowqYTAwMDpXTCC3Z5mLxTj7sdyGbbCgAXtkVVdtyggkD+dSzv5knIyDye1Ub1tjIykqhIG0DPJ6VcmeYn3FnlZQwVto756Csy8ngi2vcgrk4Eu0lfpkdKvQxyOjxuWDvwQf4vzqn5EljcSKfMjjJ5C9PyoUCXLogu2ISOS1dZMclc53D61Tby5m3KTuPVCMVYktZCr3VoqqVOWUHG8fT1p1okTDceUIyDjkeoqlExcl1KE8BJ+aFWT0bmo2trcr8oww/hbg/hWu+3O1TvTt7U59OSWLLNn6jn8Kl6CuemwFTglct/dx2qWSVgreSQqHqKoJMGdd29se/apjIm1trYBPANYxd0cttRLgSAgMDvJ5yajlmVoduHKlRweQvuKlVQ8n3mfjBJHf0p8qJFuCMHx1UnnP0pJa3LucwyRx30gbcySLgKg5J9/SqssTYwY1VQMcVoaruSVpACGznI4H0q19l8ywgkV8o6ku65bbj+Hb6+9SopycTo57JM5S2jt/tjJdqZINp3Kp2k+lZtvM8cssXA2H5RntW3cWcqX8Yk/dM3RHHJFZGqRL9pd4oxGUHKqOo96XLZM6qck2TQzs77So+b2xTb2EMMbQPTFRRyMoHlx5HB35zitq2jW6gGQSaqPvHSqnJqcjKCbgpIu2PoCaFgRHJhByv3uetaur2TRksOo/CsiJjFMxO4JnkMwyfek9HZnp0qnOrouDy2MSITvOSSe3tVO8tpF8zyYQWDbsdqS6uGkKqwHlgj96OoHpV2KX5GJZ5Acbsj26imlZ6myk1qYcrvcINi7VA5A6f59qrkbMEYaP8ua6Tyy4EbkiTsPUdsVSv4I0s5GDD5uFBXBJpx8jVVVexkSwhYlbdk8YQnNVtzM2CWIA4x2rUuHnRVV0VtoAORggfhTGt0kAKqN3ueTTctR3KySoqFXJZv4QQBinNLlgwKvt6gKaeYjMWUL8w4yDzT3SJSFYybWXBVcZ49aasxaEIlWRgWKhj0681KxcKyq4fA5AwKryW/wAxaNSMjO1uuKSNgOAqqRzz1oaQcpLHbxSIXMQA77WxiolhRpMKZAo65Of1q7dabdwaPbarPbxGxuJGjikR1PzjqrAHIP1FVYlUx79pUnrtOAKixmuWXwsd5aRg5849hzUTRx8g5BAyCefwNSZjO4JI5Zf4SwOKYiFyf9e74zgA5I/wpWFa25VkEiMrxBSoPIHBNWFadkK+RL84yGwRkdAQTVvSbWe+v4LKwg826nbZGgYAseuATgDj3qDUrmSG4mtLp5PtNuxjaJmyyFTyvXjmhkXSly31LOs/aWNuJrKwtHSPYfsqoN/+1JtYjd+VZ7QSbQCO+RjpWnrFraWFwLa31G2v08pXMlspCKWGSuT1I9RWfDIxD5ZgBxyc/hindk0tYJxKphk3ErGSV9KUtKj4wwwehqyxBUg7gCO/rSSSKFU4YAjOMU73NNRplZo/njce1VRKS5xwKsvcAquQQT6GmBN5LEg8djSUbFXY2K62BiRn3FR+ZJK5baxGeBSlgScqCO2KkicAemeM5osGoxJWRj/CT1pzOoHPLH3pxZXyGyO4OKsabYPfSyxRIxaOJpThHYcDODtBIz0GeKaQpS5VdsoPMwyCoORxtOMGtbwpoX9u3EnnTGG3hXc7EZ8w9kX3z19Kg0fSJdYvRFCcRDBeTso9PrXq2k6fFptqkFuoVUXcSeM46k+ta04J6s4MXiPZqyeoW1tFZW6xRqI1VcDHSoJJS2Pm4z2qSabeuAMrVUyK0g8vgr6rkVTl2PJ1lq9yVsrGxXhhzmsy5RLxNhLNG4ypXk+1D3d4sg8xbSbDcDDRHH15GfqKhtLtXuriJIyksREgt5fkYKepB6Muc8jI5p2ViW7DLaIwfaHNzexPLjZ++8xA3q0bA5H0INOuZ5FvxFLhLjGcqC0M3rjPK/Q1Yu2mmtUljgjUs3yrMu4gj3GOPwqgtzqUVx5xsxLhutvICR7bHxn6Zpp9DF23RNuLxsuxUZcbgOw9qmhhCP5ikFH4YDoD61DbzRXUslq5e2vE+dUljMTMD6A9foCassjQEoi7SRgqex9ab0ZF+ZCwKkbkOMZPBovUmRMqykY7UonW5tw2AH6N9RTWU4wJAfqamQ0dtB+6RJW+YNkYzyKuNJ5sQZcHA44zWUswaNCz4b19afKAjBNw5+9kYxXNHQytqWhNN5Cq5ChiCEU8/wD1qYSsMZdFwwJB5yfzpg8lSvzK4GeF4INWVMzFXfCueQp5zjpVWAr6jBBNprPkpOOSrdCPrWNYyfZbwxTySR28hBypxtrpBeSTsokjBU5LtwMjuK5rXomt4Q6sJYsfIV5Kj0PrRKPVboqnLXlY7xZMgsra3RleRckyADdyectXMLcwvPJFGGihXgKW3Hb9fetSCe2u4nMlxHHGAEcyHZ+XvntWTfyppzRzRxwPLFIpbdg4A7e4NEm5ao6abUVykkREIKjiMnjJ5FaelzZlKR5JOcAck+vSsqS4e+d7yeFFjdv3mxwApJ4OB0HI4pbG48nUCizsfKbaZYcjcvQ4+tZrR8yN91Y2gpuhJE/zOo4OPvD1rmdX09onYj7hIA9veuptJxDPJCwAIJCk9celOu4Vn4Iznt1rSSU1fqa0MRKnLyODZ5hId/lOinGSMCnEwTq7FdmBxtYsDW9faQsYUqAcnnjvWKbRhIHyytg7W3cj+lc/M09T26VWNRXQ6NZpbRWiYOygMuGz+RqhqE88xUSjy5EO7CdGPqBUxKW75bc7bfvrldvofTmqDCWYKqq8rKcBM7mx6DHWtoT0NkrampHsjtklMhcK21wVBB+nvVRil1cBzIywlupAXAxUZv5vKCJjy16r3UVJGg+VdpcMDgrQ1pdAlbUne2k+VpYSWK4ywAP6Vnz3A4WQbXXgDHNaUt28KRwxMNzDaUc5A+ncVUgib7SwKowwS5b+E0kKOm42KJri2/dIVJBJGN3Off8ApVbLJtBMYI5AP9K1UU/YlMAO/O47RkH3HpSNajLM/mSmRflYggA9vanztaDUkZk2ZvljKMDzsH8J74qW1d7Z42AeOQMCrKcEEHIIrXEhljFjPKYooSXWBmwFY9WHH9TUUoRRJCrFjk4V+cD274pE8+6aK2qaneahHFDMUkEcrS+aYVEpLckFxgsM881HBf3ULpJHfXGY4jDGUl2MiHqo9vanwQukZbegi5LDdkn8KltLrRBptxFd6ddTaixPkzxXXlRqMcZUqckc/WqtqZNRhG0Y3XkV9C1BNNvTIun2F45AEf26JpPLYchlAYAGr/iDxHqmtWZhmksBa7g2yCyjiII/2gN361jxi2QceYz+gOevpxj9an1e+N9OLgh0mMaI8eBsyBjOABj6Y4qn2IlQhKqqnLr37FC7hSIJ5E3nIyhm3ptIbHI68gHv3qKJnjwZXPzcZyOKWQFgF2kkc4A607cNo3g7c4O0fpmnaxvaysNuHAUBHdvcVUjBZwPX1NW3iYbWCKFPXDdaliuZIFmghlZYJtvmxD+PByM/T2pN2E79Ck0br1yPSnQ+5PHb1NPnlywAU5PAzT3QCIYXDYGaTY0NmQMcJ2pYeeDgeuBSbmCfMyj2zVSWTaow2D/CBQNtItyyABiQFb1z0q1oVje6nd7bCSe3jIKyzI5XK91yOtN8P6LNrNwHlPl2yn5vf6V6lptlb6ZZokaKEA4AHWtIQ5nd7Hn4rFKEeXqM0vT7bTLSOGAbVUd+pPc0tzOJG4BOT0NE8pkkyhXg4A/wqvNMsaSMXAK4A+Ukn1NXKSeiPIbcnzS3JBhSh3fLkggetU33zIqJHNHjJciXgN9B2/OmyyTfIwP7sAcMoyT606xkY3gfc4nxujClgN/8vzFOEOrFN2RUkM9zcyILncyDBjZVJ4HY8A1JDaSTSW9nPEglSRvKmUbZkJHQ56jI+hzU01y0WoF5BcFnco5TBwSeeMfoKjm3zWivE0VxHGx2TeQVdSOMHBHGfancyk29C+JZ2hit7hcPE37yMr3/ALw9jUd5G5yYCcbi+1hxU1sZZ4Y5n2k4CNjJxnuD25xU0ke2Mpggg4BU9ab11MV7uhRuymoWIiukV9pDIJACFb1HpVPZciEGzfcq8fZpznB7hX6gexyKvz2Uggfy3wufukVSXeg+aXOeduc/lUvsWop6odbujTMrr5TsNzRuMMrd+PSpNkYJKbWzUV1a/a41KybZIzujY9V9vpSRMpPzpskXgg9D70tydjrmQSnCdM8884+lOC+XuZCsuRyvUj8agmPkTlXUsp6lRk094sbZY2UAkn1I+o7VytNCQKzGMlgSMcjmrJmeUBim8D5eDxn0qnIZArOMrGDwRzmpra9ZFA8za/GFxwT71pFiaLMlxAoyUCpxxjgUy8EckCuixrE3yc4Y4Pf2qheuApZ2JfdlgDn/AD0qazuVnuRLbJgY/iOecdqpyXNYXLpc5q/82G6jgV02MSoUqD+Wam1mO6vU8hZg9igVAXhCngcZIFW/ENsbiDcir5kZDLg0aJMsqMkkjfKdwVFzhvU57UkrSt3NObRSOQSOTT52jcFIidwCDg+1aM1s7KUWZXuUxtVMsHBGeo71p6tbjyZEEZ8iRdyEjhjk4YetZVreRx26kc3UTgg7iCAOq/j61MoJOxrGpzK6FfUPPkWRpQ0hUNLxgoem059Mdq1LC/3nZI3y4GD3rmbyIJIJlKvHKNxABwpPbPrSJKMgJk55HtWUotbM6IWeh20gVlIPORXN63bSxfNbp8p5YDgD1596s6RqahfKuW7/ACnHatWRFnBBwUIpq01Z7m1Ko6MvI89uPmypdsZ/iBz/ADplo01vOl1ZmW2nhOVljYqV+h/wrotW0nAbyNy56ntis2aBQVDQKAPUnkY6VLvE9qnXhUiY/ILuxYk9WAznPrUlvKY43KSspK/LgcEVI8721xH9mKqysHGV3Dg5HXqKteMNVtNZ1pr2x0tdOjeNRJGmB5knO6QgcDJPQccVcX3NHOXOo8uj6lOC4gXopkZ8Zz1B7mtGe+gihbY/8ONuM8evWsK3WLzladmVD95kALKuecAkZNavijTDpWpKqWWpWthcKHtm1BAssqADLYXjr29CKrqTKcVNQfUZBcxi0dioWYjCkP1/LoasJKhsEjjJ+VdxUvjH+NYE3zvkADHU9PwqV5ZJEw5DIo5HHSh6mjgjStZxIYxE7RAL99+Bn0B/xq077riE3hhDKNqkH5nB79eKoR3kf2ZVlGYhwFKjIHse9WIpoUtZFVF8l/4nGSffNJomWo29mY3BSJBHtIB+bcDjuanWOJ5UeZ4UyCQGO0Z9Rj+tZv2qVmbacl+oQdabc3gJHloTKfvblyw+lLXoJx0sXXsgirIpMQ4IDHr6kelRvClxKogdyx5JZeDj0qnbTgSZ8tJDnkSLz+dW7i58kukYMe44wDx/n6VSE7rQYYH86SORwx25yQABVXLSELKy7VPBUdfy4pWkKI6rCrRpgs3p75qFpYtm5iQT056U76hYlZZI5PlRSWyQSM8fhUTFVOSCQPfFVzdEEgDarddvH60LKTJ5W0vuYAKOWJ7YHXNIXMluSSMDyCFb0xyaleJYona4lVWChgMjLZ7D3H9KrTwTpcNHcI8DqcFJFKsPqD0rZ0kxyWslgxUo53sqRbmcjorOPmI9FBA7mi5E5u147GA5aU4T5V/U1v8Ahzw413IslyGWLPQnk10OieGY4tslwiueuGP8x2ro3liigCxrkgbQRxn6VcI9ZHBiMWlpDVjra3hsYVRFUBeAAAMfWoriV7i4SOJSwb5VUHknNQNDdXKtsiPkjGCXB65IwT9DWf8AaGe3YLuIcby7Jjb+OKuU3stjztW+Zu7L3nAxggsuTg46gd8VHNPayTiCKSaJ3XkOQ+cDueAR+RArGYWtzFl4szoAsMwRXHHQHOcj6Uy0FpdQRwOrWV8DkxjIjmx0eI98d14I9xRFEy03NgGaZzDu23CIFIxuA9GB7imtJdSXLteSyI4Ut5scACg9iNuDjiorWOZLyNlffOilmUZyyHgsoHX1x2retGcNIs7AhSGyoPIxnA4HIOK25LanM6mtuhk2xvJGuJLXULXcQQYZ7TfuBHZg4JI7ZqusuovI0M01is5wVZlli3egb7wP1ro5rSG5Vt6rIkabxK3Bz6ZHNQtFKyED51K7cSjO045GazldB7rK9jf31tO9vLpuwkfMLa4SQSD+8obaSP5Vbl1S1yfO8625x/pUDRf+PY2/rUQhBAiuFZJE+aORD9wjuP5H1FWLS58wOHdUnTiRAcA+hHqCORTi+5nJO4BmMReI71b+JTuB/EVlm3G9lBXGc+9XZbK3LM8P+jzHq9udpP1A4b8RVeUujqs7xs38LKDg/UdjVblRk0QyxhV4OD2NQBhnL4ap3ZWyHBP0pjQwqQUOQah2LXmdb57biWRZVcYJY/dJ7fX3qIIyk7eUI5TdyRToGUFjllccghuF+g71GzbZXMqkZPykD7p9R6Vg9jNChniO9PLcsOBn9DUcRJUsIwcfw9cUsgLIxaPJDbScYINRQqUJdJGjkHQEfePpUapj6ErpJIjYXMYGccZ/CnwzMA4UqcMFG1eSOp9wPeokuXDZBGcYxjBFRmNJSdwUHn5jn8zWq1dxW7kkkUs8JTbwDnlcc/Wucma507Uyr/6mQblbHpwRXQEmMBFIzjJBPA9DVDWIWu7d2QpBIqkpv52nsB65qmtBxdnqT2rxtAriB2uFQo0hlJJB6AL0AArnvESR2tsLdrXbdRy+cJlZgwjbrGV6e+at6NqE8TxRDT7wXIxvCYIB74JI4+taNy8up3LpfSQWw814gZGDEk4PIHA9OWpp3jYTfLI59VjGmAWz7tx2TrjK/wCywz09Kx7+KC0mXbdGS2bLJIsZBbnHT0zWhqkQ03UHt1gkTK4Il+ZR7g9yeuO1MSMCzS2YCVSC5O3BHXK5PXsanl+yzohLqZnn/vQUAVQoxgnnHfnvW1pmryRFVYqydM1zEWGkkif/AFaEJkdT9P61FM/2Irskyu7hfQVhOHVHXGSloz0qKaO6Q7MFj1B6isvUrLzF+Ycf0rD0zUWX/VtkYBxXR2Wpw3DeXL1I6+tOM76SKi3Td4nNyWZgAZUDBccrgYOPfoPpVK6t1O3YTkAkg8H613FxZoSHTLIRjg9BWNfWLI58sMOc5Xv9aJR6o9CjjE9JHJNCTEXRCVX+P1qWHUZo9PntJNtxbTLwspJMTjo6Hse3oRWpNE0I23CLhjllHAz7HvVAW4n3NGnyghc428/SlzdzsUozWpTDDaM4GevepbuSyk06JIYWW+RmMs3n7kdewCY+Uj69qa9sS6qnGSeAc9K0L3VryXTksLu3sZYkUIk32VPOjUdAHAB/OmmFRttcqv8AOxnWzW5g3Pjzl7E8Gh3ieFY2IyOR2zk9fpUSxIQW3dOgxiut12abSdJh0hr201WyniZo0kgRjanPBjdWJByTxn8Ke7JqVeRqK1bOauFjhjQRN8zDpnJqmFeNyzMAT0z3rYsNPsZYDcTaxbWjByv2dopJZgvqMDDfmKqFFku4mnEksAf5hGQjFPQHnBI+tSmWqid0uhTU9SxO39ac8cgQSNvwOhParupQWxleWyVY4ZMOkIlMrQjP3GYgZbjJ+tMMUrhMDcT95V4zT5ilJNXI47C9udPe6ht5GtI3EckoA2qxGQCf8apJGQe4OcHjJroXeRdHgtX8japLKYYFSVgc8M/VgCe4NVLDS7y+mH2a32ITgySt5aZ92PFNO+xlGe7noZslvubAAVfWujtdTubWyszpUlpYXEKNbb7Ndk8oJBLOTkknsRjvVmHwzJcSGFpUuDGCXNsrMEA7k+lb2nabZ6dED5aJjHXk/XJq4029zkxGIotdznLfQZNSuvPnWVEkwWaRizu3dueTn3rqrKxs9MKeXbxPzxEwO1uO+D09qgutWt4InEYbdng5BBXHOe4OazrmWcrHHwvmorqyuGyCPUH6jHahSjHbU4qlWdXR6I1L7VGlkkyU3sST5ahVBPoBxVB5y0uN2R03UZgEasqsHjjUbmlAy3JfKgc5OMcjGKymu8zMEtyq9vOlCgj2wDT1ZkrJWNW3QXkxh+1R2VrLndLJEZSgxyQBgnn+dcxHpaRXIls3PnR4Y+XIIgQfULxyPXNT39haXxie5ht4WdQQ5j80sc9m4GPqKmfQYIY/KT980yjKvH5YXDAjbt4PQHkEetaqPVnNKWuiG2OZ7qKN7gNbvLsMk0pQxnnG1kID98ZAHvWpqmlQ3jrCk16kRCkF5CXhlz8knzjIPY9iPas660y38uZdY0mzuIWQpFe2saoschIxvXovpn7vPY1c0K1sWZtN1K3ktr2CMiGZJTC0qLgZznBkXgEdxhu5FaJWVjnlUbd1sW9OOoPaHzYoXurSR4vMi+9G6/e+XOCp7jrzxXT2kxewSWBN/mtkqwxJGx6j8K5dIb+x1BfOurl4p1JBMXnBnTn5lwCCY+4PVa6WyvHmQTWptLlWZn8yCUqzr/DlWzyPXd3ppmTvcvLGZFVVVvnbBwOW+h70QoGO1snDbmYsO9RrcCNgGjeMnJ+dcoSe2RkCltiuNxRCMHkc/jSe4+hFOvyMUUZz3GKqTxjzkm2YbPlsB6Hp+R/ma0uTAMcrjtyKztTx5Mn8BGDnJqG7FLUXAWUkoFxxkcYqs8gQsCm7PUmngOX3YJHrTZY3z1Bz3NTF9SkiMDcD8oxVc5Dfc4zTjI8JZZEJz/EKepO0sjmomrjehr5eAoCXBznFWZrtJkCmNE2oA4Zjl2B6j/Corp4mXJySB93+H8PTFQTYYq2GxtABY5rJ6bMN9y27o0YMSb0A2HcvzD2/Cop3BT5FLcckHOSDxn0PvUVmxa7/AHexSw45xmluFKzIbaZBg9e7ehPp9KV7rUdrMJnUhW8s5+uPrTY5GjJ53K3y/MM49s0wYztd3LkksjD7vvnpzTLgHbxvKpznPOPemn1BpbDz5bKyhCOPlA67u1Ph82MRuyR7R944zkdP8aFdZreNsBow+Rngj1z71DOpSTY+4Yy2Qev4e1bXuifIp3nnWk5ubeOPI+Rif4h6j+dWomWzdWD+Z9qYyBBt2xN/e9Dn1qG5DzwlY42yqkcng571k2zGCWS3ut0u4jaU4A/HtUqVmOyaNfVbSK/tYnnADxN5hUcZGeevcjv6VgahZXFrdvBJE0QcF4TnchjPRlYfeA5BIrp4NiwtcSvCl2h/doScY9fTj0rH8TxTXEMeqQStIFJSRQfug54A9M54HFav3lfqKLs7GA8kFpaCyeOLzZ23i5dMsu3Jbae4Oeay7m2/0WRnTODuY9cfSrcdw2oTsHIaC2QrbnuoJy5/EgflUt0X+yzsQfKSLLknl13DOB7CoTTNk+XUx7d5YpmNsVyoHmKw4YnnH4cVZt79g6hwR3Bp89qunmHYcrKiyo7HO7d3/PI/CmXyJJatMrLujUnk4yegA/E9KmVJPQ6I1rbm1p2tSwv13DuK3odStrtSrHy2PQjoa85MrLOm1iTsXOM/eHBzVmO+ZMFzjnqB0rLllDY0tGep3V7YpLFHgrKFbOV5rKuNNeMMpXeMZO8Y/l2rLtdYeJgAwzn161tQa8xXZKgKnuef1ock/iNYTqQ21M0ae652pmQjK8fL9fSori04Ls0mFHTbnJ+npXSw3tmw5TaMdARipnOnSqDuAbqQR3qlCL2ZosbJPVHGi13DcARxyqj7p9yaiOnMrMQmME7vlwOldxa29mzjzZCyFgWCsBn161PNZ6eqxtHJn5TuDMMg7j7emPWn7LXcv+0LdDhG0yUjJHXj5DxkdqkGl3CNy7HjgmMgfjXcIdNkjB8zcy5DnzV247YGMg575qNpdOVQZIzIQw4LsMqOo4PQ+vWj2a6sn6+3tE5OPRXlwSzISuW3EKB26/nWxZ6DHPGEhspbyUH7wkYr1/uKvP4kVvx6vFb5a0ttPt37lLZf5tuJ61HfeJpZYWSW4uGjx90PhfwA4/SmqdNbmFTF156RVhsHhgwbF1AWdouSdrKqtjP9xNzn8SKS4TT7eNFMk03lkqNy7UQnptHJ/M1kXWrySylo2CbhllTA7Y7VXjkhntrkyzKswKmN9xBB5yMEcgg/pVqS6IztUes2a19rrsqRKNsS9IoUWJB/wFeM+5zWRczSzTmKUNH8wDZ6r6nH0quwUIzHDcdu3r+FVJJMgBZJEU9XAzjj8aTvIpRjDYddHyhhV81WZgrZG4gdz6fyqt9qkjZVMAMecZSdc/yxSs10kZMc9vcKvUldv6r/AIVTvbl7eW3Oq27wW7j5Z1O/b6ZI5259uKIUtTKdZR1bsaNtcSvKyxWcseSViLsjqGxxnkCpdHvP7RjmWWFo7mI7JUAPyPjgg+hHIpLjTri6gii+6GGVK8McHuO9UtEmksdbiZI3a5hxDcWy5JkjJ+Vlz1AOWGenzLXQo8r0OOdd2uazRPpN6lxcOzWlx+6mQ8CE8BZQfTJ5H49jXUraQxwxoduGJQRk4VexI9O9ZVy8d6vlriRpBuCScbhjkH0OCaseH/OFm0FxIzSWgA3FgS8R+4WHUNgFT7j3quhgpNyvIQ20theTzeRPc2UwYvHHyyoeCQv8YA5I9Kr3On20NlC1tcINOmdZLO7ceabB1PH1ib7pzyAcHjkdIsCzxuLh2RyRxz0zyR9B6etZlxbn7VcC3kjQyckPHmO4buGHbPqPTkGkKUbsqTskNrLeQI8ctq6zSRq33HR8MpGeeCR1Pat6KJUmA8oMowgdQAVA5x7j/HFYunQRlp7SK22RGIyGFnBkh42cHpJEcjaRyMYPatnT5jNZW0jsi+ZEhyvO1sfMPfkGmJO5ejn/AH29ShkHzYA2446Y71EFjEzBAFLYHAxyetIdrKiOgVy+d3PTHTH9abkNGXDEqCc5AqShJAscwKYJBI9Kr3CmXhjnaeasMwK7B0x6YqGTDBRxhem3j86zehSZAVIct93tzUTgc7TyOozUsgUAlxtb1zVfDFjlcD1FQ5dClqV5Y2VwTwPXNRq5XIfBB6banmBwCGGRxxVUKpI3E/XFIq+mpsykEAA49aT5sYU7lH6VGpVlO0/MOvPaolmCO4XJLYAz0H41i9C7FrP8KnKg/iPY06bYbVHGSd2GxxgVHkq2Y8rtPQ88+lNjLkudpHqmetNL8RPUkVnEzmUiQsuNwPT0+vSllkV12/JGrdT159KTaAvlgMydVHAI7kA/jT5IkNuSCMxuFJ4zz04ppMTKhQxsSXDHP3Q3Wp4ZBcys0yAx5wSoIBPbrTQQ1qqiU7hkAn5QnfH41XkVX3H5iwGT5Yx+dNMTNAy7kKld25gF2tgH2rMuUS6txsVUkDYDKCW79aeszSwnMmCQN2eAD04HrirLTswje4VME7Cynlh0zV7k2sZ2mSyRE7iRJEflQLncvqT2x71PqNyLCyuZFiJhKFlUv0znj2BJqMTR2zvJGHMeczKq5Crnr+HTFSXCJNbyW6SKwuo2MUhIby/lyFPv2NOFtiZbnK6tY2+jahaWlqsu1rVXd3kV0Y5ONmORx1BqzrkcTeH5gIHO6BwJlOAzkblHpnjkdxWwbnTUnjl1aGeW3zslRjhpFYAbePuqCvX6VlNLDZXOo6QJZJ9MlYPBJMCrqvVXKg/eHK89arRPnKTvoY5xdW1vBAIzKU8xBgKdhAyMn0OAB71V2MjQomd65d9vouMZ/E1NokGbW6WVHaWzf7NGQ33VRuSR75H5U94BNdNMittjjVGGe/LN/SrikaJkOwzXGd/PLAYwG46fnWcUct5bYL7dzKB2zjNaU0cgVmhJDhiQxPAPUfhSTzJLdXN1aLuQWKSSxtgGJtz5GehB25HtiraT3H7RwK0qFJcxrGy7AuOTk4G4+xzTUmbC7D0+8p/pVuw8prWFTjzQoYn1yAaxpN7XCuC4IupYF2ddwyQD7YrB0rrQ0jX1szorC3F5ps08F9EL2L7ljIh3zpjqjDjI/un0qq1/LbTNGzKrxvsY7gwB+o4qrZXDWF9BeLbW00sL71WeMyRkjruXI49earMH1I3IWOJJdreZEjYGOuVHcd/Wo9nc0VWUW76o3I9Tc5EhUMp9cVN/aXRt6uCMjJyDXKaT5t5ZxO4PmsuDxw2OCas2ju1oBLGokiYoSP48Hv79KPZWNVUjKx002refDCCnyxJ5SDONq5JAA+pJqE3i+YoZCjE8Ac5FY+0TFXR3Dg7eGzmpFuZrGdQzbBKDGCwJDd8Y/wA9KXs3uVzxS0NaO+ViArHeDjBH6U6S5wCSScMCSBxzWBdXbtcCazTZPjDbwSsgHOGH58jkVXa+Yzw7i8WXAlgY9A3AYf3lzjkevanGm2yHXUfi0Ni7v7uFt6QRSxAY+WTYxHuCCtRR6y8jKf7MvwclWEGyUZHHr/OtG0tppZRDIrZBwcDIPt+QqK20VP7WvIVlMUs6rNbtG+MHow9+x/OtlS6swqYhXspGXPfSRSqLKLWLeR2OYntN8bDH90n+RFTWepPBBPd6vDIlueEaIZKnO3ayHlM4yM/nV7UtE1SKBbi3vQ01s4mhLR4Off2PQ5q4IpNV0xb+GaGETIfNjRChVgcMp56qRVKC6HLKtK+krD4LdZoy8VhfqskJaOVDAA7dgD5mCvrVaS4uE0/7Jq2mRQzNJ5cc7XieQW7KwAbDMPwPTOaZZxTx36hbgWF7KcGdFBgmPUM6HjJ9sHI69KtXW6QyQ6xujuH/AHSP1tpxnkbj909MK34E1SREpSerYzQGvLe3Fle/YDZxyGK382Zy0OekROMnvhunQVB4lgk+2W2oxG1aeJ/nEcj/ADp6Hg5H+FC2EEPnx+VPPbGPy5IgQZ4mxgFGY8gZJ556Vc0G6j1Cwu7aeVXvLBljlVV2FlI+WQIeQD3HY5HpTsY8yUrNbh4TaO5tb+1EaefpkhXAYMpjYnYM+3zL+ArSLx28sMrjyfKIErbQTJC/GM+zEN6dawdMsU0HxZHqOWW0uALS7BHyguf3MuPTeAD6Eg967+SBBm5VEVlJRogu5dp4wR+dNaoSi03GRMyi3VxMw3x5A4B2+oH44H0zTbiOKRREolVCo34ORux1/M1m6MixxfYbjLvY7UbjJdP4H/EYH1U1txNmSSBfMkDRscqBtwOc8/Q0WZotNjEutMW5tHs73/j2cjY6fKw75UjkH+dS+Hbyd4J7S9WFb62eWBmRyfMKvuLgfwttIO30OelaciRmMlkJjQ4H9498VgW8RgjjlllcNcSuZpl4KOzny3z2Kn5fo3pUfCynrqjediG/dsWXbjnJz6D2pZC0kkhKKgB5CjGMVViaeSa4iuYljuLdsTrnaMgdR9RzTZSvz4dsLkBiDmk5aXKSuPuJsRHc5Ck55psbAxMw2Df/ABN1qmVLtw3yn+8f508RsoCPgKehHeufmcndjaQsh+Q8DniqAaQTk/MD0wTirbIWQ5LYJqmyfUn/AGqicWxp2JAzoSYzgnqKjJdnznnqQRT492wHJDDsBmnM7MMquxh1PrVLYVy2BjIwN46kd6hKhZPmDYJyR61I2drEYyB19KgJwAMEsDwc9R6U3G5tcnilCFwvKt1U9P8A9dA86C4V4/u98nOah3+WvmKu4d8npT4nzs2jIPrUcvQVy40jNubH8QPTp+FI8jF9oILEfeIAP4+1RXSMT+7IUjIHHcUls20qZADNk/Qj0q1HUVtCZTH8ylVJfjLNnaf/AK9Qqxt5HZ+VycgnuO1O1PZviEUexgArENwxz19qdbv5wdHCk9FwMHI6nPbik97C6FZ1CzqQfLdWG1uwHr7+lBXciiLaFI2kHjkf/r71PcLEZMSMWJG1dv6ZzVMyPHO0ZJywO4DGD/kVQk7iPBLFDHIm10dSWTdwQOecdfWo7N4pIFtpJGSMZZMADknOD65NW4lPlBVdlR9wUe+Kabe0+zIZMpNgukichh05GOCDnPrUx3ugb0KGo201za3M7jD2gDTKxwWXpkfQVBdWX9o2kV2L+0hkUxmVpoWLhyCsaKwGWDZXj1Iq7Zr5gM8YV2QneXzhgTzkd+O1V5LaPRNctmlaSS1dll+zlsoc52nHbGePStf73Qm7vZHP6Ks1tZN0S5t123MT4Bc7vm92YHOR2xU9/AYIvtVuH8qUqd4wQpI6fXtXQeINMg0rT4tf0IG3msZ1W9h3Fg8cjfIw3cZB+UjoQR71hW16EaSz83/QpmDnC/d6ttx+nFF/ZvXVMuD5tV0M+NgQ7MxUAc8Vm3ttNFqN19mkIjuLBJFU8B1LOCPwNb99brA7iMEODlfoRn+tYyBJdZiE832eJ7RsPt3BSHz0HqeOPWtkug5a2YWGzZDuYFWhRUkUYBxzn8cn9KpzyCO4lRSVePVo5CcfwyKB/U1NozD+w0MiAC3d435yRhjj68YqHVt7yS73ZhLZZjz/AAtCQV/QgfhTtZXIcbpG3dslukSyDMskn2bBAGQ6kH+VU5dPgSdJoAYRkAMvO0+vH86j1BzJeaNIh3xyXSuFPvGx/rWmrRyCRUUgtggnr1prULNHKRtLZ3cs0alZLaUBpOoYHncRxwCf1Oa1oVcardxYAIRJVVzkZ6MP0pgKjxLImzIuLUkA9CVYbv0OKQQtY6/AkvzW1xC1vGSTuBBDAH6DIz6YotqJTko2NHRbG4e2uX2JHP8AaC0cTSKrkMm9WAJ5G0ZqHVDH5aXN0sj2scgd1Q/MBgjI6dyD1HpVbw9cw/Y5mnQyGWdyr4weGIAx7Yq5qCm5tZUVyPMBQ5HGKajpoJSk1Z9URXttGLCwmtUBlvJEUbRwyldzfpmobqK4t4sPGWtlkDwzqPmtnzwcHp/L1qv4Wna9j0Kzkbb9lFxI3GQCuI1x+DV19zFub5GAdQVYkcH2xTSMudy+LU57TvEmom1tjqW2fz3aNjbx4eOWPO4so65XnK/lV3UniUWOtRyLcWlu5850+YGNuGHHp1x14rnL+B9K12xijIVJrpJtijIDBth2+mVf6cV3qWNjeR3Zkhl8m5R4/tVsQm7jrJEeGwMj19DUrsDi7PyNg7PLkglRuuFYdCpH8sVx2nXaaZqs4LKlndTCOSRzkRycBJT7MBtPocGuj0zULBfCunRXTyJfNHJaICDsuPJARpMjJUkBeDjk5zWReWaXMQd4w1swMUkZ/iU8kGhLsUoXjdlvUNPa5s5bfcANxkiJGRkdQfY/pWbaXbwWogus3Nkcoyz4fZ6o47j0P8q2PD0bJHeaZeSvJc2iqyvn/WRuDsc/7QwVI9s96giMc9zJNbsC0ZKSZXBJH+H9adgWsSA2rQLutDJPZsMh25ltwP1ZPbkj3FWLi0uLqWGWy8g6zbR7rSUEbLqMjmFmHVWHT0bHSrdvDMkvm6ewjZQFaFz8rd/lP8P6iqrzROs9xaho3hlzPbEAeVIf4lxxg9x+I5zSb6j5fssh1ZYde8JT3NrG3l3MDo0bcMrDlo2HZgy4/DNbOgaibjT0tNWnilmj2YuVbAuEdQ0bED+IqR+Kt3rPtpYbLXUKRhYdUJMkY5UXUa5LY/20zn3UetV9Ito7G3s55CpS3d7G4OM5gMpVce6ttIxzgnFTfUVm3d7nSKQt5a3MaPtP+iTEnC+WSNj++1z/AOPGtby/LADoTIcbff1+n/1qhFmWSUSFpIrgMmM4yOQabauUicTHfcQHyiw4V+BhiPcHP1zVJ9CupYZgIwcttzjpkgf/AF6qmNJ2MJhYwyKQ2eBjGCfwodyu1VUDqwI/TrSzymYhTwxHOeffj0qZajsQLDN5ZllBMiDZIx7lePx9fxqZjuCqVC45UA5GKQK5QqrfKRvYH9Ka0aIWO3cAPp1rJgRTHEJYMAQOiiqkVw0rpnBGDjHapZGGxhwQePpUUaiEFVyCOM561i1rdFdCWZwV+ZiXA55zUBffyCQe2DzSleFchdzcYpzJhs5yRzjGOKadxPQaQznmQj2IxSAsOAxDHjk5qRXWTBVsY56UTIxPJ4x1FVyozbP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Molluscum contagiosum. Examination also revealed unilateral conjunctivitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman, W, Jaeger, E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd Edition, Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30439=[""].join("\n");
var outline_f29_46_30439=null;
var title_f29_46_30440="Atenolol: Drug information";
var content_f29_46_30440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atenolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/27/2486?source=see_link\">",
"    see \"Atenolol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=see_link\">",
"    see \"Atenolol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6172803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tenormin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Atenol&reg;;",
"     </li>",
"     <li>",
"      Ava-Atenolol;",
"     </li>",
"     <li>",
"      CO Atenolol;",
"     </li>",
"     <li>",
"      Dom-Atenolol;",
"     </li>",
"     <li>",
"      JAMP-Atenolol;",
"     </li>",
"     <li>",
"      Mint-Atenolol;",
"     </li>",
"     <li>",
"      Mylan-Atenolol;",
"     </li>",
"     <li>",
"      Nu-Atenol;",
"     </li>",
"     <li>",
"      PMS-Atenolol;",
"     </li>",
"     <li>",
"      RAN&trade;-Atenolol;",
"     </li>",
"     <li>",
"      ratio-Atenolol;",
"     </li>",
"     <li>",
"      Riva-Atenolol;",
"     </li>",
"     <li>",
"      Sandoz-Atenolol;",
"     </li>",
"     <li>",
"      Septa-Atenolol;",
"     </li>",
"     <li>",
"      Tenormin&reg;;",
"     </li>",
"     <li>",
"      Teva-Atenolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F137477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Beta-Blocker, Beta-1 Selective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F137431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 25-50 mg once daily, may increase to 100 mg/day. Doses &gt;100 mg are unlikely to produce any further benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina pectoris:",
"     </b>",
"     Oral: 50 mg once daily; may increase to 100 mg/day. Some patients may require 200 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postmyocardial infarction:",
"     </b>",
"     Oral: 100 mg/day or 50 mg twice daily for 6-9 days postmyocardial infarction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyrotoxicosis (unlabeled use):",
"     </b>",
"     Oral: 25-100 mg once or twice daily (Bahn, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F137451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=see_link\">",
"      see \"Atenolol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Children: 0.5-1 mg/kg/dose given daily; range of 0.5-1.5 mg/kg/day; maximum dose: 2 mg/kg/day up to 100 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F137432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F137433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;35 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-35 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Maximum dose: 50 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Maximum dose: 25 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Moderately dialyzable (20% to 50%) via hemodialysis; administer dose postdialysis or administer 25-50 mg supplemental dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Elimination is not enhanced; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling;  however,  atenolol undergoes minimal hepatic  metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tenormin&reg;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tenormin&reg;: 50 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tenormin&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F137402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered acutely for cardiac treatment, monitor ECG and blood pressure. May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F137401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with other agents; management of angina pectoris; secondary prevention postmyocardial infarction",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F137473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute ethanol withdrawal (in combination with a benzodiazepine), supraventricular and ventricular arrhythmias, and migraine headache prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F137486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Atenolol may be confused with albuterol, Altenol&reg;, timolol, Tylenol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tenormin&reg; may be confused with Imuran&reg;, Norpramin&reg;, thiamine, Trovan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F137475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Persistent bradycardia, hypotension, chest pain, edema, heart failure, second- or third-degree AV block, Raynaud's phenomenon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, insomnia, lethargy, confusion, mental impairment, depression, headache, nightmares",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Cold extremities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, dyspnea (especially with large doses), hallucinations, impotence, liver enzymes increased, lupus syndrome, Peyronie's disease, positive ANA, psoriasiform rash, psychosis, thrombocytopenia, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F137406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atenolol or any component of the formulation; sinus bradycardia; sinus node dysfunction; heart block greater than first-degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure; pulmonary edema; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F137386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; however, atenolol, with B",
"     <sub>",
"      1",
"     </sub>",
"     selectivity, has been used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition (efficacy of atenolol in HF has not been demonstrated).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may precipitate thyroid storm. Alterations in thyroid function tests may be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal:",
"     <b>",
"      [U.S. Boxed Warning]: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia.",
"     </b>",
"     Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ampicillin: May decrease the bioavailability of Atenolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of Atenolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F137421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Atenolol serum concentrations may be decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Dong quai has estrogenic activity. Ephedra, yohimbe, and ginseng may worsen hypertension. Garlic may have increased antihypertensive effect. Management: Avoid dong quai, ephedra, yohimbe, ginseng, and garlic.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Studies in pregnant women have demonstrated a risk to the fetus; therefore, the manufacturer classifies atenolol as pregnancy category D. Atenolol crosses the placenta and is found in cord blood. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. The maternal pharmacokinetic parameters of atenolol during the second and third trimesters are within the ranges reported in nonpregnant patients. Although atenolol has shown efficacy in the treatment of hypertension in pregnancy, it is not the drug of choice due to potential IUGR in the infant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F137436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP recommends &ldquo;use with caution&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F137410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atenolol is excreted in breast milk and has been detected in the serum and urine of nursing infants. Peak concentrations in breast milk have been reported to occur between 2-8 hours after the maternal dose and in some cases are higher than the peak maternal serum concentration. Although most studies have not reported adverse events in nursing infants, avoiding maternal use while nursing infants with renal dysfunction or infants &lt;44 weeks postconceptual age has been suggested. Beta-blockers with less distribution into breast milk may be preferred. The manufacturer recommends that caution be exercised when administering atenolol to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F137411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F137408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Atenolol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $81.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $83.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $125.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tenormin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $184.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $188.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $283.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F137396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute cardiac treatment: Monitor ECG and blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F137412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ablok (BR);",
"     </li>",
"     <li>",
"      Alonet (HK);",
"     </li>",
"     <li>",
"      Altol (IN);",
"     </li>",
"     <li>",
"      Amolin (IE);",
"     </li>",
"     <li>",
"      Anolene (KP);",
"     </li>",
"     <li>",
"      Anselol (AU);",
"     </li>",
"     <li>",
"      Antipressan (GB, IE);",
"     </li>",
"     <li>",
"      Apo-Atenol (HK);",
"     </li>",
"     <li>",
"      Arandin (KP);",
"     </li>",
"     <li>",
"      Atarox (PY);",
"     </li>",
"     <li>",
"      Atecard (IN);",
"     </li>",
"     <li>",
"      AteHexal (DE, NZ);",
"     </li>",
"     <li>",
"      Atehexal (LU);",
"     </li>",
"     <li>",
"      Atelol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Atenal (KP);",
"     </li>",
"     <li>",
"      Atendol (DE);",
"     </li>",
"     <li>",
"      Atenet (DK);",
"     </li>",
"     <li>",
"      Ateni (IL);",
"     </li>",
"     <li>",
"      Atenil (CH);",
"     </li>",
"     <li>",
"      Ateno (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Atenobene (HU);",
"     </li>",
"     <li>",
"      Atenogamma (DE);",
"     </li>",
"     <li>",
"      Atenol (IT);",
"     </li>",
"     <li>",
"      Atenolin (KP);",
"     </li>",
"     <li>",
"      Atenolol Pharmavit (HU);",
"     </li>",
"     <li>",
"      Atenolol von ct (LU);",
"     </li>",
"     <li>",
"      Atenolol-B (HU);",
"     </li>",
"     <li>",
"      Atestad (PH);",
"     </li>",
"     <li>",
"      Atinol (TW);",
"     </li>",
"     <li>",
"      Atoken (MX);",
"     </li>",
"     <li>",
"      Aveten (MY);",
"     </li>",
"     <li>",
"      B-Vasc (ZA);",
"     </li>",
"     <li>",
"      Betablok (ID);",
"     </li>",
"     <li>",
"      Betacar (CN);",
"     </li>",
"     <li>",
"      Betacard (IN, RU);",
"     </li>",
"     <li>",
"      Betaday (TH);",
"     </li>",
"     <li>",
"      Betatop Ge (FR);",
"     </li>",
"     <li>",
"      Beten (MY);",
"     </li>",
"     <li>",
"      Betenol (KP);",
"     </li>",
"     <li>",
"      Biofilen (MX);",
"     </li>",
"     <li>",
"      Bloket (PY);",
"     </li>",
"     <li>",
"      Blokium (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, GR, HU, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Blotex (MX);",
"     </li>",
"     <li>",
"      Cardioten (PH);",
"     </li>",
"     <li>",
"      Catenol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Corotenol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Durabeta (PH);",
"     </li>",
"     <li>",
"      Enolol (TH);",
"     </li>",
"     <li>",
"      Felo-Bits (AR);",
"     </li>",
"     <li>",
"      Hypernol (SG);",
"     </li>",
"     <li>",
"      Hypoten (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Internol (MX);",
"     </li>",
"     <li>",
"      Internolol (ID);",
"     </li>",
"     <li>",
"      Lotenac (ID);",
"     </li>",
"     <li>",
"      Lotenal (KP);",
"     </li>",
"     <li>",
"      Myocord (AR);",
"     </li>",
"     <li>",
"      Neotenol (BR);",
"     </li>",
"     <li>",
"      Nolol (DO);",
"     </li>",
"     <li>",
"      Normalol (IL);",
"     </li>",
"     <li>",
"      Normaten (HK, MY);",
"     </li>",
"     <li>",
"      Normiten (IL);",
"     </li>",
"     <li>",
"      Normocard (PL);",
"     </li>",
"     <li>",
"      Nortelol (HK);",
"     </li>",
"     <li>",
"      Noten (AU);",
"     </li>",
"     <li>",
"      Oraday (IN, TH);",
"     </li>",
"     <li>",
"      Ormidol (HR);",
"     </li>",
"     <li>",
"      Paesumex (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Plenacor (BR, CO, EC);",
"     </li>",
"     <li>",
"      Preloc (TH);",
"     </li>",
"     <li>",
"      Prenolol (SG, TH);",
"     </li>",
"     <li>",
"      Prenormine (AR);",
"     </li>",
"     <li>",
"      Pretenol (MY);",
"     </li>",
"     <li>",
"      Rotelol (PH);",
"     </li>",
"     <li>",
"      Serten (PH);",
"     </li>",
"     <li>",
"      Tendiol (EC);",
"     </li>",
"     <li>",
"      Tenoblock (FI);",
"     </li>",
"     <li>",
"      Tenocor (TH);",
"     </li>",
"     <li>",
"      Tenolol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, NZ, SC, SD, SG, SL, SN, TH, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Tenopress (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tenoprin (FI);",
"     </li>",
"     <li>",
"      Tenormin (AE, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, ET, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IN, IQ, IR, IT, JM, JO, JP, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, OM, PA, PE, PH, PK, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TZ, UG, UY, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Tenormin ICN (HU);",
"     </li>",
"     <li>",
"      Tenormine (FR);",
"     </li>",
"     <li>",
"      Tenorvas (PH);",
"     </li>",
"     <li>",
"      Tensig (AU);",
"     </li>",
"     <li>",
"      Tensinor (TR);",
"     </li>",
"     <li>",
"      Ternolol (HK);",
"     </li>",
"     <li>",
"      Trebanol (MX);",
"     </li>",
"     <li>",
"      Tredol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Trubloc (PH);",
"     </li>",
"     <li>",
"      Urosin (MY, TW);",
"     </li>",
"     <li>",
"      Vascoten (MY, SG);",
"     </li>",
"     <li>",
"      Velorin (MY, PH);",
"     </li>",
"     <li>",
"      Vericordin (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F137385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively blocks response to beta-adrenergic stimulation, selectively blocks beta",
"     <sub>",
"      1",
"     </sub>",
"     -receptors with little or no effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors except at high doses",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F137405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Oral: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Normal renal function: 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid, incomplete (~50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Low lipophilicity; does not cross blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 6% to 16%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Limited hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Beta:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: &le;35 hours; Mean: 16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 4.6 hours; children &gt;10 years may have longer half-life (&gt;5 hours) compared to children 5-10 years (&lt;5 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Normal renal function: 6-7 hours, prolonged with renal impairment; End-stage renal disease: 15-35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (50%); urine (40% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bahn RS (Chair), Burch HB, Cooper DS, et al, &ldquo;Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,&rdquo;",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(6):593-646.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/ 21510801/pubmed\" id=\" 21510801\" target=\"_blank\">",
"        21510801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(15):1871-909.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/14557344/pubmed\" id=\"14557344\" target=\"_blank\">",
"        14557344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geffner DL and Hershman JM, &ldquo;beta-Adrenergic Blockade for the Treatment of Hyperthyroidism,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1992, 93(1):61-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/1352658/pubmed\" id=\"1352658\" target=\"_blank\">",
"        1352658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary. A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2006, 113(11):1474-1547.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/16549646/pubmed\" id=\"16549646\" target=\"_blank\">",
"        16549646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul AB, Wetterslev J, Gluud C, et al, &ldquo;Effect of Perioperative Beta Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial. DIPOM Trial Group,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006, 332(7556):1482.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/16793810/pubmed\" id=\"16793810\" target=\"_blank\">",
"        16793810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kraus ML, Gottlieb LD, Horwitz RI, et al, \"Randomized Clinical Trial of Atenolol in Patients With Alcohol Withdrawal,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1985, 313(15):905-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/2863754/pubmed\" id=\"2863754\" target=\"_blank\">",
"        2863754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenauer PK, Pekow P, Wang K, et al, &ldquo;Perioperative Beta-Blocker Therapy and Mortality After Major Noncardiac Surgery,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(4):349-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/16049209/pubmed\" id=\"16049209\" target=\"_blank\">",
"        16049209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mangano DT, Layug EL, Wallace A, et al, &ldquo;Effect of Atenolol on Mortality and Cardiovascular Morbidity After Noncardiac Surgery. Multicenter Study of Perioperative Ischemia Research Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(23):1713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/8929262/pubmed\" id=\"8929262\" target=\"_blank\">",
"        8929262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114 (2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al, &ldquo;Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9627):1839-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/18479744/pubmed\" id=\"18479744\" target=\"_blank\">",
"        18479744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Radack K and Deck C, &ldquo;Beta-Adrenergic Blocker Therapy Does Not Worsen Intermittent Claudication in Subjects With Peripheral Arterial Disease. A Meta-Analysis of Randomized Controlled Trials,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(9):1769-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/1679624/pubmed\" id=\"1679624\" target=\"_blank\">",
"        1679624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Redelmeier D, Scales D, and Kopp A, &ldquo;Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2005, 331(7522):932.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/16210252/pubmed\" id=\"16210252\" target=\"_blank\">",
"        16210252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2005, 352(18):1899-1912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberstein SD, Holland S, Freitag F, et al, &ldquo;Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standard Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1337-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/22529202/pubmed\" id=\"22529202\" target=\"_blank\">",
"        22529202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang H, Raymer K, Butler R, et al, &ldquo;The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Am Hear J",
"      </i>",
"      , 2006, 152(5):983-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/46/30440/abstract-text/17070177/pubmed\" id=\"17070177\" target=\"_blank\">",
"        17070177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8940 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30440=[""].join("\n");
var outline_f29_46_30440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6172803\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137426\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137427\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137477\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137431\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137451\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137432\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137433\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682655\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137398\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137382\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137402\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137401\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137473\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137486\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137475\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137406\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137386\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298790\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137391\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137421\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137394\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137409\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137436\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137410\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137411\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137408\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137396\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137412\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137385\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137405\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8940\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8940|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/27/2486?source=related_link\">",
"      Atenolol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=related_link\">",
"      Atenolol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_46_30441="Gastroesophageal reflux in infants";
var content_f29_46_30441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gastroesophageal reflux in infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/46/30441/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30441/contributors\">",
"     Harland S Winter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/46/30441/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30441/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30441/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/46/30441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30441/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/46/30441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The passage of gastric contents into the esophagus (gastroesophageal reflux) is a normal physiologic process that occurs in healthy infants, children, and adults. Most episodes are brief and do not cause symptoms, esophageal injury, or other complications. In contrast, gastroesophageal reflux disease (GERD) occurs when the reflux episodes are associated with symptoms or complications. The range of symptoms and complications of GERD in children vary with the age of the child.",
"   </p>",
"   <p>",
"    The diagnosis and management of gastroesophageal reflux in infants will be reviewed here. Reflux in premature infants, and the clinical manifestations, diagnosis, and pathophysiology of GERD in older children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=see_link\">",
"     \"Gastroesophageal reflux in premature infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These issues are also discussed in an official consensus statement and systematic review issued by the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/1\">",
"     1",
"    </a>",
"    ]. The full text of these guidelines is available at the NASPGHAN website (",
"    <a class=\"external\" href=\"file://www.naspghan.org/\">",
"     www.naspghan.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the following discussion, the term \"uncomplicated gastroesophageal reflux\" is used to describe the finding of frequent regurgitation in the absence of pathological consequences. \"Gastroesophageal reflux disease\" or GERD, is used when the reflux has pathological consequences, including esophagitis, nutritional compromise, or respiratory complications.",
"   </p>",
"   <p>",
"    Strictly speaking, the term \"regurgitate\" describes reflux to the oropharynx, and \"vomit\" describes expulsion of the refluxate out of the mouth, but not necessarily repetitively or with force. The terms are not clearly distinguished in clinical practice. In this review, we will use the term \"regurgitate\" to describe obvious gastroesophageal reflux, whether or not the refluxate comes outside of the mouth; other commonly used terms are &ldquo;spitting up&rdquo; or &ldquo;spilling.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux is extremely common in healthy infants, in whom gastric fluids reflux into the esophagus 30 or more times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/2\">",
"     2",
"    </a>",
"    ]. Many, but not all of these reflux episodes result in regurgitation into the oral cavity. The frequency of reflux, as well as the proportion of reflux episodes that result in regurgitation, decreases with increasing age, such that regurgitation or vomiting decreases toward the end of the first year of life, and is unusual in children older than 18 months old [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of healthy infants younger than 13 months of age, regurgitation of at least one episode per day was reported in approximately one-half of 0- to 3-month-old infants, compared to only 5 percent of 10- to 12-month-old infants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/4\">",
"     4",
"    </a>",
"    ]. Regurgitation was most common around 4 months (61 percent), decreasing to 21 percent between 6 and 7 months. The description of regurgitation as being a \"problem\" was given by 23 percent of parents of children aged 6 months, and decreased thereafter. A change in formula, thickening of feedings, termination of breast-feeding, and use of medication to treat the regurgitation were reported by parents to be beneficial in some children. In most children with regurgitation that is considered to be a problem by their parents, the condition improves and usually resolves by the end of the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contrary to previously held beliefs, GERD does not appear to be limited to Western countries; GERD in children appears to be increasing worldwide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Association with GERD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the relationship between regurgitation during childhood and the subsequent development of GERD has not been well studied, one report suggested that frequent episodes of regurgitation during infancy may be associated with an increased likelihood of having GERD symptoms in later childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/6\">",
"     6",
"    </a>",
"    ]. The study included 693 children who were followed for two years from birth and then contacted 8 to 11 years later. Children who had a history of frequent regurgitation (defined as &gt;90 days of \"spilling\" [spitting up] during the first two years of life) were significantly more likely to report GERD symptoms during follow-up at 9 years of age (relative risk 2.3, 95% CI 1.3-4.0).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Esophageal pH and impedance monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal pH monitoring (pH probe) is rarely useful in establishing the diagnosis of gastroesophageal reflux (GER) in infants, as the observation of frequent regurgitation is in itself adequate to show that the infant experiences frequent GER. Moreover, there is a weak association between abnormal results of esophageal pH monitoring and the presence of reflux complications in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. However, in special situations, such as infants with severe discrete episodes of symptoms (such as apnea, bradycardia, cough, or oxygen desaturation), esophageal pH monitoring may be used in conjunction with monitoring of respirations, heart rate, or oxygen saturation to establish whether there is a temporal relationship between episodes of reflux episodes and these discrete events [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Apnea or apparent life-threatening events'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Reflux and irritability'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\", section on 'Esophageal pH monitoring or impedance monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An upper gastrointestinal series may be helpful to exclude anatomic abnormalities, but does not contribute to the diagnosis of GERD because infants with and without GERD may have reflux episodes observed during the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Endoscopic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper endoscopy is of diagnostic benefit in patients who have not responded to dietary or empiric clinical trials",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are suspected of having dietary protein intolerance. Biopsies of the esophagus, stomach or duodenum may reveal inflammation characteristic of dietary protein intolerance (often termed \"allergy\") or other systemic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating an infant with frequent regurgitation, the clinician should determine if the symptom is caused by underlying pathological disease, or if there is evidence that the reflux is causing secondary complications such as esophagitis or failure to thrive. In most children younger than one year of age who are thriving and who do not have evidence of gastrointestinal blood loss or recurrent pneumonia, the reflux is uncomplicated, and little intervention is required.",
"   </p>",
"   <p>",
"    A small minority of infants develop other symptoms, including failure to thrive, hematemesis, and anemia, suggesting the possibility of gastroesophageal reflux disease (GERD). A manifestation of GERD consisting of arching of the back, torsion of the neck, and lifting up of the chin (Sandifer syndrome) can be confused with torticollis. Although irritability and feeding refusal sometimes are attributed to GERD, the relationship is less clear. Underlying diseases that may be associated with regurgitation or vomiting in infants and children are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef61133 \" href=\"UTD.htm?16/63/17405\">",
"     table 1",
"    </a>",
"    ). The clinical approach to managing an infant with frequent regurgitation is described in an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef62732 \" href=\"UTD.htm?29/16/29954\">",
"     algorithm 1",
"    </a>",
"    ) and detailed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Warning signals of underlying pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of warning signals suggests that an infant's reflux may be related to an underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. These findings should prompt further evaluation for gastrointestinal or systemic disease. Warning signals include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of gastrointestinal obstruction or disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bilious vomiting",
"     </li>",
"     <li>",
"      GI bleeding: hematemesis, hematochezia*",
"     </li>",
"     <li>",
"      Consistently forceful vomiting",
"     </li>",
"     <li>",
"      Onset of vomiting after six months of life*",
"     </li>",
"     <li>",
"      Constipation",
"     </li>",
"     <li>",
"      Diarrhea",
"     </li>",
"     <li>",
"      Abdominal tenderness, distension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms or signs suggesting systemic or neurologic disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hepatosplenomegaly",
"     </li>",
"     <li>",
"      Bulging fontanelle",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Macro/microcephaly",
"      </span>",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Hypotonia",
"     </li>",
"     <li>",
"      Stigmata of genetic disorders (eg, Trisomy 21)",
"     </li>",
"     <li>",
"      Chronic infections (eg, HIV)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonspecific symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Lethargy",
"     </li>",
"     <li>",
"      Failure to thrive*",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;* may also be a symptom of GERD",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Uncomplicated gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most infants presenting with gastroesophageal reflux in the form of frequent regurgitation, warning signals will be absent. If the infant also has good weight gain, feeds well, and is not unusually irritable, he or she can be considered to have \"uncomplicated\" gastroesophageal reflux. Such children (sometimes referred to as \"happy spitters\") usually do not require specific testing. The history and physical examination usually are sufficient for establishing the diagnosis. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"     \"Patient information: Nausea and vomiting in infants and children (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Education and reassurance of the infant's parents are appropriate, and the infant can be reevaluated periodically for the appearance of warning signals or other new symptoms. The regurgitation usually resolves by 1 year of age. If the symptoms worsen or do not improve by the time the child is 18 to 24 months of age, the child should be reevaluated; if possible a pediatric gastroenterologist should be consulted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the family's quality of life is affected by the infant's gastroesophageal reflux, or if the infant has congestion or difficulty sleeping because of regurgitation while supine, conservative measures to improve the symptoms may be worthwhile. These include a trial of thickened feeds, upright positioning after feeds, or a limited trial of a hypoallergenic diet (because intolerance of cow's milk or other dietary protein may have similar symptoms). Even in children with GER, prone positioning for sleep is not recommended because of an increased risk for sudden infant death syndrome. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Lifestyle changes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reflux and poor weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with recurrent regurgitation and poor weight gain should undergo evaluation for adequacy of caloric intake and problems with swallowing (",
"    <a class=\"graphic graphic_algorithm graphicRef62732 \" href=\"UTD.htm?29/16/29954\">",
"     algorithm 1",
"    </a>",
"    ). Poor weight gain despite an adequate intake of calories should prompt evaluation for causes of regurgitation and weight loss other than GERD. This evaluation may include laboratory testing (stool testing for occult blood, complete blood count, electrolytes, liver function tests, serum ammonia, glucose, urinalysis, urine ketones and reducing substances, and a review of newborn screening tests). An upper gastrointestinal series should be done to exclude anatomic abnormalities such as malrotation, antral web, annular pancreas, or a large pancreatic rest; note that this study is not intended to exclude or confirm the diagnosis of GERD.",
"   </p>",
"   <p>",
"    In older infants who have been exposed to wheat, rye or barley, serologic screening for celiac disease should be performed (preferably tissue transglutaminase, tTG, as well as a total IgA to rule out false-negative testing due to IgA deficiency). An IgG-based tTG (tTG-IgG) is available for children who are IgA deficient. In young children an anti-endomysial antibody may be a useful screening test, because children with celiac disease and negative tTG have been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients, gastroesophageal reflux and poor weight gain are caused by dietary protein induced gastroenteropathy, also known as \"allergic gastroenteritis\". Because cow's milk protein is the most common cause, the disorder is often termed \"cow's milk protein intolerance\". The presence of eczema, a strong family history of atopic disease, or gross or occult blood in the stool all suggest this disorder.",
"   </p>",
"   <p>",
"    Infants with dietary protein gastroenteropathy may or may not have evidence of colitis as revealed by gross or occult rectal bleeding. To investigate this diagnosis in formula-fed infants, an empiric trial of a hypoallergenic formula can be performed. In breast-fed infants cow's milk, foods containing dairy and beef should be completely eliminated from the mother's diet. A change in the infant's symptoms may not be seen for a few days, until the offending antigens clear the breast milk. If there is not a clear response to the diet change within a few weeks, other diagnoses and treatments should be explored. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Milk-free diet'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link&amp;anchor=H11#H11\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\", section on 'Food protein-induced enteropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If GERD is established or continues to be suspected after the above evaluation, treatment options include thickening the formula or of expressed breast milk, an increase in the caloric density of the formula, or a limited trial of suppression of gastric acidity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Lifestyle changes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If an infant fails to respond to these treatment trials or is ill-appearing, evaluation with upper endoscopy may be appropriate. Treatment depends on the gross and histological findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\", section on 'Endoscopy and histology'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H26\">",
"     'Esophagitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Occasionally, patients may require hospitalization or enteral feedings. Antireflux surgery is rarely indicated prior to one year of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Reflux and irritability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritability and disturbed sleep are non-specific symptoms and are associated with a variety of pathological and non-pathological conditions in infants. The common belief that reflux causes pain in infants is largely extrapolated from studies in adults.",
"   </p>",
"   <p>",
"    In infants, irritability is a poor indicator of acid reflux. Even in an infant with frequent regurgitation, there is little evidence suggesting that the reflux causes esophageal pain. A few studies have shown an association between reflux as documented by esophageal pH monitoring or esophagitis and measures of apparent discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/13\">",
"     13",
"    </a>",
"    ]. However, multiple other studies have failed to demonstrate an association between irritability and GERD in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. As an example, in several placebo-controlled trials of infants presenting with irritability, acid suppression had no effect on irritability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/12,15,16\">",
"     12,15,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16570602\">",
"     'Uncomplicated reflux'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In infants presenting with these symptoms, a careful history should be taken to exclude causes other than reflux. If the history suggests a strong temporal association between regurgitation and irritability, supportive measures, changing to a hypoallergenic formula, or even a limited empiric two-week trial of acid suppression therapy may be helpful (",
"    <a class=\"graphic graphic_algorithm graphicRef62732 \" href=\"UTD.htm?29/16/29954\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Lifestyle changes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Feeding refusal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of disorders are associated with infants who refuse feeding, and diagnostic testing should depend on associated symptoms and evaluation of possible psychosocial contributors. If a strong suspicion of GERD remains, the evaluation and treatment is similar to that of an infant with reflux and poor weight gain, and an empiric trial of a milk-free diet or a limited trial of drug therapy can be considered (",
"    <a class=\"graphic graphic_algorithm graphicRef62732 \" href=\"UTD.htm?29/16/29954\">",
"     algorithm 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Symptoms rarely caused by GERD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Apnea or apparent life-threatening events",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between GERD and apparent life-threatening events (ALTE) is frequently considered, but rarely established with certainty. Neurologic or cardiac disorders and respiratory conditions such as laryngospasm may initially present with ALTE, apnea, or cyanosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=see_link\">",
"     \"Apparent life-threatening event in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Persistent wheezing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although reflux may be associated with respiratory disorders in infants, including recurrent stridor, chronic cough, recurrent pneumonia, and reactive airway disease, the presence of such symptoms should prompt an evaluation for causes other than GERD. Although associations between wheezing and GERD have been demonstrated in adults and in some groups of children, there is little evidence for this association in infants except for a few non-randomized studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Before considering a trial of empiric treatment, infants with persistent wheezing should be carefully evaluated for other causes of these respiratory symptoms, including a reaction to dietary protein (cow's milk or soy sensitivity), congenital airway anomalies, hypogammaglobulinemia, and cystic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=see_link\">",
"     \"Approach to chronic cough in children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lifestyle changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of lifestyle changes have been investigated for infants with either uncomplicated reflux or GERD.",
"   </p>",
"   <p>",
"    For uncomplicated reflux, no intervention is required for most infants. Over-feeding and exposure to tobacco smoke should be avoided. A trial of a milk-free diet and thickening of feeds may be considered if the reflux is causing significant adverse effects on quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/1\">",
"     1",
"    </a>",
"    ]. Like other infants, infants with gastroesophageal reflux should be placed supine for sleep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link&amp;anchor=H6286188#H6286188\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\", section on 'Sleep position and environment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Milk-free diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies report that up to 40 percent of infants with gastroesophageal reflux have a cow's milk protein intolerance, or \"dietary protein-induced gastroenteropathy\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The majority of these infants will be sensitive to cow's milk protein alone, but a substantial number are also sensitive to soy proteins. Thus, in formula-fed infants, substitution of soy-based formulas is not recommended. Because this is generally a clinical diagnosis, initiating a one- to two-week trial of a hypoallergenic diet is appropriate, particularly if the condition is complicated by poor weight gain, irritability, or feeding refusal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. If the infant has a history of atopic symptoms, elimination of additional intact dietary proteins or use of an amino acid based formula may be necessary.",
"   </p>",
"   <p>",
"    Breast-fed infants can be treated with careful elimination of all cow's milk proteins and beef from the mother's diet. Major sources of soy protein may need to be eliminated as well. The response to this change is often more delayed than in formula-fed infants because it takes longer to eliminate the offending protein from breast milk and small amounts of milk or beef protein may be found in foods. These diets are difficult to follow and adherence to the diet may become an issue over time. Some families may have improved compliance if both parents commit to taking the same diet, for convenience and to provide support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link&amp;anchor=H11#H11\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\", section on 'Food protein-induced enteropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants who respond are generally maintained on a milk-free diet until one year of age, at which time many (although not all) infants will have become tolerant to the protein. Infants who do not respond to dietary restriction initially may respond to a trial of other lifestyle changes as outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Breast versus formula feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast feeding may have a protective effect on regurgitation in infants. Limited data suggest that breast-fed neonates (age 2 to 8 days) experience less nocturnal esophageal acid exposure compared to formula-fed neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/26\">",
"     26",
"    </a>",
"    ]. Mechanisms for this protective effect of breast feeding might include differences in gastric emptying or differential exposure of infants with a cow's milk protein intolerance, but these possibilities have not been assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Thickening feeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milk-thickening agents appear to modestly improve some of the symptoms and objective measures of reflux frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/27-32\">",
"     27-32",
"    </a>",
"    ]. In a meta-analysis of eight studies, thickened feeds significantly reduced the regurgitation severity score and the frequency of emesis, although not the reflux index [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/30\">",
"     30",
"    </a>",
"    ]. There is no direct evidence to suggest that this symptomatic improvement corresponds to an improvement in reflux-related pathology, such as esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thickening of feeds with cereal can increase the caloric density of the formula, which may be helpful in children who are underweight as a result of having GERD. The caloric density of one ounce of formula thickened with one tablespoonful of rice cereal is approximately 34 Kcal per ounce (1 tablespoon per 2 ounce formula provides a caloric density of 27 Kcal per ounce). The caloric density of formulas thickened with other substances varies. Providers and families should be alert for signs of excessive weight gain in infants fed thickened formulas, and should discontinue formula thickening as soon as it is no longer needed to control reflux symptoms.",
"   </p>",
"   <p>",
"    Standard formulas or expressed breast milk usually are thickened by adding rice cereal. The nipple of the bottle may need to be adjusted to permit adequate flow of the thickened formula. Premixed formulas thickened with rice starch are available in some countries including the United States, although their efficacy in GERD has not been extensively evaluated. Formulas thickened with carob flour or locust bean gum also are available in some countries and may possibly decrease regurgitation and esophageal acid exposure compared to unthickened formulas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thickening formulas with cereal appears to be safe, although one study suggested that this may increase coughing during feedings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, concerns have been raised about the use of a thickening agent that contains xanthan gum (&ldquo;SimplyThick&rdquo;) because of a possible association with necrotizing enterocolitis; both premature and term infants appear to be at risk. The United States Food and Drug Administration (FDA) has issued a",
"    <a class=\"external\" href=\"file://www.fda.gov/ForConsumers/ConsumerUpdates/ucm256250.htm\">",
"     warning",
"    </a>",
"    about the use of this thickening agent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=see_link&amp;anchor=H22#H22\">",
"     \"Gastroesophageal reflux in premature infants\", section on 'Diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Positioning therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants younger than 12 months of age should generally be placed in the supine position for sleep, even if they have reflux. Although the prone position tends to reduce measures of reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/38-42\">",
"     38-42",
"    </a>",
"    ], it is also associated with a higher risk for sudden infant death syndrome (SIDS), and this risk generally outweighs the potential beneficial effect of prone sleeping on reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/1,43\">",
"     1,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some infants with severe GERD (eg, those at high risk of aspiration, such as the neurologically impaired), the risks associated with persistent GERD may outweigh the risks associated with prone positioning. This decision can be made on a case-by-case basis.",
"   </p>",
"   <p>",
"    Semi-supine positioning (in an infant seat) is not helpful, as it increases reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/42\">",
"     42",
"    </a>",
"    ]. Similarly, elevation of the head of the crib has no effect on reflux for infants placed in the supine position [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lateral positioning is not recommended to treat reflux in this age group. The left lateral decubitus position improved reflux in studies on adults as compared to the right lateral decubitus position [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/44\">",
"     44",
"    </a>",
"    ]. However, results of studies in young infants are inconsistent about the effect of side positioning on reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Moreover, side positioning is associated with an increased risk for SIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/43,45\">",
"     43,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acid suppression and prokinetic medications have a limited role in the treatment of infants with regurgitation. They are not valuable in the treating children less than one year of age with uncomplicated gastroesophageal reflux (\"happy spitters\").",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16570602\">",
"    <span class=\"h3\">",
"     Uncomplicated reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest NOT using acid-suppressing or other drugs to treat infants with uncomplicated reflux. Many infants with symptoms suggestive of gastroesophageal reflux disease, including parent-reported discomfort and irritability during episodes of reflux or feeding, will improve over time with conservative measures alone. In an observational study, over 50 percent of such infants demonstrated clinically significant improvement or resolution of symptoms with conservative measures alone, including thickened feeds, avoidance exposure to tobacco smoke,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elimination of cow's milk proteins from their diet (semi-elemental formula or restriction of milk from mother's diet if breastfed) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Lifestyle changes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Analysis of practice patterns in the United States suggest that medications that suppress acid are probably over-prescribed. In a study of infants referred to a specialist in pediatric gastroenterology, most were treated with acid suppressive drugs before the consultation, but discontinuation of the medications did not cause symptoms to become worse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preponderance of evidence suggests that acid suppressing medications are not effective in infants for treatment of symptoms such as regurgitation and irritability, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of infants diagnosed with GERD using a standardized questionnaire of symptoms as reported by their parents, there was no difference in symptoms among infants treated with a proton pump inhibitor as compared with those treated with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial found no difference in reflux symptoms in infants treated with a proton pump inhibitor as compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/16\">",
"       16",
"      </a>",
"      ]. This study also reported that GERD symptoms worsened when infants were switched from the proton pump inhibitor to placebo, but this may have been due to acid rebound which has been described in other populations after withdrawal from proton pump inhibitor therapy.",
"     </li>",
"     <li>",
"      Based on these and other findings, a systematic review also concluded that proton pump inhibitors are not effective in reducing symptoms of irritability or regurgitation in infants [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30477024\">",
"    <span class=\"h2\">",
"     Other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited trial of acid suppression (two weeks) may be appropriate for infants with significant symptoms suspected to be caused by gastroesophageal reflux disease such as marked irritability, feeding refusal or poor weight gain, and in whom conservative measures including milk-free diet have failed. Infants with esophageal atresia, chronic neuromuscular diseases, chronic respiratory disease or diaphragmatic hiatal defects are more likely to develop erosive esophageal disease over time and may benefit from early PPI treatment if clinically indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Esophagitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When acid suppression is chosen as a treatment or for a limited trial, a proton pump inhibitor (PPI) is generally preferred. Based on small short-term trials in infants, PPIs appear to be effective in suppressing gastric acid production [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/12,51\">",
"     12,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Note that studies raise doubts about the role of acid suppression for many infants with symptoms of GERD, as discussed above (see",
"    <a class=\"local\" href=\"#H16570602\">",
"     'Uncomplicated reflux'",
"    </a>",
"    above). Moreover, there are safety concerns about PPIs, including short-term acid rebound, and increased risks for pneumonia and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. In addition, studies in adults have raised theoretical concerns that long-term use of PPIs may be associated with increased risk for gastric cancer and osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link&amp;anchor=H59974871#H59974871\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prokinetic agents currently have a minimal role in the treatment of gastroesophageal reflux in this age group. Because gastroesophageal reflux is essentially a motility disorder, it should theoretically lend itself to treatment with prokinetic agents that enhance gastric emptying and increase resting lower esophageal sphincter pressure. However, the few prokinetic agents with any established efficacy also have significant safety concerns, including central nervous system side effects for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , and cardiac arrhythmias for cisapride. Cisapride was removed from the market in the United States and Canada because of these concerns. Thus, prokinetic agents should be considered for use only in carefully selected and informed patients and with appropriate monitoring for these safety concerns and drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more detailed discussion of pharmacological therapy for the pediatric age group, including safety considerations, is provided separately. Specific issues related to premature infants are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\", section on 'Pharmacotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=see_link&amp;anchor=H24#H24\">",
"     \"Gastroesophageal reflux in premature infants\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infant with reflux-related esophagitis documented by endoscopic biopsies should be treated with lifestyle changes and acid suppression therapy. Note, however, that mild morphometric abnormalities seen on biopsy may not be clinically significant. In a study of 19 infants with histological abnormalities including basal cell layer hyperplasia who were treated with placebo for one year as part of a randomized trial, over half displayed improvement or resolution of symptoms during the placebo treatment, although the appearance of the biopsies did not change [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients with only mild esophagitis can be assessed based upon the degree of symptom relief. Those with erosive esophagitis should undergo a repeat endoscopy to demonstrate healing.",
"   </p>",
"   <p>",
"    For initial treatment of esophagitis in infants, a proton-pump inhibitor (PPI) is most effective. Randomized trials in adults show that PPIs lead to more rapid healing of esophagitis than histamine type 2 receptor antagonists (H2RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/56\">",
"     56",
"    </a>",
"    ]. There are no similar comparative, randomized trials in children, but several case series report that PPIs have healed severe esophagitis that had been unresponsive to H2RA therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Infants and younger children metabolize PPIs more rapidly than older children and require higher per-kilogram dosing than older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/51,59,60\">",
"     51,59,60",
"    </a>",
"    ]. To be most effective, they should be taken 30 minutes prior to the first",
"    <span class=\"nowrap\">",
"     meal/feeding",
"    </span>",
"    of the day. Unlike histamine type 2 receptor antagonists, PPIs do not lose efficacy with prolonged use.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/23/24952?source=see_link\">",
"     Omeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=see_link\">",
"     lansoprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/38/21095?source=see_link\">",
"     esomeprazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/45/22231?source=see_link\">",
"     pantoprazole",
"    </a>",
"    have all been studied in young children, and some have formulations that facilitate administration to infants and young children. Of these PPIs, only esomeprazole is currently approved by the United States Food and Drug Administration for use in infants greater than one month of age with erosive esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30441/abstract/1,61\">",
"     1,61",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Prokinetic agents have not been consistently effective for treatment of esophagitis, and also have significant side effects, so these are not generally recommended as adjuncts to acid suppression. The choice of drugs to treat esophagitis is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\", section on 'Pharmacotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If eosinophilic esophagitis or enteritis is found, treatment with acid suppression, dietary restriction (usually a strict milk-free diet to start), and sometimes steroids (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    ) or a leukotriene inhibitor may be effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/24/43394?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux) in babies (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastroesophageal reflux and regurgitation are extremely common during infancy and typically resolve on their own by one year of age. Most infants with frequent, uncomplicated regurgitation do not require intervention or evaluation beyond a careful history and physical examination. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Uncomplicated gastroesophageal reflux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants presenting with frequent regurgitation should be evaluated for the presence of warning signs suggestive of underlying pathological disease. In most cases, a careful history and physical examination will be adequate to exclude these warning signs. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Warning signals of underlying pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT using acid-suppressing or other drugs to treat infants with uncomplicated reflux (\"happy spitters\") (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Education and reassurance without any other specific intervention usually is sufficient. Other treatment options include thickening of the formula or expressed breast milk, or initiating a brief trial of eliminating cow's milk and beef from the diet. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Uncomplicated gastroesophageal reflux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For formula-fed infants with frequent regurgitation, thickening of feeds may improve reflux symptoms and some objective measures of esophageal reflux. However, there is little evidence that this approach reduces complications of reflux such as esophagitis. Therefore, thickened feeds may not be effective as the sole intervention for infants with pathological gastroesophageal reflux (GERD). Furthermore, breast feeding should not be stopped for the purposes of thickening feeds. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Thickening feeds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that infants with reflux be positioned supine for sleep (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Although prone positioning tends to decrease reflux, it also is a significant risk factor for SIDS. Semi-supine positioning (eg, in an infant seat) is not helpful and even exacerbates reflux. Lateral positioning may or may not improve reflux, and is also associated with an increased risk for SIDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link\">",
"       \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H24\">",
"       'Positioning therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In some infants, gastroesophageal reflux and poor weight gain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea is caused by dietary protein enteropathy, which is usually caused by exposure to cow's milk protein in formula or in breast milk. Such infants may or may not have evidence of colitis as revealed by gross or occult rectal bleeding. To address this possibility, we suggest an empiric trial of a milk-free diet (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A milk-free diet can be accomplished with a hypoallergenic formula for formula-fed infants; breast-fed infants can be treated with a careful maternal milk-free diet. Other diagnoses and treatments should be explored if there is not a clear response to the diet change within a few weeks (",
"      <a class=\"graphic graphic_algorithm graphicRef62732 \" href=\"UTD.htm?29/16/29954\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link&amp;anchor=H11#H11\">",
"       \"Food protein-induced proctitis/colitis and enteropathy of infancy\", section on 'Food protein-induced enteropathy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H21\">",
"       'Milk-free diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many causes of irritability in infants. If the history suggests a strong temporal association between episodes of irritability and reflux, a limited empiric trial of acid suppression",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evaluation with esophageal pH monitor or endoscopy is appropriate. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Reflux and irritability'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For infants with esophagitis documented by endoscopic biopsies, we recommend treatment with lifestyle changes in conjunction with an acid-suppressing medication (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For initial treatment, we suggest choosing a proton-pump inhibitor (PPI) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Further evaluation depends on the severity of esophagitis at baseline and on the degree of symptom relief following treatment. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Esophagitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of gastroesophageal reflux disease in children and adolescents\", section on 'Pharmacotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical procedures to treat reflux, such as fundoplication, are rarely indicated in infants younger than one year of age. However, some children who present with reflux during infancy may ultimately require surgical management later in childhood (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of gastroesophageal reflux disease in children and adolescents\", section on 'Surgery'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/1\">",
"      Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/2\">",
"      Vandenplas Y, Goyvaerts H, Helven R, Sacre L. Gastroesophageal reflux, as measured by 24-hour pH monitoring, in 509 healthy infants screened for risk of sudden infant death syndrome. Pediatrics 1991; 88:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/3\">",
"      Campanozzi A, Boccia G, Pensabene L, et al. Prevalence and natural history of gastroesophageal reflux: pediatric prospective survey. Pediatrics 2009; 123:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/4\">",
"      Nelson SP, Chen EH, Syniar GM, Christoffel KK. Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/5\">",
"      Nelson SP, Chen EH, Syniar GM, Christoffel KK. One-year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatric Practice Research Group. Pediatrics 1998; 102:E67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/6\">",
"      Martin AJ, Pratt N, Kennedy JD, et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 2002; 109:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/7\">",
"      Hyams JS, Ricci A Jr, Leichtner AM. Clinical and laboratory correlates of esophagitis in young children. J Pediatr Gastroenterol Nutr 1988; 7:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/8\">",
"      Heine RG, Cameron DJ, Chow CW, et al. Esophagitis in distressed infants: poor diagnostic agreement between esophageal pH monitoring and histopathologic findings. J Pediatr 2002; 140:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/9\">",
"      Salvatore S, Hauser B, Vandemaele K, et al. Gastroesophageal reflux disease in infants: how much is predictable with questionnaires, pH-metry, endoscopy and histology? J Pediatr Gastroenterol Nutr 2005; 40:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/10\">",
"      Colletti RB, Christie DL, Orenstein SR. Statement of the North American Society for Pediatric Gastroenterology and Nutrition (NASPGN). Indications for pediatric esophageal pH monitoring. J Pediatr Gastroenterol Nutr 1995; 21:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/11\">",
"      Stephen TC, Younoszai MK, Massey MP, Fellows RA. Diagnosis of gastroesophageal reflux in pediatrics. J Ky Med Assoc 1994; 92:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/12\">",
"      Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003; 143:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/13\">",
"      Feranchak AP, Orenstein SR, Cohn JF. Behaviors associated with onset of gastroesophageal reflux episodes in infants. Prospective study using split-screen video and pH probe. Clin Pediatr (Phila) 1994; 33:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/14\">",
"      Vandenplas Y, Badriul H, Verghote M, et al. Oesophageal pH monitoring and reflux oesophagitis in irritable infants. Eur J Pediatr 2004; 163:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/15\">",
"      Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/16\">",
"      Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr 2010; 50:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/17\">",
"      Sheikh S, Stephen T, Howell L, Eid N. Gastroesophageal reflux in infants with wheezing. Pediatr Pulmonol 1999; 28:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/18\">",
"      Eid NS, Shepherd RW, Thomson MA. Persistent wheezing and gastroesophageal reflux in infants. Pediatr Pulmonol 1994; 18:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/19\">",
"      Iacono G, Carroccio A, Cavataio F, et al. Gastroesophageal reflux and cow's milk allergy in infants: a prospective study. J Allergy Clin Immunol 1996; 97:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/20\">",
"      Salvatore S, Vandenplas Y. Gastroesophageal reflux and cow milk allergy: is there a link? Pediatrics 2002; 110:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/21\">",
"      Nielsen RG, Bindslev-Jensen C, Kruse-Andersen S, Husby S. Severe gastroesophageal reflux disease and cow milk hypersensitivity in infants and children: disease association and evaluation of a new challenge procedure. J Pediatr Gastroenterol Nutr 2004; 39:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/22\">",
"      Forget P, Arends JW. Cow's milk protein allergy and gastro-oesophageal reflux. Eur J Pediatr 1985; 144:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/23\">",
"      Cavataio F, Iacono G, Montalto G, et al. Gastroesophageal reflux associated with cow's milk allergy in infants: which diagnostic examinations are useful? Am J Gastroenterol 1996; 91:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/24\">",
"      Hill DJ, Heine RG, Cameron DJ, et al. Role of food protein intolerance in infants with persistent distress attributed to reflux esophagitis. J Pediatr 2000; 136:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/25\">",
"      Hill DJ, Roy N, Heine RG, et al. Effect of a low-allergen maternal diet on colic among breastfed infants: a randomized, controlled trial. Pediatrics 2005; 116:e709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/26\">",
"      Heacock HJ, Jeffery HE, Baker JL, Page M. Influence of breast versus formula milk on physiological gastroesophageal reflux in healthy, newborn infants. J Pediatr Gastroenterol Nutr 1992; 14:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/27\">",
"      Vandenplas Y, Sacr&eacute; L. Milk-thickening agents as a treatment for gastroesophageal reflux. Clin Pediatr (Phila) 1987; 26:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/28\">",
"      Bailey DJ, Andres JM, Danek GD, Pineiro-Carrero VM. Lack of efficacy of thickened feeding as treatment for gastroesophageal reflux. J Pediatr 1987; 110:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/29\">",
"      Orenstein SR, Magill HL, Brooks P. Thickening of infant feedings for therapy of gastroesophageal reflux. J Pediatr 1987; 110:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/30\">",
"      Craig WR, Hanlon-Dearman A, Sinclair C, et al. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Syst Rev 2004; :CD003502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/31\">",
"      Vanderhoof JA, Moran JR, Harris CL, et al. Efficacy of a pre-thickened infant formula: a multicenter, double-blind, randomized, placebo-controlled parallel group trial in 104 infants with symptomatic gastroesophageal reflux. Clin Pediatr (Phila) 2003; 42:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/32\">",
"      Horvath A, Dziechciarz P, Szajewska H. The effect of thickened-feed interventions on gastroesophageal reflux in infants: systematic review and meta-analysis of randomized, controlled trials. Pediatrics 2008; 122:e1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/33\">",
"      Vandenplas Y, Hachimi-Idrissi S, Casteels A, et al. A clinical trial with an \"anti-regurgitation\" formula. Eur J Pediatr 1994; 153:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/34\">",
"      Borrelli O, Salvia G, Campanozzi A, et al. Use of a new thickened formula for treatment of symptomatic gastrooesophageal reflux in infants. Ital J Gastroenterol Hepatol 1997; 29:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/35\">",
"      Wenzl TG, Schneider S, Scheele F, et al. Effects of thickened feeding on gastroesophageal reflux in infants: a placebo-controlled crossover study using intraluminal impedance. Pediatrics 2003; 111:e355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/36\">",
"      Orenstein SR, Shalaby TM, Putnam PE. Thickened feedings as a cause of increased coughing when used as therapy for gastroesophageal reflux in infants. J Pediatr 1992; 121:913.",
"     </a>",
"    </li>",
"    <li>",
"     FDA expands caution about SimplyThick. FDA consumer update, September 2012. Available at: file://www.fda.gov/ForConsumers/ConsumerUpdates/ucm256250.htm (Accessed on February 05, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/38\">",
"      Meyers WF, Herbst JJ. Effectiveness of positioning therapy for gastroesophageal reflux. Pediatrics 1982; 69:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/39\">",
"      Vandenplas Y, Sacre-Smits L. Seventeen-hour continuous esophageal pH monitoring in the newborn: evaluation of the influence of position in asymptomatic and symptomatic babies. J Pediatr Gastroenterol Nutr 1985; 4:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/40\">",
"      Tobin JM, McCloud P, Cameron DJ. Posture and gastro-oesophageal reflux: a case for left lateral positioning. Arch Dis Child 1997; 76:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/41\">",
"      Orenstein SR. Prone positioning in infant gastroesophageal reflux: is elevation of the head worth the trouble? J Pediatr 1990; 117:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/42\">",
"      Orenstein SR, Whitington PF, Orenstein DM. The infant seat as treatment for gastroesophageal reflux. N Engl J Med 1983; 309:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/43\">",
"      American Academy of Pediatrics Task Force on Sudden Infant Death Syndrome. The changing concept of sudden infant death syndrome: diagnostic coding shifts, controversies regarding the sleeping environment, and new variables to consider in reducing risk. Pediatrics 2005; 116:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/44\">",
"      Khoury RM, Camacho-Lobato L, Katz PO, et al. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 1999; 94:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/45\">",
"      Li DK, Petitti DB, Willinger M, et al. Infant sleeping position and the risk of sudden infant death syndrome in California, 1997-2000. Am J Epidemiol 2003; 157:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/46\">",
"      Orenstein SR, McGowan JD. Efficacy of conservative therapy as taught in the primary care setting for symptoms suggesting infant gastroesophageal reflux. J Pediatr 2008; 152:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/47\">",
"      Khoshoo V, Edell D, Thompson A, Rubin M. Are we overprescribing antireflux medications for infants with regurgitation? Pediatrics 2007; 120:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/48\">",
"      van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 2011; 127:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/49\">",
"      Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/50\">",
"      Hassall E. Co-morbidities in childhood Barrett's esophagus. J Pediatr Gastroenterol Nutr 1997; 25:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/51\">",
"      Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs 2003; 5:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/52\">",
"      Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117:e817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/53\">",
"      Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 2008; 53:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/54\">",
"      Chen IL, Gao WY, Johnson AP, et al. Proton pump inhibitor use in infants: FDA reviewer experience. J Pediatr Gastroenterol Nutr 2012; 54:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/55\">",
"      Orenstein SR, Shalaby TM, Kelsey SF, Frankel E. Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am J Gastroenterol 2006; 101:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/56\">",
"      Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/57\">",
"      Hassall E. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr 2005; 146:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/58\">",
"      Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000; 137:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30441/abstract/59\">",
"      Litalien C, Th&eacute;or&ecirc;t Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44:441.",
"     </a>",
"    </li>",
"    <li>",
"     Phillips JO, Parsons DS, Fitts SW. Flavored lansoprazole suspension in pediatric GERD. World congress of Pediatric Gastroenterology, Hepatology, and Nutrition 2000. Abstract 750966.",
"    </li>",
"    <li>",
"     Nexium (esomeprazole magnesium) prescribing information [Astra Zeneca]. Available at: file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4853677-1622-4037-688b-fdf533a11d96 (Accessed on January 25, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5876 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30441=[""].join("\n");
var outline_f29_46_30441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Association with GERD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Esophageal pH and impedance monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Endoscopic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Warning signals of underlying pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Uncomplicated gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reflux and poor weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Reflux and irritability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Feeding refusal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Symptoms rarely caused by GERD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Apnea or apparent life-threatening events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Persistent wheezing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lifestyle changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Milk-free diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Breast versus formula feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Thickening feeds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Positioning therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16570602\">",
"      - Uncomplicated reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30477024\">",
"      Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5876\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5876|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/16/29954\" title=\"algorithm 1\">",
"      Algorithm poor weight vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5876|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/63/17405\" title=\"table 1\">",
"      DDx vomiting infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=related_link\">",
"      Apparent life-threatening event in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=related_link\">",
"      Approach to chronic cough in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=related_link\">",
"      Approach to wheezing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=related_link\">",
"      Gastroesophageal reflux in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/24/43394?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in babies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=related_link\">",
"      Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_46_30442="Treatment of relapsed or refractory chronic lymphocytic leukemia";
var content_f29_46_30442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsed or refractory chronic lymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/46/30442/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30442/contributors\">",
"     Kanti R Rai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30442/contributors\">",
"     Michael J Keating, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/46/30442/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30442/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/46/30442/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/46/30442/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/46/30442/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin.",
"   </p>",
"   <p>",
"    CLL is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B-cell neoplasm small lymphocytic lymphoma (SLL), one of the indolent non-Hodgkin lymphomas. The term CLL is used when the disease manifests primarily in the bone marrow and blood while the term SLL is used when involvement is primarily nodal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients undergoing chemotherapy for CLL will have an initial complete or partial response. However, with the exception of some of those treated with hematopoietic cell transplantation, disease relapse invariably occurs after treatment has been discontinued. The treatment of relapsed or refractory",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    will be reviewed here. The initial treatment of CLL, the use of hematopoietic cell transplantation in CLL, and the management of complications of CLL and its treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDENTIFYING RELAPSED OR REFRACTORY DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178511\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Workshop Group on CLL (IWCLL) response criteria are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17671?source=see_link\">",
"     \"Evaluating response to treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapsed disease occurs in patients who have previously achieved either a complete or partial remission by these criteria but then develop progressive disease after a period of six months or more.",
"     </li>",
"     <li>",
"      Patients who fail to achieve either a partial or complete remission with therapy or those that develop disease progression within six months of therapy have refractory disease. These treatment failures include patients with stable disease, nonresponsive, or progressive disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This distinction is principally made because many patients with progressive disease occurring more than 6 to 12 months after the discontinuation of treatment can be successfully retreated using the same medication, or by switching to other available treatments. In contrast, patients who have refractory disease are unlikely to respond to a trial of the previously used therapy and have a much poorer prognosis.",
"   </p>",
"   <p>",
"    Before a patient is considered to have refractory CLL, the diagnosis of CLL must be reconfirmed. Disorders such as histologic transformation of CLL to large cell lymphoma, the leukemic phase of mantle cell lymphoma, and other malignancies must first be ruled out by the use of appropriate biopsy, cytogenetic, and molecular studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link&amp;anchor=H22#H22\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\", section on 'Histologic transformation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178576\">",
"    <span class=\"h2\">",
"     Time to progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IWCLL response criteria for relapsed and refractory disease described above were originally developed using data from patients treated with single agents (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ). As first line therapy has evolved, the overall response rate and median progression-free survival (PFS) have increased. The definitions of relapsed and refractory disease will likely change as therapy improves [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of treatment at relapse should take into account the patient's response to initial therapy. Patients who have an initial response duration significantly less than the median PFS for an individual treatment regimen may be considered for more aggressive treatment at relapse, such as the use of reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation (HCT), ideally within the context of a clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PFS differs greatly by treatment regimen. As examples, prospective trials have reported median PFS following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (FCR), fludarabine plus rituximab (FR), and single agent fludarabine of 52 months, 42 months, and 18 months, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. As such, patients progressing within six months of fludarabine treatment or within 24 months of FR or FCR may be considered to have aggressive disease. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, relapsed disease occurs in patients who have previously achieved either a complete or partial remission with therapy but then develop progressive disease at least six months after completing therapy. The ideal treatment of these patients is not known. However, it is our clinical experience that many of these patients can be successfully retreated using the same medication, or by switching to other available treatments. Specifically, patients initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    can often achieve another complete or partial response upon retreatment.",
"   </p>",
"   <p>",
"    These observations are supported by a prospective phase II trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    in patients with CLL that followed 13 patients who responded to initial therapy with fludarabine and, at the time of relapse, were retreated with fludarabine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/6\">",
"     6",
"    </a>",
"    ]. Complete and partial responses were obtained in eight and three patients in this group, respectively.",
"   </p>",
"   <p>",
"    It is not clear how patients initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based combination therapy (eg. FCR or FR),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    will respond to re-treatment with these agents at the time of disease progression. However, a trial of retreatment seems reasonable.",
"   </p>",
"   <p>",
"    Other treatment options for patients with relapsed disease include therapy with agents used for refractory disease or consideration of a hematopoietic cell transplantation (HCT). Data on the use of HCT are limited to small case series; however, there is some evidence that patients in complete response at the time of HCT will have a better prognosis. As such, even patients who plan to undergo HCT should be initially treated with chemotherapy at the time of relapse. For patients with disease that has relapsed more than six months after an initial response, we suggest retreatment with the same therapy that provided that initial response rather than treatment with another agent or upfront HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT OF REFRACTORY DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104640834\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with CLL will ultimately develop refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/1\">",
"     1",
"    </a>",
"    ]. As most newly diagnosed patients today are initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based regimens, the majority of information on refractory disease reflects that gathered from patients refractory to fludarabine. The prognosis of such patients is poor. As an example, one series reported that the median survival of 42 patients unresponsive to fludarabine was 48 weeks and only 11 percent responded to other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy is the main treatment modality used for refractory CLL, either alone or in combination with hematopoietic cell transplantation (HCT). The ideal chemotherapy regimen for patients with refractory CLL is unknown and patients should be encouraged to participate in prospective clinical trials. The treatment of patients refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , on the other hand, may include the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Nucleoside (purine) analogs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Splenectomy, obtained either surgically or via splenic irradiation, may be useful in patients with splenomegaly and profound cytopenias unresponsive to chemotherapy. Radiation therapy is an option for patients with bulky disease compromising critical structures. Leukapheresis is seldom used in CLL. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Splenectomy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Radiation therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Leukapheresis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal chemotherapy regimen for refractory CLL is unknown and there have been no prospective randomized trials comparing potential agents in this setting. As such, participation in prospective clinical trials is encouraged. Options for patients who are not candidates for clinical trials or those who do not want to participate in a clinical trial are presented below.",
"   </p>",
"   <p>",
"    Young patients with a good performance status and few comorbidities may be considered for hematopoietic cell transplantation (HCT) performed as part of a clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nucleoside (purine) analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purine analogs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ) are now the major first line treatment agents for CLL. However, a few patients may still undergo initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    . Such patients may demonstrate responses to fludarabine-based therapy despite being refractory to chlorambucil.",
"   </p>",
"   <p>",
"    As an example, a prospective randomized trial that enrolled 509 patients with previously untreated CLL randomly assigned initial therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    for a maximum of 12 cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients in either arm who did not obtain a partial remission or who had evidence of disease progression were allowed to cross-over to treatment with the other agent. Of the 79 patients who crossed over from chlorambucil to fludarabine, 46 percent obtained a complete or partial remission. By comparison, only two of the 29 patients who crossed over from fludarabine to chlorambucil had a response.",
"   </p>",
"   <p>",
"    As such, for patients with refractory CLL after initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    treatment, we suggest a trial of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based regimen. These regimens are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link&amp;anchor=H5622422#H5622422\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Fludarabine-based therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, patients with CLL refractory to single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    may respond to treatment with fludarabine in combination with other agents; however, response rates are still low. As an example, a randomized study of 241 patients with relapsed or refractory CLL who had received at least one prior fludarabine-containing regimen, addition of the Bcl-2 antisense oligonucleotide oblimersen to",
"    <span class=\"nowrap\">",
"     fludarabine/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"    </span>",
"    (FC) increased the rate of attainment of CR plus nodular PR versus those treated with FC alone (17 versus 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/9\">",
"     9",
"    </a>",
"    ]. Rates of five-year overall survival were similar (25 versus 15 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/10\">",
"     10",
"    </a>",
"    ]. However, in an unplanned subgroup analysis of those patients achieving a complete or partial response with treatment, the addition of oblimersen resulted in significantly higher five-year overall survival rates (47 versus 24 percent, respectively). Treatment with oblimersen was associated with thrombocytopenia, tumor lysis syndrome, and cytokine release reactions.",
"   </p>",
"   <p>",
"    Better responses have been obtained using the following triple combination regimens. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (FCR) versus FC in 552 patients with previously treated CLL (18 percent previously exposed to fludarabine) reported that FCR resulted in significantly superior median progression-free survival times (31 versus 21 months) with slightly greater toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phase II trial of FCR in 284 patients with previously treated CLL (19 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      refractory and 35 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      refractory) reported overall and complete response rates of 74 and 30 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/12\">",
"       12",
"      </a>",
"      ]. The estimated median progression-free and overall survivals were 21 and 47 months, respectively. On subgroup analysis, patients with the following characteristics had shorter survival rates: fludarabine-refractory disease; chromosome 17 abnormalities; or &gt;3 prior treatments.",
"     </li>",
"     <li>",
"      A study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (PCR) in 32 patients with previously treated CLL reported overall and complete response rates of 75 and 25 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/13\">",
"       13",
"      </a>",
"      ]. There were no differences in response rates for the subgroups of patients &ge;70 years of age, creatinine clearance &le;70",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      performance status &ge;1, or beta 2-microglobulin level &gt;4.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/14\">",
"       14",
"      </a>",
"      ]. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      infections developed in 28 percent of patients. Trials of PCR in previously untreated patients achieved lower rates of severe infection when lower doses of pentostatin were used along with aggressive prophylaxis with antibiotics, antiviral agents, and growth factor support [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, we prefer FCR to PCR because the number of patients that have been treated globally with FCR is much greater and because the two regimens have never been directly compared.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    (Campath-1H), an antibody directed against CD52, can be used for the treatment of previously untreated or",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/16\">",
"     16",
"    </a>",
"    ]. While responses may be seen in approximately one-third of patients with disease that is refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , the majority of these responses are partial remissions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least six single-arm prospective studies have evaluated the use of single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in patients with relapsed or refractory CLL after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/17-23\">",
"     17-23",
"    </a>",
"    ]. A 2007 systematic review reported a pooled overall response rate of 38 percent with 6 percent complete responses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/24\">",
"     24",
"    </a>",
"    ]. Eradication of minimal residual disease has been seen in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The most common side effects include infusion-related side effects, myelosuppression, and infection-related toxicities as described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypersensitivity reactions to this agent are common with the initial doses. Subcutaneous administration appears to be better tolerated than intravenous [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H40#H40\">",
"       \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Alemtuzumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia, thrombocytopenia, or anemia can be seen in approximately 40, 30, and 8 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       Alemtuzumab",
"      </a>",
"      increases the vulnerability of advanced stage CLL patients to opportunistic infections, including fatal bacterial, viral, fungal, and protozoal infection, as well as reactivation of cytomegalovirus (CMV), indicating that appropriate antibacterial and antiviral prophylaxis must be instituted when this agent is employed [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/19,28-37\">",
"       19,28-37",
"      </a>",
"      ]. The most commonly reported prophylaxis regimens include cotrimoxazole together with antiviral therapy. CMV viremia should be measured by quantitative PCR at least every 2 to 3 weeks during treatment. The approach to CMV management varies by center. Some use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      prophylaxis if viremia is present while others use it only if the viral load is rising [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/35\">",
"       35",
"      </a>",
"      ]. Our typical practice is to monitor patients as above. If a patient converts from CMV negative to CMV positive status or if a patient previously positive for CMV has an increase in viral load, we suspend therapy with alemtuzumab and begin treatment of CMV. With this approach, the CALBG cooperative group has noted a reduction in the morbidity and mortality from CMV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    , alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , is the only FDA-approved agent that reportedly has activity in cells lacking p53 function, as seen in patients with CLL and chromosome 17p deletion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/16,20,38,39\">",
"     16,20,38,39",
"    </a>",
"    ]. Such patients have high risk disease and are resistant to treatment with standard agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , purine analogs alone or in combination,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/16,40-43\">",
"     16,40-43",
"    </a>",
"    ]. A retrospective analysis of 105 patients with relapsed or refractory CLL treated with alemtuzumab included 35 patients with 17p deletion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/44\">",
"     44",
"    </a>",
"    ]. When compared with the entire study population, patients with 17p deletion demonstrated a similar overall response rate (49 versus 43 percent), median progression-free survival (7.1 versus 7.0 months), but shorter median overall survival (19.1 versus 32.8 months). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\", section on 'p53 tumor suppressor gene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    is least effective in patients with bulky lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/19,28\">",
"     19,28",
"    </a>",
"    ]. As an example, one study reported overall response rates of 87, 40, and 9 percent and rates of attainment of minimal residual disease of 39, 11, and zero percent in patients with no lymphadenopathy, those whose largest node was &le;5 cm, and those whose largest node was &gt;5 cm, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As such, we would favor the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in patients with chromosome 17p deletion and would discourage its use in patients with bulky lymphadenopathy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    has also been used in combination with other agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase III trial, 335 patients with relapsed or refractory CLL (15 percent of whom had received prior",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ) were randomly assigned to treatment with either single agent fludarabine (25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day on days 1 to 5) or combination therapy with fludarabine (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day on days 1 to 3) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      (30 mg per day on days 1 to 3), each given for six 28-day cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/45\">",
"       45",
"      </a>",
"      ]. Combination therapy resulted in a significantly longer median progression-free survival (24 versus 17 months), but was associated with higher rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities (67 versus 55 percent). Serious adverse events that were more common with combination therapy included cytopenias and infectious complications.",
"     </li>",
"     <li>",
"      In a study that included 32 patients with relapsed or refractory CLL, OR to a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      was 52 percent, with 8 percent CRs [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/30\">",
"       30",
"      </a>",
"      ]. Infections occurred in 52 percent of the patients.",
"     </li>",
"     <li>",
"      A phase II trial evaluated treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      (CFAR) in 80 patients with relapsed or refractory CLL and a good performance status, adequate organ function, and no uncontrolled life-threatening infection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/46\">",
"       46",
"      </a>",
"      ]. The overall response rate was 65 percent (29 percent complete). However, when compared with FCR, CFAR was not associated with an improved progression-free survival and appeared to have inferior overall survival. There was a high rate of infectious complications (46 percent) that limit this regimen&rsquo;s clinical use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ofatumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=see_link\">",
"     Ofatumumab",
"    </a>",
"    is a fully humanized monoclonal anti-CD20 monoclonal antibody, which has demonstrated activity in patients with CLL refractory to both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    . In this setting, the partial response rate is approximately 50 percent with no complete responses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    dose-escalating multicenter trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=see_link\">",
"     ofatumumab",
"    </a>",
"    in 33 patients with relapsed or refractory CLL who had received a median of three prior treatment regimens reported an objective response rate of 44 percent with no complete responses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/47,50\">",
"     47,50",
"    </a>",
"    ]. Four weekly infusions of ofatumumab were administered. Premedications included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , an intravenous antihistamine, and an intravenous glucocorticoid. Infusion reactions developed in 44 percent of patients receiving their first infusion with rigors, pyrexia, fatigue, rash, and sweating within the first few hours of infusion. Infusion reactions decreased in number and intensity with subsequent infusions. The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities included thrombocytopenia (9 percent), neutropenia (6 percent), anemia (3 percent), and infections (9 percent).",
"   </p>",
"   <p>",
"    Another phase II trial evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=see_link\">",
"     ofatumumab",
"    </a>",
"    in 138 patients with CLL that were either refractory to both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (59 patients) or refractory to fludarabine with lymphadenopathy greater than 5cm (79 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients had received a median of five prior therapies. Overall response rates were 58 and 47 percent in the two patient groups, respectively. There were no complete responses. Median overall survival was 13.7 and 15.4 months, respectively. The activity of ofatumumab appeared to be independent of whether the patients had previously received the anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Food and Drug Agency granted accelerated approval to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=see_link\">",
"     ofatumumab",
"    </a>",
"    for the treatment of patients with CLL refractory to both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20589433\">",
"    <span class=\"h3\">",
"     Bendamustine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alkylating agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    has demonstrated activity in patients with CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/53\">",
"     53",
"    </a>",
"    ]. The most common toxicities are neutropenia, thrombocytopenia, and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/54\">",
"     54",
"    </a>",
"    ]. Infusion is associated with a hypersensitivity reaction in approximately 5 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link\">",
"     \"Infusion reactions to systemic chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data regarding the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    in CLL come largely from a phase III randomized trial in patients with previously untreated disease that demonstrated a superior response rate when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/54\">",
"     54",
"    </a>",
"    ]. Studies in the relapsed setting have been limited to small phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trials and retrospective analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      in 16 patients with relapsed or refractory CLL after a median of three prior regimens reported responses in nine patients, two of which were complete [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/56\">",
"       56",
"      </a>",
"      ]. The median duration of response was 43 months.",
"     </li>",
"     <li>",
"      In a retrospective analysis of 109 patients with relapsed (43 percent) or refractory (57 percent) CLL treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      alone (20 percent) or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      reported an overall response rate of 79 percent with 29 percent complete responses [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/55\">",
"       55",
"      </a>",
"      ]. Response rates were higher among patients with relapsed disease and among patients treated with bendamustine plus rituximab. After a median follow-up of approximately eight months, the median progression-free and overall survivals were 16 and 17 months, respectively.",
"     </li>",
"     <li>",
"      A multicenter phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      (70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 2) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 78 patients with relapsed or refractory CLL reported an overall response rate of 59 percent (9 percent complete) with a median duration of response of 15 months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/58\">",
"       58",
"      </a>",
"      ]. After a median follow-up of two years, the median event-free and overall survivals were 14.7 and 34 months, respectively. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      side effects were hematologic toxicities (50 percent) and infections (13 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     Bendamustine",
"    </a>",
"    is approved by the US Food and Drug Administration for both previously untreated as well as relapsed CLL. The use of bendamustine in previously untreated disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link&amp;anchor=H23868301#H23868301\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Bendamustine-based therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , have been administered as single agents in CLL, usually in an initial dose of 20 to 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by mouth, with dose reduction occurring in a graduated fashion thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/59\">",
"     59",
"    </a>",
"    ]. With steroid therapy alone, one-third of patients have shrinkage of lymph nodes and reduction in splenic size. An increase in the lymphocyte count often occurs in the first one to two months of treatment, followed by a subsequent decline. A shift of lymphocytes from lymphoid organs and bone marrow into the blood is thought to be responsible for this initial increase in blood lymphocyte count.",
"   </p>",
"   <p>",
"    The major indication for corticosteroids in CLL is in the management of antibody-mediated (autoimmune) anemia and thrombocytopenia, which improve in approximately two-thirds of patients. Three to six months of treatment are usually required for achievement of clinical response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Autoimmune hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to psychiatric, metabolic (eg, hyperglycemia), gastrointestinal, and musculoskeletal toxicities, a major side effect of chronic corticosteroid therapy in patients with CLL is increased susceptibility to infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High-dose corticosteroids have been used in CLL as salvage therapy in patients with end-stage or treatment-resistant disease. It is common to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in the doses employed in the vincristine-adriamycin-dexamethasone (VAD) regimen. Usual starting doses are 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO on days 1 through 4, 9 through 12, and 17 through 20, every 28 days. Clinical responses can occasionally be gratifying, although toxicity in the form of susceptibility to infection is common and troublesome, often requiring dose reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the anti-CD20 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (Rituxan) can produce partial responses when used as a single agent for the treatment of refractory CLL, these responses are short lived with a median response time of 20 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. However, rituximab may enhance response rates when used in combination with other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/55,58,65-67\">",
"     55,58,65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 78 patients with relapsed or refractory CLL demonstrated an overall response rate of 59 percent (9 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H20589433\">",
"       'Bendamustine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A randomized trial compared six cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (FC) with six cycles of FC plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (FCR) in 552 patients with previously treated CLL who had not received prior rituximab [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/11\">",
"       11",
"      </a>",
"      ]. After a median follow-up of 25 months, FCR resulted in significantly longer median progression-free survival (20.6 versus 30.6 months). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nucleoside (purine) analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another prospective trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      in 14 patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -refractory CLL, 21 percent of whom had previously received rituximab, reported an overall response rate of 93 percent with a median time to progression of 15 months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with CLL who develop splenomegaly and profound cytopenia will initially respond to chemotherapy. However, some patients, especially those with advanced disease, will demonstrate marked splenomegaly along with cytopenias refractory to treatment with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. Splenectomy is preferred for the management of these patients since it provides long-term benefit. Splenic irradiation can achieve a temporary improvement in blood counts in patients that are not surgical candidates.",
"   </p>",
"   <p>",
"    A number of reports have demonstrated the hematologic and survival benefits of splenectomy in patients with splenomegaly, often massive and with mechanical symptoms,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cytopenias unresponsive to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/68-75\">",
"     68-75",
"    </a>",
"    ]. Platelet count increments on the order of",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    and hemoglobin concentration increments of &gt;2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    can be achieved in up to 80 to 90 percent of patients and improvement in absolute neutrophil count in 60 percent. Improvements in hemoglobin and neutrophil counts appear to correlate with splenic weight. In addition, a case-control retrospective analysis reported a trend towards improved survival among Rai stage IV patients undergoing splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/73\">",
"     73",
"    </a>",
"    ]. Perioperative mortality (9 percent) is more common in patients with a preoperative performance status &ge;2 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major indication for radiation therapy in CLL is the presence of large, bulky lymphoid masses causing compression symptoms, especially if the CLL has been unresponsive to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/76\">",
"     76",
"    </a>",
"    ]. CLL lymphocytes are extremely radiation sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]; treatment usually results in a rapid shrinkage of lymphoid masses. However, in most cases the benefits have been only temporary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    used in a palliative setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Splenic irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic irradiation (SI) has been performed in patients with painful splenic enlargement or cytopenias thought to be related to hypersplenism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, 52 patients with stages II to IV CLL were treated with a median SI dose of 7 Gy, given in weekly treatments of 1 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/80\">",
"     80",
"    </a>",
"    ]. Clinical response was noted in 82 percent, with a median remission duration of nine months (range: 3 to 24 months). Since splenic irradiation does not usually result in long-term control, splenectomy is the preferred option if the patient is in a satisfactory clinical state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Leukapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukapheresis is seldom urgently necessary in CLL, since leukostasis-causing symptoms due to increased whole blood hyperviscosity is rare unless the white cell count exceeds",
"    <span class=\"nowrap\">",
"     400,000/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=see_link\">",
"     \"Hyperleukocytosis and leukostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178725\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CLL are generally elderly with a median age older than 70 years, and due to the relatively benign course of the disease in the majority of patients, only selected patients are candidates for intensive treatments such as hematopoietic cell transplantation (HCT). The determination of transplant eligibility should be made based on a risk-benefit assessment, and the needs and wishes of the patient.",
"   </p>",
"   <p>",
"    The ideal timing of HCT in CLL is unknown and transplants should be carried out in the context of a clinical trial whenever possible. Such trials may be appropriate for young patients with clinically aggressive relapsed or refractory CLL or for those with high risk genetic factors including 11q22 and 17p13 abnormalities. HCT may also be considered for patients with histologic transformation to a more aggressive histology. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many agents are under active investigation. These include combinations of agents already used in CLL; agents approved for other diseases (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ); new antibodies (eg, anti-CD37 antibodies); and other novel agents (eg, flavopiridol, Bruton&rsquo;s tyrosine kinase inhibitors, and PI3-kinase inhibitors) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/81-89\">",
"     81-89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only known curative therapy for CLL is allogeneic hematopoietic cell transplantation. However, most patients are not candidates for this approach. Ongoing studies are investigating the use of chimeric antigen receptor T cells (CAR-T cells) directed at CD19 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/90-93\">",
"     90-93",
"    </a>",
"    ]. As an example, an intriguing report described three patients with relapsed or refractory CLL who received autologous T cells modified with a lentiviral vector expressing chimeric antigen receptor with specificity for CD19, coupled with CD137 and CD3-zeta signalling domains after a preparatory regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/90\">",
"     90",
"    </a>",
"    ]. All three patients demonstrated a tumor response, which persisted in one for at least 10 months. Toxicity included severe tumor lysis syndrome. Further follow-up of these patients and larger trials are needed to determine the efficacy of this approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23253612\">",
"    <span class=\"h2\">",
"     Bruton's tyrosine kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bruton&rsquo;s tyrosine kinase (BTK) inhibitors (eg, ibrutinib) are thought to block survival signals transmitted from the microenvironment to CLL tumor cells through the B-cell receptor signaling pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. Initial studies of BTK inhibitors as single agents in patients with CLL demonstrated that they were well tolerated and produced an unexpected lymphocytosis accompanied by a rapid and sustained decrease in lymphadenopathy in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. This response is thought to be due to release of tumor cells from the lymph node and bone marrow microenvironments into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Preliminary results of trials combining a BTK inhibitor with other agents have demonstrated rapid responses in the lymph nodes without an accompanying lymphocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/99-101\">",
"     99-101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Flavopiridol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flavopiridol, a synthetic flavone, has potentially antiproliferative and apoptosis-inducing properties independent of p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/102,103\">",
"     102,103",
"    </a>",
"    ], and may eliminate tumor cells resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/40,104,105\">",
"     40,104,105",
"    </a>",
"    ]. Using a pharmacologically-derived dosing schedule, overall response rates up to 53 percent in heavily pretreated patients have been achieved, including those with del(17p), del(11q), and bulky disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/106-108\">",
"     106-108",
"    </a>",
"    ]. Tumor lysis syndrome, which can be hyperacute and require hemodialysis, has been noted in patients treated with this agent, as has cytokine release syndrome and secretory diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/107,109-111\">",
"     107,109-111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional studies of this agent, requiring strict attention to renal function and the tumor lysis syndrome, are underway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lenalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial reports on the use of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    derivative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    in CLL have been promising [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/113-116\">",
"     113-116",
"    </a>",
"    ]. Several questions still remain regarding the potential use of lenalidomide for refractory CLL including the most active dose, the risk of tumor flare, and the need for prophylaxis against opportunistic infections:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      25 mg daily in 45 previously treated patients with CLL reported overall and complete response rates of 47 and 9 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/114\">",
"       114",
"      </a>",
"      ]. Fatigue, thrombocytopenia, and neutropenia were frequently seen. Most concerning, however, was the occurrence of tumor flare reactions characterized by the development of painful and swollen lymphadenopathy with or without fever and bone pain reported in 58 percent of patients.",
"     </li>",
"     <li>",
"      A case series of four patients with relapsed or refractory CLL treated with a 25 mg daily dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      reported tumor flare in three of the four patients, one of which was fatal [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/117\">",
"       117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second prospective phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      in 44 patients with CLL relapsed or refractory after purine analog-based chemotherapy investigated the use of lenalidomide starting at a dose of 10 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/113\">",
"       113",
"      </a>",
"      ]. An overall response was seen in 32 percent of patients with three patients achieving a complete response. The most common toxicity was myelosuppression. Low grade tumor flare was seen in 10 percent of courses and severe tumor flare requiring narcotics was seen in 2 percent. Tumor flare was successfully managed with a short course of oral steroids.",
"     </li>",
"     <li>",
"      A phase II trial evaluated the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 59 adults with relapsed or refractory CLL, the vast majority of whom had received rituximab previously [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/116\">",
"       116",
"      </a>",
"      ]. Rituximab (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      was administered weekly during the first 28-day cycle, and then on day 1 only for cycles 3 to 12. Lenalidomide (10 mg daily) was started on day 9 of cycle 1 and then continued until progression. The overall response rate was 66 percent (12 percent complete) and did not differ significantly for patients with chromosome 17p deletion. At a median follow-up of 33 months, the median time to treatment failure was 17 months, the median overall survival had not been reached, and the estimated survival at 36 months was 71 percent. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia (73 percent), thrombocytopenia (34 percent), anemia (15 percent), febrile or infectious events (24 percent), and fatigue (14 percent). There was one case of grade 3 tumor lysis. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies in",
"    <strong>",
"     previously untreated",
"    </strong>",
"    patients suggest that a lower starting dose may be associated with less toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]; however, the safest dosing remains to be determined. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single-arm prospective trial of single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      in 25 patients with previously untreated CLL described excessive toxicity in the first two patients treated with an initial dose of 10 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/118\">",
"       118",
"      </a>",
"      ]. These toxicities were decreased after a protocol amendment to begin lenalidomide at 2.5 mg daily with monthly escalations, depending upon tolerability, to a target dose of 10 mg and extended tumor lysis prophylaxis. With this protocol, severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia (72 percent), anemia (20 percent), thrombocytopenia (28 percent), and infection (36 percent). Tumor flare was seen in 88 percent of patients.",
"     </li>",
"     <li>",
"      Another single-arm prospective trial in 60 older adults (&gt;65 years) with previously untreated CLL administered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      5 mg daily for 56 days followed by dose titration up to 25 mg daily, as tolerated, and continued treatment until disease progression [",
"      <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/119\">",
"       119",
"      </a>",
"      ]. The overall response rate was 65 percent (10 percent complete) and the estimated two-year progression-free survival rate was 60 percent. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia (34 percent of treatment cycles, 83 percent of patients) and thrombocytopenia (12 percent of cycles, 47 percent of patients). Thirteen percent of patients experienced at least one major infection or neutropenic fever. Tumor flare was seen in 52 percent, but was mild (grade",
"      <span class=\"nowrap\">",
"       1/2)",
"      </span>",
"      and usually responded to dose adjustment or a short course of nonsteroidal anti-inflammatory drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lower dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    is undergoing further evaluation in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy for patients with previously untreated CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/46/30442/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Workshop on CLL (IWCLL) published a revised version of guidelines initially developed by the National Cancer Institute Working Group",
"      <span class=\"nowrap\">",
"       (NCI/WG)",
"      </span>",
"      on CLL for the diagnosis of CLL and the evaluation of treatment response:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Relapsed disease occurs in patients who have previously achieved either a complete or partial remission by these criteria but then develop progressive disease after a period of six months or more.",
"     </li>",
"     <li>",
"      Patients who fail to achieve either a partial or complete remission with therapy or those that develop disease progression within six months of therapy have refractory disease. These treatment failures include patients with stable disease, nonresponsive disease, progressive disease, or death from any cause.",
"      <br/>",
"      <br/>",
"      This distinction is principally made because many patients with progressive disease occurring more than 6 to 12 months after the discontinuation of treatment can be successfully retreated using the same medication, or by switching to other available treatments. In contrast, patients who have refractory disease are unlikely to respond to a trial of the previously used therapy and have a much poorer prognosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Identifying relapsed or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with disease that has",
"      <strong>",
"       relapsed",
"      </strong>",
"      more than six months after an initial response, we suggest retreatment with the same therapy that provided that initial response, rather than treatment with another agent or upfront hematopoietic cell transplantation (HCT) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment of relapsed disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemotherapy is the main treatment modality used for refractory CLL, either alone or in combination with (HCT). The ideal chemotherapy regimen for patients with",
"      <strong>",
"       refractory",
"      </strong>",
"      CLL is unknown and patients should be encouraged to participate in prospective clinical trials. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment of refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are not candidates for clinical trials or those who do not wish to participate in clinical trials, potential chemotherapy regimens for refractory disease include nucleoside analogs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -based therapy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      known as PCR),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      , corticosteroids, or rituximab based therapy. A choice between these agents is made based upon information regarding the prior therapy received, tumor characteristics, and patient comorbidities. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with",
"      <strong>",
"       refractory",
"      </strong>",
"      CLL after initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      treatment, we suggest a trial of a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -based regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These regimens are described in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link&amp;anchor=H5622422#H5622422\">",
"       \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Fludarabine-based therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We would favor the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      in patients with chromosome 17p deletion and would discourage its use in patients with bulky lymphadenopathy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Alemtuzumab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major indication for corticosteroids in CLL is in the management of antibody-mediated (autoimmune) anemia and thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Corticosteroids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Autoimmune hemolytic anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Splenectomy, obtained either surgically or via splenic irradiation, may be useful in patients with splenomegaly and profound cytopenias unresponsive to chemotherapy. Radiation therapy is an option for patients with bulky disease compromising critical structures. Leukapheresis is seldom used in CLL. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Splenectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Leukapheresis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/1\">",
"      Montserrat E, Moreno C, Esteve J, et al. How I treat refractory CLL. Blood 2006; 107:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/2\">",
"      Zenz T, Gribben JG, Hallek M, et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012; 119:4101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/3\">",
"      Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/4\">",
"      Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/5\">",
"      Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114:3382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/6\">",
"      Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81:2878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/7\">",
"      Seymour JF, Robertson LE, O'Brien S, et al. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma 1995; 18:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/8\">",
"      Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/9\">",
"      O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/10\">",
"      O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27:5208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/11\">",
"      Robak T, Dmoszynska A, Solal-C&eacute;ligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/12\">",
"      Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117:3016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/13\">",
"      Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006; 24:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/14\">",
"      Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007; 109:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/15\">",
"      Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/16\">",
"      Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103:3278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/17\">",
"      Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/18\">",
"      Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20:3891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/19\">",
"      O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/20\">",
"      Ravandi F, O'brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 2006; 24:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/21\">",
"      Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/22\">",
"      Karlsson C, Lundin J, Kimby E, et al. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 2009; 144:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/23\">",
"      Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009; 27:3994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/24\">",
"      Fraser G, Smith CA, Imrie K, et al. Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol 2007; 14:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/25\">",
"      Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/26\">",
"      Montillo M, Schinkoethe T, Elter T. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest 2005; 23:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/27\">",
"      Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/28\">",
"      Fiegl M, Falkner A, Hopfinger G, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006; 107:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/29\">",
"      Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23:7024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/30\">",
"      Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101:3413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/31\">",
"      Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/32\">",
"      Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003; 98:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/33\">",
"      Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol 2006; 132:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/34\">",
"      Rezvany MR, Tehrani MJ, Karlsson C, et al. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 2006; 135:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/35\">",
"      O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008; 111:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/36\">",
"      Osterborg A, Fo&agrave; R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009; 23:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/37\">",
"      Skoetz N, Bauer K, Elter T, et al. Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012; 2:CD008078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/38\">",
"      Osuji NC, Del Giudice I, Matutes E, et al. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005; 90:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/39\">",
"      Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/40\">",
"      Wierda WG. Current and investigational therapies for patients with CLL. Hematology Am Soc Hematol Educ Program 2006; :285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/41\">",
"      Stilgenbauer S, D&ouml;hner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/42\">",
"      Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/43\">",
"      Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/44\">",
"      Fiegl M, Erdel M, Tinhofer I, et al. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol 2010; 21:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/45\">",
"      Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011; 12:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/46\">",
"      Badoux XC, Keating MJ, Wang X, et al. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 2011; 118:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/47\">",
"      Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/48\">",
"      Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/49\">",
"      Chowdhury O, Varghese A, Pattinson J, et al. Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme. Br J Haematol 2011; 155:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/50\">",
"      Coiffier B, Losic N, R&oslash;nn BB, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br J Haematol 2010; 150:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/51\">",
"      Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011; 118:5126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/52\">",
"      Lemery SJ, Zhang J, Rothmann MD, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010; 16:4331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/53\">",
"      Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010; 10:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/54\">",
"      Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27:4378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/55\">",
"      Iannitto E, Morabito F, Mancuso S, et al. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. Br J Haematol 2011; 153:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/56\">",
"      Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005; 90:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/57\">",
"      Lissitchkov T, Arnaudov G, Peytchev D, Merkle Kh. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006; 132:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/58\">",
"      Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29:3559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/59\">",
"      Ezdinli EZ, Stutzman L, Aungst CW, Firat D. Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia. Cancer 1969; 23:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/60\">",
"      Molica S. High-dose dexamethasone in refractory B-cell chronic lymphocytic leukemia patients. Am J Hematol 1994; 47:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/61\">",
"      Friedenberg WR, Anderson J, Wolf BC, et al. Modified vincristine, doxorubicin, and dexamethasone regimen in the treatment of resistant or relapsed chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group study. Cancer 1993; 71:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/62\">",
"      O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/63\">",
"      Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/64\">",
"      Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/65\">",
"      Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008; 22:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/66\">",
"      Klepfish A, Rachmilewitz EA, Kotsianidis I, et al. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM 2008; 101:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/67\">",
"      Hillmen P, Cohen DR, Cocks K, et al. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. Br J Haematol 2011; 152:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/68\">",
"      Coad JE, Matutes E, Catovsky D. Splenectomy in lymphoproliferative disorders: a report on 70 cases and review of the literature. Leuk Lymphoma 1993; 10:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/69\">",
"      Majumdar G, Singh AK. Role of splenectomy in chronic lymphocytic leukaemia with massive splenomegaly and cytopenia. Leuk Lymphoma 1992; 7:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/70\">",
"      Neal TF Jr, Tefferi A, Witzig TE, et al. Splenectomy in advanced chronic lymphocytic leukemia: a single institution experience with 50 patients. Am J Med 1992; 93:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/71\">",
"      Thiruvengadam R, Piedmonte M, Barcos M, et al. Splenectomy in advanced chronic lymphocytic leukemia. Leukemia 1990; 4:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/72\">",
"      Pegourie B, Sotto JJ, Hollard D, et al. Splenectomy during chronic lymphocytic leukemia. Cancer 1987; 59:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/73\">",
"      Seymour JF, Cusack JD, Lerner SA, et al. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol 1997; 15:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/74\">",
"      Delpero JR, Gastaut JA, Letreut YP, et al. The value of splenectomy in chronic lymphocytic leukemia. Cancer 1987; 59:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/75\">",
"      Ferrant A, Michaux JL, Sokal G. Splenectomy in advanced chronic lymphocytic leukemia. Cancer 1986; 58:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/76\">",
"      Keating MJ. Immunosuppression with purine analogues--the flip side of the gold coin. Ann Oncol 1993; 4:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/77\">",
"      Rossier C, Schick U, Miralbell R, et al. Low-dose radiotherapy in indolent lymphoma. Int J Radiat Oncol Biol Phys 2011; 81:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/78\">",
"      Chan EK, Fung S, Gospodarowicz M, et al. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 81:e781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/79\">",
"      J&oacute;hannsson J, Specht L, Mejer J, Jensen BA. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 2002; 54:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/80\">",
"      Chisesi T, Capnist G, Dal Fior S. Splenic irradiation in chronic lymphocytic leukemia. Eur J Haematol 1991; 46:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/81\">",
"      Furman RR, Byrd JC, Brown JR, et al. CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (abstract 55). Blood 2010; 116:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/82\">",
"      Furman RR, Andritsos L, Flinn IW, et al. Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIPTM Protein In Relapsed and Refractory CLL (abstract 56). Blood 2010; 116:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/83\">",
"      Amrein PC, Attar EC, Takvorian T, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011; 17:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/84\">",
"      Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118:3603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/85\">",
"      Herman SE, Lapalombella R, Gordon AL, et al. The role of phosphatidylinositol 3-kinase-&delta; in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011; 117:4323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/86\">",
"      Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-&delta; inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/87\">",
"      Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/88\">",
"      Walensky LD. From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J Clin Oncol 2012; 30:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/89\">",
"      Furman RR, Barrientos JC, Sharman JP, et al. A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3K&delta;) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (abstract 6518). J Clin Oncol 2012; 30:420s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/90\">",
"      Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/91\">",
"      Brentjens RJ, Rivi&egrave;re I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118:4817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/92\">",
"      Koehler P, Schmidt P, Hombach AA, et al. Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol 2012; 2012:595060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/93\">",
"      Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/94\">",
"      Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117:6287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/95\">",
"      Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/96\">",
"      de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/97\">",
"      Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/98\">",
"      Byrd JC, Furman RR, Coutre S, et al. The bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naive (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study (abstract 189). Blood 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/99\">",
"      Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and related diseases (abstract 6508). J Clin Oncol 2012; 30:418s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/100\">",
"      O'Brien SM, Barrientos JC, Flinn IW, et al. Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study (abstract 6515). J Clin Oncol 2012; 30:419s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/101\">",
"      Burger JA, Keating MJ, Wierda WG, et al. The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients (abstract 187). Blood 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/102\">",
"      Pepper C, Thomas A, Hoy T, et al. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 2001; 114:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/103\">",
"      Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92:3804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/104\">",
"      Lin TS, Fischer B, Moran ME, et al. Flavopiridol, fludarabine and rituximab (FFR) is an active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma (MCL) (abstract). J Clin Oncol 2006; 24:446s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/105\">",
"      Lanasa MC, Andritsos L, Brown JR, et al. Interim analysis of ERC6663, a multicenter phase 2 study of Alvocidib (flavopiridol), demonstrates clinical responses among patients with fludarabine refractory CLL (abstract 58). Blood 2010; 116:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/106\">",
"      Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/107\">",
"      Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27:6012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/108\">",
"      Stephens DM, Ruppert AS, Blum K, et al. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica 2012; 97:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/109\">",
"      Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002; 20:4074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/110\">",
"      Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007; 13:4467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/111\">",
"      Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113:2637.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute website www.cancer.gov/clinicaltrials/CLLRC-OSU-0491#EntryCriteria_CDR0000404350 (Accessed on June 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/113\">",
"      Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111:5291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/114\">",
"      Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24:5343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/115\">",
"      Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009; 27:5404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/116\">",
"      Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013; 31:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/117\">",
"      Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008; 26:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/118\">",
"      Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2011; 29:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/119\">",
"      Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011; 118:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/46/30442/abstract/120\">",
"      James DF, Brown JR, Werner L, et al. Phenotypic changes associated with acute reductions in leukemia cell counts in patients with chronic lymphocytic leukemia receiving lenalidomide as initial therapy (abstract 59). Blood 2010; 116:33.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4520 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30442=[""].join("\n");
var outline_f29_46_30442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDENTIFYING RELAPSED OR REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1178511\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1178576\">",
"      Time to progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OF RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT OF REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104640834\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nucleoside (purine) analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ofatumumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20589433\">",
"      - Bendamustine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Splenic irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Leukapheresis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1178725\">",
"      HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INVESTIGATIONAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23253612\">",
"      Bruton's tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Flavopiridol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lenalidomide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4520\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4520|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17671?source=related_link\">",
"      Evaluating response to treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=related_link\">",
"      Hematopoietic cell transplantation in chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=related_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=related_link\">",
"      Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_46_30443="Rx of torsades de pointes";
var content_f29_46_30443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of torsades de pointes due to long QT syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"1\" rowspan=\"1\">",
"       Acquired LQTS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Pharmacologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Magnesium sulfate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Isoproterenol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Lidocaine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Phenytoin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"1\">",
"       Sodium bicarbonate (for quinidine-related arrhythmia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Nonpharmacologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Temporary pacing (atrial or ventricular)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Congenital LQTS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Pharmacologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Beta blockers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mexiletine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Nonpharmacologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Permanent dual chamber pacemaker",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Left cardiac sympathetic denervation (cardiothoracic sympathectomy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Implantable cardioverter-defibrillator",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30443=[""].join("\n");
var outline_f29_46_30443=null;
var title_f29_46_30444="Paternity index example";
var content_f29_46_30444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of the paternity index (PI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       STR locus",
"      </td>",
"      <td class=\"subtitle1\">",
"       PI for alleged father #1",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mother",
"      </td>",
"      <td class=\"subtitle1\">",
"       Child",
"      </td>",
"      <td class=\"subtitle1\">",
"       Alleged father #1",
"      </td>",
"      <td class=\"subtitle1\">",
"       Alleged father #2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D8S1179",
"      </td>",
"      <td>",
"       10.30",
"      </td>",
"      <td>",
"       13,",
"       <span class=\"red\">",
"        14",
"       </span>",
"      </td>",
"      <td>",
"       <span class=\"red\">",
"        14",
"       </span>",
"       , 16",
"      </td>",
"      <td>",
"       13, 16",
"      </td>",
"      <td>",
"       17, 21",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       THO1",
"      </td>",
"      <td>",
"       2.32",
"      </td>",
"      <td>",
"       7,",
"       <span class=\"red\">",
"        9.3",
"       </span>",
"      </td>",
"      <td>",
"       8,",
"       <span class=\"red\">",
"        9.3",
"       </span>",
"      </td>",
"      <td>",
"       7, 8",
"      </td>",
"      <td>",
"       11, 4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CSF1PO",
"      </td>",
"      <td>",
"       17.75",
"      </td>",
"      <td>",
"       <span class=\"red\">",
"        10",
"       </span>",
"       , 11",
"      </td>",
"      <td>",
"       7,",
"       <span class=\"red\">",
"        10",
"       </span>",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       5, 9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Notes:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"6\">",
"       The alleles of different STR loci are inherited as Mendelian genetic markers; diploid parents pass one of their two alleles to their offspring. In the example above, at STR locus D8S1179, the child carries a STR allele that has 14 repeats inherited from its mother. The child also has a STR allele that has 16 repeats inherited from its father.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"6\">",
"       Alleged father #1 and the child share the D8S1179 STR locus. The PI is 10.3, which means that results from the analysis of this specific STR locus indicate that alleged father #1 is 10.30 times more likely to be the biological father of this child than a random man in the general population.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"6\">",
"       Additional markers are tested and the PI's for each marker are multiplied together to give the Combined Paternity Index (CPI, ratio of the chance that the tested man is the biological father compared to the chance that a random man is the biological father). The CPI is then converted into a Probability of Paternity value. A CPI of 100 means that the tested man is 100 times more likely to be the biological father of this child than a random man in the general population.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"6\">",
"       The PI for alleged father #2 is zero at each tested locus since none of the child's markers match his markers. To exclude alleged father #2 as the child's biological father, exclusions at three or more different STR loci need to be demonstrated to reduce the possibility that a de novo mutation is responsible for the absence of shared markers.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <span class=\"red\">",
"      Red",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30444=[""].join("\n");
var outline_f29_46_30444=null;
var title_f29_46_30445="Hypothermia RO";
var content_f29_46_30445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview: Management of hypothermia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       General",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Definition: core temperature lower than 35&deg;C (95&deg;F)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Mild: 32-35&deg;C (90-95&deg;F)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Moderate: 28-32&deg;C (82-90&deg;F)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Severe: Below 28&deg;C (82&deg;F)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use a low-reading core thermometer if hypothermia suspected; standard oral thermometers do not read below 34&deg;C (93&deg;F)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypothermia secondary to other disease (infection, hypoglycemia, adrenal insufficiency, hypothyroidism, overdose, many others) must be considered",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Clinical aspects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Physical examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Vital signs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Mild hypothermia: tachypnea, tachycardia, hyperventilation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Moderate hypothermia: expect bradycardia; tachycardia suggests hypoglycemia, hypovolemia, or overdose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Severe hypothermia: hypotension, cardiovascular collapse",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Neurological examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Mild hypothermia: ataxia, dysarthria, impaired judgement; suspect CNS pathology if patient comatose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Moderate hypothermia: CNS depression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Severe hypothermia: areflexia, coma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Laboratory evaluation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Obtain coagulation studies, complete blood count, basic electrolytes, BUN and creatinine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Clinical coagulopathy present despite normal measured coagulation times",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Increased hematocrit may reflect hemoconcentration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; May see low bicarbonate, suggesting anion-gap acidosis; if so, obtain arterial blood gas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Electrocardiogram",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Rhythm abnormalities (atrial fibrillation, sinus bradycardia) may be present",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Intervals (PR, QRS and QTc) may be prolonged",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Osborn J waves characteristic of hypothermia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Occurs at junction of QRS and ST segments, most prominent in V2-V5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Distortion of the earliest phase of membrane depolarization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Computer misinterprets as ischemic injury pattern",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endotracheal intubation may be necessary in obtunded patients and those with bronchorrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Treat hypotension with warmed crystalloid (42&deg;C) initially, dopamine if necessary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid rough movements and activity, which may induce ventricular fibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Rewarming techniques are based on degree of hypothermia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Mild hypothermia: passive external rewarming",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Remove wet clothing, cover with blankets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Moderate hypothermia: active external and internal rewarming",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Warmed humidified oxygen, forced air warming systems",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Beware of initial paradoxical drop in core temperature due to return of cold blood from extremities to core circulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Rewarm trunk first to minimize risk of core temperature afterdrop",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Severe hypothermia: active internal rewarming (active core rewarming) and active external rewarming",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Warmed humidified oxygen, warmed IV fluids (42&deg;C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Pleural and peritoneal irrigation with warm saline (40 to 42&deg;C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Extracorporeal options: continuous venovenous rewarming, hemodialysis, continuous arteriovenous rewarming, and cardiopulmonary bypass",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Treatment of arrhythmias",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Arrhythmias may persist until patient rewarmed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Ignore atrial arrhythmias with slow ventricular response",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Ventricular fibrillation a common rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       May be precipitated by physical jostling",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Manage according to ACLS protocol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Electrical defibrillation may be attempted but is rarely successful until core temperature is above 30&deg;C",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30445=[""].join("\n");
var outline_f29_46_30445=null;
var title_f29_46_30446="UDCA response in PBC";
var content_f29_46_30446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59511%7EGAST%2F82631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59511%7EGAST%2F82631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Response to ursodeoxycholic acid in primary biliary cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Probability of response (defined as the absence of treatment failure) to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis. Patients were randomized to UDCA (solid line) or placebo (dashed line) for the first 24 months and then all patients were treated with UDCA for the next 24 months. The probability of a beneficial response at four years was significantly higher in the patients treated with UDCA throughout the study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group, N Engl J Med 1994; 330:1342.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Ursodeoxycholic acid slows disease progression in primary biliary cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 254px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of ursodeoxycholic acid (UDCA) on progression to liver transplantation or death in primary biliary cirrhosis. Patients were randomized to UDCA (dashed line) or placebo (solid line) for the first 24 months and then all patients were treated with UDCA for the next 24 months. The relative risk for liver transplantation or death was 0.32 in patients treated with UDCA throughout the study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group, N Engl J Med 1994; 330:1342.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30446=[""].join("\n");
var outline_f29_46_30446=null;
var title_f29_46_30447="Ungrounded electrocautery risks";
var content_f29_46_30447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hazards of electrocautery with an ungrounded endoscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 201px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Current leaking onto the endoscope from a unipolar instrument can flow through the endoscopist, producing burns to the eyes (A) and hands (B). A burn to the patient (C) can result if tissue contacts exposed metal on the endoscope. The use of a grounded safety cord provides a direct, low resistance pathway for current to return to the generator, thus avoiding the undesired pathways indicated by the broken lines.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Barlow, DE, Gastrointest Endosc 1982; 28:73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_46_30447=[""].join("\n");
var outline_f29_46_30447=null;
